ASLAN Pharmaceuticals (ASLN) 20-F 12 Apr 24 2023 FY Annual report (foreign) Financial data

Document and Entity Information

Document and Entity Information	12 Months Ended
	Dec. 31, 2023 shares
Document Information [Line Items]
Document Type	20-F
Amendment Flag	false
Document Period End Date	Dec. 31, 2023
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	FY
Entity Registrant Name	ASLAN Pharmaceuticals Limited
Entity Central Index Key	0001722926
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Interactive Data Current	Yes
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Well-known Seasoned Issuer	No
Entity Shell Company	false
Entity Emerging Growth Company	false
Entity File Number	001-38475
Entity Incorporation, State or Country Code	E9
Entity Address, Address Line One	3 Temasek Avenue Level 18 Centennial Tower
Entity Address, City or Town	Singapore
Entity Address, Country	SG
Entity Address, Postal Zip Code	039190
Document Annual Report	true
Document Transition Report	false
Document Shell Company Report	false
Document Registration Statement	false
Document Accounting Standard	International Financial Reporting Standards
ICFR Auditor Attestation Flag	true
Document Financial Statement Error Correction [Flag]	false
Auditor Firm ID	1046
Auditor Name	Deloitte & Touche LLP
Auditor Location	Singapore
American Depositary Shares (ADSs), each representing five ordinary shares, par value NT$10 per ordinary share
Document Information [Line Items]
Title of 12(b) Security	American Depositary Shares (ADSs), each representing twenty-five ordinary shares, par value $0.01 per share
Trading Symbol	ASLN
Security Exchange Name	NASDAQ
Ordinary shares, par value NT$10 per share
Document Information [Line Items]
Title of 12(b) Security	Ordinary shares, par value $0.01 per share *
Security Exchange Name	NASDAQ
No Trading Symbol Flag	true
Ordinary Shares
Document Information [Line Items]
Entity Common Stock, Shares Outstanding	587,074,700
American Depositary Share
Document Information [Line Items]
Entity Common Stock, Shares Outstanding	23,482,987
Business Contact
Document Information [Line Items]
City Area Code	+65
Local Phone Number	6817 9598
Contact Personnel Name	Carl Firth
Entity Address, Address Line One	3 Temasek Avenue Level 18 Centennial Tower
Entity Address, City or Town	Singapore
Entity Address, Country	SG
Entity Address, Postal Zip Code	039190
Contact Personnel Email Address	investor@aslanpharma.com

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2023	Dec. 31, 2022
CURRENT ASSETS
Cash and cash equivalents (Note 6)	$ 21,252,058	$ 56,902,077
Other assets (Note 7)	2,877,934	3,976,350
Total current assets	24,129,992	60,878,427
NON-CURRENT ASSETS
Investments in equity instrument at fair value through other comprehensive income (Notes 9 and 22)	235,567
Investment in associate company (Note 11)		8,587
Property, plant and equipment, net	29,268	43,140
Right-of-use assets	229,982	249,601
Intangible assets	1,716	5,836
Total non-current assets	496,533	307,164
TOTAL ASSETS	24,626,525	61,185,591
CURRENT LIABILITIES
Trade payables (Note 12)	7,918,607	12,784,485
Other payables (Note 12)	3,081,329	2,325,038
Current borrowings (Notes 13 and 21)	1,800,387	7,748,831
Lease liabilities – current (Note 21)	226,187	215,671
Financial liabilities at fair value through profit or loss (Notes 8, 21 and 22)	88,394	90,213
Total current liabilities	13,114,904	23,164,238
NON-CURRENT LIABILITY
Long-term borrowings (Notes 13 and 21)	24,798,552	29,656,133
Total non-current liability	24,798,552	29,656,133
TOTAL LIABILITIES	37,913,456	52,820,371
EQUITY ATTRIBUTABLE TO STOCKHOLDERS OF THE COMPANY (Note 14)
Ordinary shares	63,931,993	63,019,962
Capital surplus	243,791,693	223,910,955
Accumulated deficit	(321,067,236)	(278,386,749)
Other reserves	56,619	(178,948)
Total equity attributable to stockholders of the Company	(13,286,931)	8,365,220
Total equity/(Capital deficiency)	(13,286,931)	8,365,220
TOTAL LIABILITIES AND EQUITY/(CAPITAL DEFICIENCY)	$ 24,626,525	$ 61,185,591

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Loss - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Statement Of Comprehensive Income [Line Items]
NET REVENUE (Note 24)	$ 12,000,000
GROSS PROFIT	12,000,000
OPERATING EXPENSES
General and administrative expenses	(13,240,218)	$ (9,881,993)	$ (11,825,131)
Research and development expenses	(42,495,379)	(38,000,494)	(22,021,321)
Total operating expenses	(55,735,597)	(47,882,487)	(33,846,452)
LOSS FROM OPERATIONS	(43,735,597)	(47,882,487)	(33,846,452)
NON-OPERATING INCOME AND EXPENSES
Interest income	404,981	354,457	219
Other income (Note 16a)	462,321	386,138	1,108,072
Gain on dilution of subsidiary and recognition of associate			2,307,735
Other gains and losses (Note 16b)	3,121,606	(29,583)	1,106,510
Finance costs (Note 16c)	(4,331,661)	(3,675,689)	(1,860,954)
Total non-operating income and expenses	(342,753)	(2,964,677)	2,661,582
Share in losses of associate company, accounted for using equity method (Note 10)	(8,587)	(436,032)	(405,712)
LOSS BEFORE INCOME TAX (Note 16)	(44,086,937)	(51,283,196)	(31,590,582)
INCOME TAX EXPENSE (Note 17)	(132,667)	(99,221)
NET LOSS FOR THE YEAR	(44,219,604)	(51,382,417)	(31,590,582)
Items that will not be reclassified subsequently to profit or loss:
Unrealized gain on investments in equity instruments at fair value through other comprehensive income	235,567
TOTAL COMPREHENSIVE LOSS FOR THE YEAR	(43,984,037)	(51,382,417)	(31,590,582)
NET LOSS ATTRIBUTABLE TO
Stockholders of the Company	(44,219,604)	(51,382,417)	(31,321,618)
Non-controlling interests			(268,964)
NET LOSS FOR THE YEAR	(44,219,604)	(51,382,417)	(31,590,582)
TOTAL COMPREHENSIVE LOSS ATTRIBUTABLE TO
Stockholders of the Company	(43,984,037)	(51,382,417)	(31,321,618)
Non-controlling interests			(268,964)
TOTAL COMPREHENSIVE LOSS FOR THE YEAR	$ (43,984,037)	$ (51,382,417)	$ (31,590,582)
LOSS PER ORDINARY SHARE (Note 18)
Basic	$ (0.11)	$ (0.15)	$ (0.1)
Diluted	(0.11)	(0.15)	(0.1)
American Depositary Share
LOSS PER ORDINARY SHARE (Note 18)
Basic	(2.69)	(3.68)	(2.4)
Diluted	$ (2.69)	$ (3.68)	$ (2.4)

Consolidated Statements of Chan

Consolidated Statements of Changes in Equity - USD ($)		Total	Ordinary Shares	Capital Surplus	Capital Surplus Ordinary Surplus	Capital Surplus Share Options Reserve	Capital Surplus Equity Instruments	Capital Surplus Other	Accumulated Deficit	Unrealized Valuation (Loss)/Gain on Equity Instrument at Fair Value Through Other Comprehensive Income	Non-controlling Interests
Beginning balance at Dec. 31, 2020		$ (10,152,284)	$ 61,826,237	$ 123,582,460	$ 115,754,741	$ 6,406,791		$ 1,420,928	$ (195,682,714)	$ (178,948)	$ 300,681
Beginning balance, shares at Dec. 31, 2020			209,675,470
Issuance of new share capital		101,555,708	$ 1,167,371	100,388,337	100,388,337
Issuance of new share capital, shares			136,412,540
Transaction costs attributable to the issuance of ordinary shares		(4,576,671)		(4,576,671)	(4,576,671)
Exercise of employee share options (Note 19)		221,710	$ 5,900	215,810	726,976	(511,166)
Exercise of employee share options (Note 19), share			590,000
Recognition of employee share options expense by the Company (Note 19)		2,428,128		2,428,128		2,428,128
Warrants exercised (Note 14d)		825,800	$ 20,454	805,346	805,346
Warrants exercised (Note 14d), shares			2,045,355
Non-controlling interests derecognised due to dilution of subsidiary		(31,717)									(31,717)
Reclassification of capital reserve to profit or loss		(1,376,349)		(1,376,349)				(1,376,349)
Net loss		(31,590,582)							(31,321,618)		(268,964)
TOTAL COMPREHENSIVE LOSS FOR THE YEAR		(31,590,582)							(31,321,618)		$ (268,964)
Ending balance at Dec. 31, 2021		57,303,743	$ 63,019,962	221,467,061	213,098,729	8,323,753		44,579	(227,004,332)	(178,948)
Ending balance, shares at Dec. 31, 2021			348,723,365
Recognition of employee share options expense by the Company (Note 19)		2,443,894		2,443,894		2,443,894
Net loss		(51,382,417)							(51,382,417)
TOTAL COMPREHENSIVE LOSS FOR THE YEAR		(51,382,417)							(51,382,417)
Ending balance at Dec. 31, 2022		8,365,220	$ 63,019,962	223,910,955	213,098,729	10,767,647		44,579	(278,386,749)	(178,948)
Ending balance, shares at Dec. 31, 2022			348,723,365
Issuance of new share capital		7,681,312	$ 912,031	6,769,281	6,769,281
Issuance of new share capital, shares			91,203,115
Issuance of Pre-Funded Warrant (Notes 14 and A)		8,262,698		8,262,698			$ 8,262,698
Issuance of Tranche Warrants (Notes 14 and A)		3,712,402		3,712,402			3,712,402
Expiry of Tranche Warrants (Notes 14 and A)				(1,539,117)			(1,539,117)		1,539,117
Transaction costs attributable to the issuance of ordinary shares	[1]	(93,805)		(93,805)	(93,805)
Recognition of employee share options expense by the Company (Note 19)		2,769,279		2,769,279		2,769,279
Net loss		(44,219,604)							(44,219,604)
Other comprehensive gain, net of income tax		235,567								235,567
TOTAL COMPREHENSIVE LOSS FOR THE YEAR		(43,984,037)							(44,219,604)	235,567
Ending balance at Dec. 31, 2023		$ (13,286,931)	$ 63,931,993	$ 243,791,693	$ 219,774,205	$ 13,536,926	$ 10,435,983	$ 44,579	$ (321,067,236)	$ 56,619
Ending balance, shares at Dec. 31, 2023			439,926,480
[1] A total of $ 23,027,787 net proceeds was raised which comprised of $ 19,994,760 from a private placement (Note 14a) and $ 3,033,027 from an ATM offering (Note 14c) of which an amount of $ 3,465,180 was recorded as financial liabilities measured at fair value through profit or loss as at the inception date relating to Tranche 1B & 2B warrants (Note 14a). Included within the private placement is Tranche 1A Warrant of $ 1,539,897 which lapsed during the year and has been subsequently reclassified from equity instruments to accumulated deficit (Note 14a).

Consolidated Statements of Ch_2

Consolidated Statements of Changes in Equity (Parenthetical)	12 Months Ended
	Dec. 31, 2023 USD ($)
Net Proceeds from offering of shares	$ 23,027,787
Private Placement
Net Proceeds from offering of shares	19,994,760
ATM Offering
Net Proceeds from offering of shares	3,033,027
Tranche 1A Warrants
Reclassification adjustments from equity instruments to accumulated deficit	1,539,897
Tranche 1B & 2B Warrants
Financial liabilities measured at fair value through profit or loss	$ 3,465,180

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
CASH FLOWS FROM OPERATING ACTIVITIES
Loss before income tax	$ (44,086,937)	$ (51,283,196)	$ (31,590,582)
Adjustments for:
Depreciation expenses	344,378	327,632	279,660
Amortization expenses	4,120	4,120	2,564
Net gain on fair value changes of financial assets and liabilities at fair value through profit or loss	(3,466,999)	(133,139)	(488,255)
Finance costs	4,331,661	3,675,689	1,860,954
Interest income	(125,825)	(1,312)	(219)
Interest income from money market fund	(279,156)	(353,145)
Gain on dilution of subsidiary and recognition of associate			(2,307,735)
Share of loss of associates accounted for using equity method	8,587	436,032	405,712
Compensation costs recognized of share-based payment transactions and long-term incentive plan	2,703,200	1,976,760	2,193,367
Gain on disposal of property, plant and equipment	(148)	(1,172)
Unrealized (gain)/loss on foreign exchange, net	198,842	88,866	(230,619)
Gain on lease termination		(14,115)
Interest accretion income on short-term investment, net of management fee		(87,493)
Others		50,109
Changes in operating assets and liabilities
(Increase) Decrease in other assets	1,097,877	(357,724)	(2,490,143)
Increase (Decrease) in trade payables	(4,865,880)	9,667,699	797,228
(Decrease) Increase in other payables	816,241	41,545	(2,157,966)
Decrease in other current labilities			(269,735)
Cash used in operations	(43,320,039)	(35,962,844)	(33,995,769)
Interest received	125,825	1,312	219
Interest paid	(3,318,576)	(2,338,715)
Income tax paid	(126,208)	(105,000)
Net cash used in operating activities	(46,638,998)	(38,405,247)	(33,995,550)
CASH FLOWS FROM INVESTING ACTIVITIES
Payments for property, plant and equipment	(10,781)	(27,111)	(36,448)
Proceeds from disposal of property, plant and equipment	148	1,172
Payments for intangible assets			(12,360)
Decrease in refundable deposits			20,653
Interest income from money market fund	279,156	353,145
Purchase of short-term investments		(16,512,507)
Proceeds from maturities of short-term investments		16,600,000
Net cash (used in) from investing activities	268,523	414,699	(28,155)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from long-term borrowings		5,000,000	20,000,000
Repayment on long-term borrowings	(12,000,000)		(7,784,087)
Repayment of the principal portion of lease liabilities	(296,920)	(262,798)	(353,649)
Repayment of the interest portion of lease liabilities	(10,411)	(12,544)	(21,510)
Proceeds from exercise of employee share options			1,047,510
Proceeds from new shares capital	7,681,312		101,555,708
Issuance of Pre-Funded Warrants and Tranche Warrants classified as equity instruments	11,975,100
Issuance of Tranche Warrants classified as financial liabilities	3,465,180
Payments for transaction costs attributable to the issuance of ordinary shares	(93,805)		(4,576,671)
Net cash from financing activities	10,720,456	4,724,658	109,867,301
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	(35,650,019)	(33,265,890)	75,843,596
CASH AND CASH EQUIVALENTS AT THE BEGINNING OF THE YEAR	56,902,077	90,167,967	14,324,371
CASH AND CASH EQUIVALENTS AT THE END OF THE YEAR	$ 21,252,058	$ 56,902,077	$ 90,167,967

Nature of Operations

Nature of Operations	12 Months Ended
	Dec. 31, 2023
Disclosure Of Nature Of Operations [Abstract]
Nature of Operations	1. NATURE OF OPERATIONS ASLAN Pharmaceuticals Limited (“ASLAN Cayman”) was incorporated in the Cayman Islands in June 2014 and is the listing vehicle for the listing on the Nasdaq Global Market sponsored with its issuance of American Depositary Shares (“ADSs”) in the United States. ASLAN Cayman and its subsidiaries (collectively referred to as the “Company”) is a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients. The Company’s portfolio is led by eblasakimab (also known as ASLAN004), a potential first-in-class human monoclonal antibody that binds to the IL-13 receptor, blocking signaling of two pro-inflammatory cytokines, IL-4 and IL-13 which are central to triggering symptoms of atopic dermatitis, such as redness and itching of the skin. ASLAN Pharmaceuticals Pte. Ltd. was incorporated in Singapore in April 2010 and ASLAN Cayman was incorporated in Cayman Islands in June 2014 as the listing vehicle. The Company’s ADSs have been listed on the Nasdaq Global Market or the Nasdaq Capital Market since May 2018. On September 14, 2022, ASLAN Cayman submitted to the Listing Qualifications Department of Nasdaq an application to transfer the listing of its American Depositary Shares ("ADSs") representing ordinary shares of the Company from the Nasdaq Global Market to the Nasdaq Capital Market. On September 27, 2022, the Company received notice from Nasdaq that its application to transfer listing of its ADSs had been approved. The transfer was effective at the opening of business on September 29, 2022. The Company continues to trade under the symbol "ASLN". The Company has financed its operations to date primarily through the issuance of common shares or ADSs. The Company has incurred net losses since inception. Please refer to Notes 14 and 25(c) for details of the Company’s fund-raising activities.

Approval of Financial Statement

Approval of Financial Statements	12 Months Ended
	Dec. 31, 2023
Disclosure Of Authorization To Issue Financial Statements [Abstract]
Approval of Financial Statements	2. APPROVAL OF FINANCIAL STATEMENTS The consolidated financial statements were approved by the Company’s board of directors on April 12, 2024.

Application of New Amended and

Application of New Amended and Revised Standards and Interpretations	12 Months Ended
	Dec. 31, 2023
Disclosure of initial application of standards or interpretations [abstract]
Application of New Amended and Revised Standards and Interpretations	3. APPLICATION OF NEW, AMENDED AND REVISED STANDARDS AND INTERPRETATIONS a. In the current year, the Company has applied a number of amendments to IFRS Accounting Standards issued (IFRS Accounting Standards) by the International Accounting Standards Board (IASB) that are mandatorily effective for an accounting period that begins on or after January 1, 2023. Their adoption has not had any material impact on the disclosure or on the amounts reported in these financial statements. The application of the Amendments to IAS 1 and IFRS Accounting Standard Practice Statement 2 Disclosure of accounting policies , Amendment to IAS 8 Definition of accounting estimates , IFRS 17 Insurance Contracts and Amendment to IAS 12 Deferred tax related to assets and liabilities arising from a single transaction and International Tax Reform - Pillar Two Model Rules has had no material impact on disclosures or amounts in the Company’s consolidated financial statements. b. New and revised IFRS Accounting Standards issued but not yet effective At the date of authorization of these financial statements, the Company has not applied the following new and revised IFRS Accounting Standards that have been issued but are not yet effective: New IFRS Accounting Standards Description IFRS 10 and IAS 28 (amendments) Sale or Contribution of Assets between an Investor and its Associate or Joint Venture Amendments to IAS 1 Classification of Liabilities as Current or Non-current Amendments to IAS 1 Non-current Liabilities with Covenants Amendments to IAS 7 and IFRS 7 Supplier Finance Agreement Amendments to IAS 21 Lack of Exchangeability Amendments to IFRS 16 Lease Liability in a Sale and Leaseback The Company anticipates that the application of these amendments may have an impact on the consolidated financial statements in future periods and is in the process of assessing the potential impact of these amendments.

Summary of Material Accounting

Summary of Material Accounting Policies	12 Months Ended
	Dec. 31, 2023
Disclosure Of Significant Accounting Policies [Abstract]
Summary of Material Accounting Policies	4. SUMMARY OF MATERIAL ACCOUNTING POLICIES a. Statement of compliance The material accounting policies applied in the preparation of these consolidated financial statements are set out below. These policies have been consistently applied to all the periods presented, unless otherwise stated. The accompanying consolidated financial statements have been prepared in conformity with IFRS Accounting Standards issued by the IASB. b. Basis of preparation The consolidated financial statements have been prepared on the historical cost basis except for financial instruments and long-term incentive plan payable arising from cash-settled share-based payment arrangements which are measured at fair value. c. Going concern Through December 31, 2023, the Company has an accumulated deficit of $ 321 million arising from recurring losses from operations and negative cash flows from operating activities. The Company’s activities have been funded primarily through public and private offerings. As the Company is in the clinical research and development phase, it will be seeking future funding based on the requirements of our business operations. The Company intends to continue to explore various means of fundraising to meet our funding requirements to carry out our business operations, such as offerings of ADSs via its at the market offering sales agreement, follow-on offerings of ADSs, venture debt and shareholder loans. It may also use other means of financing such as out-licensing, which is subject to negotiation, to generate revenue and cash. The Company has the ability to exercise discretion and flexibility to deploy our capital resources used in research and development activities according to the amount and timing of the financing activities. In March 2024, the Company raised additional funds of $ 5.0 million in gross proceeds pursuant to the Securities Purchase Agreement. See Note 25 c) for details. The Company will incur additional losses as it continues to focus its resources on advancing the development of its therapeutic candidates that will result in negative cash flows from operating activities. The Company’s current cash resources are not sufficient to complete the research and development activities of all of its therapeutic candidates in the absence of any additional funding. Management believes that there is presently insufficient funding available to allow the Company to fund its activities for a period exceeding one year and meet its obligations as they become due within one year from the date of this filing. In the absence of additional funding, these conditions and events indicate that there is substantial doubt about the Company’s ability to continue as a going concern. The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. d. Basis of consolidation The consolidated financial statements include the financial statements of ASLAN Cayman and entities controlled by ASLAN Cayman (its subsidiaries). The consolidated financial statements incorporate the financial statements of ASLAN Cayman and entities controlled by ASLAN Cayman (its subsidiaries) made up to December 31 each year. Control is achieved when the Company: • Has the power over the investee; • Is exposed, or has rights, to variable returns from its involvement with the investee; and • Has the ability to use its power to affects its returns. The Company reassesses whether or not it controls an investee if facts and circumstances indicate that there are changes to one or more of the three elements of control listed above. When the Company has less than a majority of the voting rights of an investee, it considers that it has power over the investee when the voting rights are sufficient to give it the practical ability to direct the relevant activities of the investee unilaterally. The Company considers all relevant facts and circumstances in assessing whether or not the Company’s voting rights in an investee are sufficient to give it power, including: • The size of the Company’s holding of voting rights relative to the size and dispersion of holdings of the other vote holders; • Potential voting rights held by the Company, other vote holders or other parties; • Rights arising from other contractual arrangements; and • Any additional facts and circumstances that indicate that the Company has, or does not have, the current ability to direct the relevant activities at the time that decisions need to be made, including voting patterns at previous shareholders’ meetings. Consolidation of a subsidiary begins when the Company obtains control over the subsidiary and ceases when the Company loses control of the subsidiary. Specifically, the results of subsidiaries acquired or disposed of during the year are included in profit or loss from the date the Company gains control until the date when the Company ceases to control the subsidiary. When necessary, adjustments are made to the financial statements of subsidiaries to bring their accounting policies into line with those used by the Company. All intragroup assets and liabilities, equity, income, expenses and cash flows relating to transactions between the members of the Company are eliminated on consolidation. Non-controlling interests in subsidiaries are identified separately from the Company’s equity therein. Those interests of non-controlling shareholders that are present ownership interests entitling their holders to a proportionate share of net assets upon liquidation may initially be measured at fair value or at the non-controlling interests’ proportionate share of the fair value of the acquiree’s identifiable net assets. The choice of measurement is made on an acquisition-by-acquisition basis. Other non-controlling interests are initially measured at fair value. Subsequent to acquisition, the carrying amount of non-controlling interests is the amount of those interests at initial recognition plus the non-controlling interests’ share of subsequent changes in equity. Profit or loss and each component of other comprehensive income are attributed to the stockholders of the Company and to the non-controlling interests. Total comprehensive income of the subsidiaries is attributed to the stockholders of the Company and to the non-controlling interests even if this results in the non-controlling interests having a deficit balance. Changes in the Company’s ownership interests in subsidiaries that do not result in the Company losing control over the subsidiaries are accounted for as equity transactions. The carrying amounts of the interests of the Company and the non-controlling interests are adjusted to reflect the changes in their relative interests in the subsidiaries. Any difference between the amount by which the non-controlling interests are adjusted and the fair value of the consideration paid or received is recognized directly in equity and attributed to stockholders of the Company. When the Company loses control of a subsidiary, the gain or loss on disposal recognized in profit or loss is calculated as the difference between (i) the aggregate of the fair value of the consideration received and the fair value of any retained interest and (ii) the previous carrying amount of the assets (including goodwill), less liabilities of the subsidiary and any non-controlling interests. All amounts previously recognized in other comprehensive income in relation to that subsidiary are accounted for as if the Company had directly disposed of the related assets or liabilities of the subsidiary (i.e. reclassified to profit or loss or transferred to another category of equity as required/permitted by applicable IFRS Accounting Standards). The fair value of any investment retained in the former subsidiary at the date when control is lost is regarded as the fair value on initial recognition for subsequent accounting under IFRS 9 when applicable, or the cost on initial recognition of an investment in an associate or a joint venture. Associates An associate is an entity over which the Company has significant influence and that is neither a subsidiary nor an interest in a joint venture. Significant influence is the power to participate in the financial and operating policy decisions of the investee but is not control or joint control over those policies. The results and assets and liabilities of associates are incorporated in these financial statements using the equity method of accounting, except when the investment is classified as held for sale, in which case it is accounted for in accordance with IFRS 5 “Non-current Assets Held for Sale and Discontinued Operations”. Under the equity method, an investment in an associate is initially recognized in the consolidated balance sheet at cost and adjusted thereafter to recognize the Company’s share of the profit or loss and other comprehensive income of the associate. When the Company’s share of losses of an associate exceeds the Company’s interest in that associate (which includes any long-term interests that, in substance, form part of the Company’s net investment in the associate), the Company discontinues recognizing its share of further losses. Additional losses are recognized only to the extent that the Company has incurred legal or constructive obligations or made payments on behalf of the associate. An investment in an associate is accounted for using the equity method from the date on which the investee becomes an associate. On acquisition of the investment in an associate, any excess of the cost of the investment over the Company’s share of the net fair value of the identifiable assets and liabilities of the investee is recognized as goodwill, which is included within the carrying amount of the investment. Any excess of the Company’s share of the net fair value of the identifiable assets and liabilities over the cost of the investment, after reassessment, is recognized immediately in profit or loss in the period in which the investment is acquired. The requirements of IAS 36 Impairment of Assets are applied to determine whether it is necessary to recognize any impairment loss with respect to the Company’s investment in an associate. When necessary, the entire carrying amount of the investment (including goodwill) is tested for impairment in accordance with IAS 36 as a single asset by comparing its recoverable amount (higher of value in use and fair value less costs of disposal) with its carrying amount, any impairment loss recognized forms part of the carrying amount of the investment. Any reversal of that impairment loss is recognized in accordance with IAS 36 to the extent that the recoverable amount of the investment subsequently increases. e. Foreign currencies Both the functional currency and presentation currency of the Company is the U.S. dollar. Monetary assets and liabilities denominated in currencies other than the applicable functional currencies are translated into the functional currencies at the prevailing rates of exchange at the end of the reporting period. Nonmonetary assets and liabilities are remeasured into the applicable functional currencies at historical exchange rates. Transactions in currencies other than the applicable functional currencies during the year are converted into the functional currencies at the applicable rates of exchange prevailing at the dates of the transactions. Exchange differences are recognized in “other gains and losses, net” in the consolidated statement of comprehensive loss. f. Impairment of tangible and intangible assets At the end of each reporting period, the Company reviews the carrying amounts of its tangible and intangible assets in order to determine whether there is any indication that those assets have suffered any impairment loss. If any such indication exists, the recoverable amount of an asset is estimated in order to determine the extent of the impairment loss. When it is not possible to estimate the recoverable amount of an individual asset, the Company estimates the recoverable amount of the cash-generating unit to which the asset belongs. Intangible assets with indefinite useful lives and intangible assets not yet available are not subject to amortization but are tested annually for impairment or more frequently if there are indicators of impairment. In respect of the impairment indicators, the Company considers both internal and external sources of information to determine whether an asset may be impaired, which may include the significant underperformance of the business in relation to expectations, significant negative industry or economic trends, and significant changes or planned changes with adverse effects in the use of the assets, as well as the internal reporting which indicates the economic performance of an asset is worse than expected. If any such indicators exist, the Company will estimate the recoverable amount of such indefinite-lived intangible asset and compare it with its carrying amount. The recoverable amount is the higher of fair value less costs of disposal and value in use. If the recoverable amount of an asset or cash-generating unit is estimated to be less than its carrying amount, the carrying amount of the asset or cash-generating unit is reduced to its recoverable amount, with the resulting impairment loss recognized in profit or loss. When an impairment loss is subsequently reversed, the carrying amount of the corresponding asset or cash-generating unit is increased to the revised estimate of its recoverable amount, but only to the extent of the carrying amount that would have been determined had no impairment loss been recognized on the asset or cash-generating unit in prior years. A reversal of an impairment loss is recognized in profit or loss. g. Research and development expenses Elements of research and development expenses primarily include: 1) Payroll and other related costs of personnel engaged in research and development activities; 2) Costs related to preclinical testing of the Company’s technologies under development and clinical trials, such as payments to contract research organizations (“CROs”), investigators and clinical trial sites that conduct the Company’s clinical studies; 3) Costs to develop the product candidates, including raw materials, supplies and product testing related expenses; and 4) Other research and development expenses. Research and development expenses are expensed as incurred when these expenditures relate to the Company’s research and development services and have no alternative future uses. The conditions enabling the capitalization of development costs as an asset have not yet been met and, therefore, all development expenditures are recognized in profit or loss when incurred. h. Financial instruments Financial assets and financial liabilities are recognized when a Company becomes a party to the contractual provisions of the instruments. Financial assets and financial liabilities are initially measured at fair value. Transaction costs that are directly attributable to the acquisition or issuance of financial assets and financial liabilities (other than financial assets and financial liabilities at fair value through profit or loss (i.e., FVTPL)) are added to or deducted from the fair value of the financial assets or financial liabilities, as appropriate, on initial recognition. Transaction costs directly attributable to the acquisition of financial assets or financial liabilities at FVTPL are recognized immediately in profit or loss. 1) Financial asset All regular way purchases or sales of financial assets are recognized and derecognized on a trade date basis. a) Measurement categories Financial assets are classified into the following categories: Financial assets at FVTPL, financial assets at amortized cost and equity instruments at fair value through other comprehensive income (i.e., FVOCI). i. Financial assets at FVTPL Money market funds are classified as FVTPL as they do not meet the conditions to be classified as amortized cost or FVOCI. Financial assets at FVTPL are subsequently measured at fair value, with any gains or losses arising on remeasurement recognized in other gains or losses. ii. Financial assets at amortized cost A financial asset shall be measured at amortized cost if both of the following conditions are met: i) The financial asset is held within a business model whose objective is to hold financial assets in order to collect contractual cash flows; and ii) The contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding. For the financial assets measured at amortized cost (including cash and cash equivalents and refundable deposits), the Company applies the effective interest method to the gross carrying amount at amortized cost less any impairment from initial recognition. Any foreign exchange gains and losses are recognized in profit or loss. Interest income is calculated by applying the effective interest rate to the gross carrying amount of such a financial asset. Short-term investments have been purchased during the year and have matured before the end of the year. These have been assessed to be financial assets held at amortized cost. Interest accretion income on short-term investment is recognized in profit or loss and as part of "Other Income" line item. Cash equivalents include time deposits and money markets funds, which are highly liquid, readily convertible to a known amount of cash and are subject to an insignificant risk of changes in value. These cash equivalents are held for the purpose of meeting short-term cash commitments. iii. Investments in equity instruments at FVOCI On initial recognition, the Company may make an irrevocable election to designate investments in equity instruments as at FVOCI. Designation as at FVOCI is not permitted if the equity investment is held for trading or if it is contingent consideration recognized by an acquirer in a business combination. Investments in equity instruments at FVOCI are subsequently measured at fair value with gains and losses arising from changes in fair value recognized in other comprehensive income and accumulated in other equity. The cumulative gain or loss will not be reclassified to profit or loss on disposal of the equity investments; instead, it will be transferred to retained earnings. Dividends on these investments in equity instruments are recognized in profit or loss when the Company’s right to receive the dividends is established, unless the dividends clearly represent a recovery of part of the cost of the investment. Fair value hierarchy levels 1 to 3 are based on the degree to which the fair value is observable: • Level 1 fair value measurements are those derived from quoted prices (unadjusted) in active markets for identical assets or liabilities; • Level 2 fair value measurements are those derived from inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly (i.e. as prices) or indirectly (i.e. derived from prices); and • Level 3 fair value measurements are those derived from valuation techniques that include inputs for the asset or liability that are not based on observable market data (unobservable inputs). b) Impairment of financial assets The Company recognizes a loss allowance for expected credit losses on financial assets at amortized cost. For financial instruments, the Company recognizes lifetime expected credit losses (i.e., ECLs) when there has been a significant increase in credit risk since initial recognition. If, on the other hand, the credit risk on a financial instrument has not increased significantly since initial recognition, the Company measures the loss allowance for that financial instrument at an amount equal to 12-month ECLs. Expected credit losses reflect the weighted average of credit losses with the respective risks of default occurring as the weights. Lifetime ECLs represent the expected credit losses that will result from all possible default events over the expected life of a financial instrument. In contrast, 12-month ECLs represent the portion of lifetime ECLs that is expected to result from default events on a financial instrument that are possible within 12 months after the reporting date. The Company recognizes an impairment gain or loss in profit or loss for all financial instruments with a corresponding adjustment to their carrying amount through a loss allowance account. c) Derecognition of financial assets The Company derecognizes a financial asset only when the contractual rights to the cash flows from the asset expire or when it transfers the financial asset and substantially all the risks and rewards of ownership of the asset to another party. On derecognition of a financial asset at amortized cost in its entirety, the difference between the asset’s carrying amount and the sum of the consideration received and receivable is recognized in profit or loss. On derecognition of an investment in an equity instrument at FVOCI, the cumulative gain or loss previously accumulated in the investments revaluation reserve is reclassified to profit or loss. In contrast, on derecognition of an investment in an equity instrument which the group has elected on initial recognition to measure at FVOCI, the cumulative gain or loss previously accumulated in the investments revaluation reserve is not reclassified to profit or loss, but is transferred to retained earnings. 2) Equity instruments Debt and equity instruments issued by the Company entity are classified as either financial liabilities or as equity in accordance with the substance of the contractual arrangements and the definitions of a financial liability and an equity instrument. Equity instruments issued by the Company entity are recognized at the proceeds received, net of direct issue costs. Expired equity instruments will be reclassified to accumulated deficit. No gain or loss is recognized in profit or loss on the issuance of the Company’s own equity instruments. 3) Financial liabilities a) Subsequent measurement Except the following situations, all financial liabilities are measured at amortized cost using the effective interest method: 1) Financial liabilities at FVTPL Financial liabilities are classified as at FVTPL when such financial liabilities are either held for trading or are designated as at FVTPL. Financial liabilities held for trading are stated at fair value, and any gains or losses on such financial liabilities are recognized in other gains or losses. Fair value is determined in the manner described in Note 22. b) Derecognition of financial liabilities The difference between the carrying amount of a financial liability derecognized and the consideration paid and payable, including any non-cash assets transferred or liabilities assumed, is recognized in profit or loss. When the Company exchanges with the existing lender one debt instrument into another one with substantially different terms, such exchange is accounted for as an extinguishment of the original financial liability and the recognition of a new financial liability. Similarly, the Company accounts for substantial modification of terms of an existing liability or part of it as an extinguishment of the original financial liability and the recognition of a new liability. It is assumed that the terms are substantially different if the discounted present value of the cash flows under the new terms, including any fees paid net of any fees received and discounted using the original effective rate is at least 10 per cent different from the discounted present value of the remaining cash flows of the original financial liability. If the modification is not substantial, the difference between: (1) the carrying amount of the liability before the modification; and (2) the present value of the cash flows after modification is recognized in profit or loss as the modification gain or loss within other gains and losses. 4) Compound instruments The component parts of compound instruments issued by the Company are classified separately as financial liabilities and equity in accordance with the substance of the contractual arrangements and the definitions of a financial liability and an equity instrument. A component part that will be settled by the exchange of a fixed amount of cash or another financial asset for a fixed number of the Company’s own equity instruments is an equity instrument. At the date of issue, the fair value of the liability component is estimated using the prevailing market interest rate for similar non-convertible instruments. This amount is recorded as a liability on an amortized cost basis using the effective interest method until extinguished upon conversion or upon the instrument’s maturity date. 5) Derivative financial instruments Derivatives embedded in non-derivative host contracts that are not financial assets that is within the scope of IFRS 9 (e.g. financial liabilities) are treated as separate derivatives when they meet the definition of a derivative; their risks and characteristics are not closely related to those of the host contracts; and the host contracts are not measured at FVTPL. The derivatives are measured at FVTPL (Notes 13(b) and 14(a)). i. Share-based payment arrangements Equity-settled share-based payments to employees are measured at the fair value of the equity instruments at the grant date. The fair value determined at the grant date of the employee share options is expensed on a straight-line basis over the vesting period, based on the Company’s estimate of the number of employee share options that will eventually vest, with a corresponding increase in “capital surplus - share options reserve”. The fair value determined at the grant date of the employee share options is recognized as an expense in full at the grant date when the share options granted vest immediately. At the end of each reporting period, the Company revises its estimate of the number of employee share options expected to vest. The impact of the revision of the original estimates is recognized in profit or loss such that the cumulative expense reflects the revised estimate, with a corresponding adjustment to the capital surplus. The LTIPs qualify as cash-settled share-based payment transactions. For cash-settled share-based payments, the fair value of the amount payable to beneficiaries in respect of bonus entitlement unit grants, which are settled in cash, is recognized as an expense with a corresponding increase in liabilities, over the period during which the beneficiaries become unconditionally entitled to payment. The amount is remeasured at each reporting date and at settlement based on the fair value of the bonus entitlement units. Any changes in the liability are recognized in profit or loss. Modification of the terms on which equity instruments were granted may have an effect on the expense that will be recorded. In accordance with IFRS 2, modifications also apply to instruments modified after their vesting date. If the fair value of the new instruments is more than the fair value of the old instruments (e.g., by reduction of the exercise price or issuance of additional instruments), the incremental amount is recognized over the remaining vesting period in a manner similar to the original amount. If the modification occurs after the vesting period, the incremental amount is recognized immediately. If the fair value of the new instruments is less than the fair value of the old instruments, the original fair value of the equity instruments granted is expensed as if the modification never occurred. j. Taxation The provision for income tax recognized in profit or loss comprises current and deferred tax. Current tax is income tax paid and payable for the current year based on the taxable profit of the year and any adjustments to tax payable (or receivable) in respect of prior years. Deferred tax is accounted for using the balance sheet liability method in respect of temporary differences arising from differences between the carrying amount of assets and liabilities in the financial statements and the corresponding tax basis used in the computation of taxable profit or loss. Deferred tax assets are recognized to the extent that it is probable that future taxable profits will be available against which the temporary differences can be utilized. The carrying amount is reviewed at the end of each reporting period on the same basis. Deferred tax is measured at the tax rates that are expected to apply in the period in which the asset or liability is settled, based on tax rates that have been enacted or substantively enacted by the end of the reporting period. k. Revenue recognition Revenue comprises the fair value of the consideration received or receivable for the out-licensing of experimental drugs that have reached ‘proof of concept’ to business partners for ongoing global development and launch, in the ordinary course of the Company’s activities. Revenue is presented, net of goods and services tax, rebates and discounts. See Note 15 for details of the Company’s licensing agreements. The Company recognizes revenue when it has completed the out-licensing of the experimental drug to business partners, and such partners have accepted the products. Thus, the collectability of the related receivables is reasonably assured. Typically the consideration received from out-licensing may take the form of upfront payments, option payments, milestone payments, and royalty payments on licensed products. To determine revenue recognition for contracts with customers, the Company performs the following five steps: 1) Identify the contract with a customer; 2) Identify the performance obligations in the contract; 3) Determine the transaction price; 4) Allocate the transaction price to the performance obligations in the contract; and 5) Recognize revenue when (or as) the Company satisfies the performance obligations. At the inception of a contract, the Company assesses the goods or services promised within each contract to determine whether each promised good or service is distinct and identify those that are performance obligations. The Company recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. Upfront License Fees If a license to the Company’s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company will recognize revenues from non-refundable, upfront fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other distinct performance obligations, the Company uses judgment to assess the nature of the combined performance obligation to determine whether it is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress at the end of each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. Milestone Payments At the inception of each contract with customers that includes development or regulatory milestone payments (i.e., the variable consideration), the Company includes some or all amount of variable consideration in the transaction price estimated only to the extent that it is highly probable that a significant reversal in the amount of cumulative revenue recognized would not occur when the uncertainty related to the variable consideration is subsequently resolved. Milestone payments that are contingent upon the achievement of events that are uncertain or not controllable, such as regulatory approvals, are generally not considered highly probable of being achieved until those approvals are received. Therefore, they are not included in the transaction price. At the end of each reporting period, the Company evaluates the probability of achievement of such milestone payments and any related constraints and, if necessary, adjusts the Company’s estimate of the overall transaction price. Royalties For arrangements that include sales-based royalties, including commercial milestone payments based on the level of sales, and for which the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of the following: 1) When the subsequent sales occur, or 2) When the

Critical Accounting Judgments a

Critical Accounting Judgments and Key Sources of Estimation Uncertainty	12 Months Ended
	Dec. 31, 2023
Disclosure Of Accounting Judgements And Estimates [Abstract]
Critical Accounting Judgments and Key Sources of Estimation Uncertainty	5. CRITICAL ACCOUNTING JUDGMENTS AND KEY SOURCES OF ESTIMATION UNCERTAINTY In applying the Company’s accounting policies, which are described in Note 4, the directors are required to make judgements (other than those involving estimations) that have a significant impact on the amounts recognized and to make estimates and assumptions about the carrying amounts of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates. The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimate is revised if the revision affects only that period, or in the period of the revision and future periods if the revision affects both current and future periods. Critical judgements and estimation in applying the Company’s accounting policies Key Sources of Estimation Uncertainty The below are the critical estimation, that the management have made in the process of applying the Company’s accounting policies and that have the most significant effect on the amounts recognized in financial statements. Fair value measurements and valuation processes Some of the Company’s assets and liabilities are measured at fair value for financial reporting purposes. The Head of Finance is responsible to determine the appropriate valuation techniques and inputs for fair value measurements. In estimating the fair value of an asset or a liability, the Company uses market-observable data to the extent it is available. Where Level 1 inputs are not available, the Company engages third party qualified valuers to assist in performing the valuation. The senior management team reports to the board of directors of the Company quarterly to explain the cause of fluctuations in the fair value of the assets and liabilities. The valuations of the Company’s assets and liabilities that are measured at fair value are sensitive to changes in one or more unobservable inputs which are considered reasonably possible within the next financial year. Further information on the carrying amounts of these assets and the sensitivity of those amounts to changes in significant unobservable inputs are provided in Note 22. Critical judgements in applying the Company’s accounting policies The following are the critical judgements, apart from those involving estimations (which are presented separately above), that the management have made in the process of applying the Company’s accounting policies and that have the most significant effect on the amounts recognized in financial statements. Zenyaku agreement (Note 15) On June 22, 2023, the Company entered into a collaborative, development and commercialization agreement (the “Zenyaku Agreement”) with Zenyaku Kogyo Co., Ltd (“Zenyaku”), which the Company granted Zenyaku the exclusive rights to develop and commercialize eblasakimab in Japan for which a payment of $ 12 million was received. Under the terms of the Zenyaku Agreement, the Company will have an option right to buy back the license granted to Zenyaku. The Company has reviewed the buy-back option and determined that costs to buy-back the rights is not currently executable as there is insufficient cash and it will require either a third party global partner or an acquisition by a third party, both of which are not within our control. Accordingly, the contract is accounted for under IFRS 15. Please see note 15 for details of the Company’s material licensing agreements.

Cash and Cash Equivalents

Cash and Cash Equivalents	12 Months Ended
	Dec. 31, 2023
Cash and cash equivalents [abstract]
Cash and Cash Equivalents	6. CASH AND CASH EQUIVALENTS December 31, December 31, 2022 2023 Cash in hand $ 256 $ 648 Cash in banks 26,456,482 21,251,410 Money market fund 30,445,339 — $ 56,902,077 $ 21,252,058 Cash and cash equivalents consist of cash, short-term deposits and money market fund in prior year. In February 2022, the Company engaged an asset management bank to obtain better returns on the Company’s cash pursuant to Company’s Investment Policy which is designed to permit the Company to earn an attractive rate and return on its investments while limiting the risk, conserve capital and maintain liquidity. On March 29, 2023, the Company gave notice of termination with the asset management bank and transferred all the money market fund to cash in banks. Subsequently, this money market fund has been liquidated on November 22, 2023. The Company classified all highly liquid investments with stated maturities of three months or less from date of purchase as cash equivalents as they were subject to an insignificant risk of changes in value. The money market fund was highly liquid and invested in quality short-term money market instruments and was readily convertible to a known amount of cash that was subject to an insignificant risk of change. The Company discloses gains arising from such investments as cash flows arising from investing activities in the cash flow statement consistently.

Other Assets

Other Assets	12 Months Ended
	Dec. 31, 2023
Other Assets Current And Non Current [Abstract]
Other Assets	7. OTHER ASSETS December 31, December 31, 2022 2023 Other receivable $ — $ 171,441 Prepayments $ 2,942,936 $ 1,681,465 Refundable deposits 1,033,414 1,025,028 $ 3,976,350 $ 2,877,934 The prepayments are the advanced funds paid to the Company’s contract research organizations (“CROs”) for commencement of the Company’s clinical trials and related preparation work. The refundable deposits are the receivables due from the Company’s CRO upon the project completion and office deposits refundable in normal course of business. All refundable deposits are current as of December 31, 2022, and 2023.

Financial Instruments at Fair V

Financial Instruments at Fair Value Through Profit or Loss	12 Months Ended
	Dec. 31, 2023
Financial assets at fair value through profit or loss [abstract]
Financial Instruments at Fair Value Through Profit or Loss	8. FINANCIAL INSTRUMENTS AT FAIR VALUE THROUGH PROFIT OR LOSS December 31, December 31, 2022 2023 Financial liabilities at fair value through profit or loss (FVTPL) Derivative financial liabilities – K2HV warrants $ 90,213 $ 87,693 Derivative financial liabilities – Tranche 2B warrants — 701 $ 90,213 $ 88,394

Financial Instruments at Fair_2

Financial Instruments at Fair Value Through Other Comprehensive Income	12 Months Ended
	Dec. 31, 2023
Disclosure of fair value of investments in equity instruments designated at fair value through other comprehensive income [abstract]
Financial Instruments at Fair Value Through Other Comprehensive Income	9. FINANCIAL INSTRUMENTS AT FAIR VALUE THROUGH OTHER COMPREHENSIVE INCOME December 31, December 31, 2022 2023 Financial asset at fair value through other comprehensive income (FVOCI) Investment in equity instruments at FVOCI - Foreign unlisted ordinary shares $ — $ 235,567 In July 2018, the Company acquired ordinary shares of DotBio Pte. Ltd., which were not held for trading. The management believes that to recognize short-term fluctuations in the investments’ fair value in profit or loss would not be consistent with the Company’s purpose of holding the investments. As a result, the Company elected to designate the investments in equity instruments as at FVOCI.

Subsidiaries

Subsidiaries	12 Months Ended
	Dec. 31, 2023
Disclosure of subsidiaries [abstract]
Subsidiaries	10. SUBSIDIARIES Proportion of December 31 Investor Investee Nature of Activities 2022 2023 Subsidiaries ASLAN ASLAN New drug research 100 % 100 % ASLAN ASLAN New drug research 100 % 100 % ASLAN ASLAN New drug research 100 % 100 % ASLAN ASLAN New drug research 100 % 100 % ASLAN ASLAN New drug research 100 % 100 %

Investment in Associate Company

Investment in Associate Company	12 Months Ended
	Dec. 31, 2023
Disclosure of associates [abstract]
Investment in Associate Company	11. INVESTMENT IN ASSOCIATE COMPANY As of December 31, 2022, and 2023 the Company's 35 % equity holding in Jaguahr Therapeutics Pte. Ltd. was an investment in an associate company and is accounted for using the equity method in the consolidated financial statements. Summarized financial information of Jaguahr Therapeutics Pte. Ltd. is set out below. The summarized financial information below represents amounts in associate company financial statements prepared in accordance with IFRS Accounting Standards. December 31 December 31 2022 2023 Current asset $ 54,906 $ 192,641 Current liabilities ( 30,371 ) ( 543,278 ) Equity/(Capital deficiency) $ 24,535 $ ( 350,637 ) JAGUAHR's loss for the years ended December 31, 2022 and 2023 were $ 1,245,805 and $ 375,171 and net cash (outflow)/inflow from operating activities were ($ 1,329,339 ) and $ 137,735 respectively. The Company share in losses of associate amount to $ 486,141 and $ 8,587 for the years ended December 31, 2022 and December 31, 2023, and the balance of investment in associate company were $ 8,587 and $ 0 as of December 31, 2022 and December 31, 2023, respectively.

Trade And Other Payables

Trade And Other Payables	12 Months Ended
	Dec. 31, 2023
Trade and other payables [abstract]
Trade and Other Payables	12. TRADE AND OTHER PAYABLES Trade payables Trade payables are the amounts billed to the Company by the vendors and suppliers for goods delivered to or services consumed by the Company in the ordinary course of business. As of December 31, 2022, and December 31, 2023, the carrying amounts of those trade payables were $ 12,784,485 and $ 7,918,607 , respectively and repayable on demand or within the normal credit terms. Other payables December 31, December 31, 2022 2023 Payables for cash-settled long-term incentive plan (Note 19) $ 234,448 $ 46,699 Payables for salaries and bonuses 1,375,627 1,748,901 Payables for professional fees 560,578 1,098,536 Others 154,385 187,193 Total other payables $ 2,325,038 $ 3,081,329 Maturity analysis: On demand or within 1 year $ 2,325,038 $ 3,081,329

Borrowings

Borrowings	12 Months Ended
	Dec. 31, 2023
Borrowings [abstract]
Borrowings	13. BORROWINGS December 31, December 31, 2022 2023 Unsecured borrowings at amortized cost Loans from government (a) $ 11,855,579 $ 12,496,831 Secured borrowings at amortized cost Other long-term borrowings (b) $ 25,549,385 $ 14,102,108 Total borrowings $ 37,404,964 $ 26,598,939 Analyzed as: Current and repayable on demand or within 1 year $ 7,748,831 $ 1,800,387 Non-current and repayable more than 1 year $ 29,656,133 $ 24,798,552 Total borrowings $ 37,404,964 $ 26,598,939 a. Loans from government (unsecured) On April 27, 2011, the Singapore Economic Development Board (EDB) awarded the Company a repayable grant (the “Grant”) not exceeding SGD 10 million (equivalent to $ 7,390,655 and $ 7,509,524 as at December 31, 2022 and 2023 respectively) to support the Company’s drug development activities over a five-year qualifying period commencing February 24, 2011 (the “Project”). The Project was successfully implemented, resulting in substantially the full amount of the Grant being disbursed to the Company. In the event any of the Company’s clinical product candidates achieve commercial approval after Phase 3 clinical trials and accompanied by a positive cash flow situation, the Company will be required to repay the funds disbursed to the Company under the Grant plus interest of 6 %. As at December 31, 2023 none of its clinical product candidates have commenced Phase 3. As of December 31, 2022, and December 31, 2023, the amounts of funds disbursed to the Company plus accrued interest were $ 11,855,579 and $ 12,496,831 , respectively. b. Other long-term borrowings (secured) Loan and Security Agreement with K2 HealthVentures On July 12, 2021, ASLAN Cayman and ASLAN Pharmaceuticals (USA) Inc. as borrowers entered into a Loan, Guaranty, and Security Agreement (the K2HV Loan Agreement) with K2 HealthVentures LLC (K2HV) as administrative agent, and Ankura Trust Company, LLC as collateral agent, pursuant to which K2HV agreed to provide a four -year facility for up to $ 45 million (the K2HV Facility). The K2HV Facility consists of a $ 20 million initial term loan funded at closing, with the remaining $ 25 million available in tranches subject to certain terms and conditions. Due to the K2 Warrant described below, the fair value of the first tranche loan on July 12, 2021, was $ 19,311,676 . The term loans bear interest at a floating rate equal to the greater of (i) the prime rate published by Wall Street Journal plus 5.00% or (ii) 8.25 % per annum, payable monthly. The Company paid the lenders a one-time $ 255,000 facility fee at closing and will be obligated to pay for an additional facility fee equal to 0.85 % of any term loans borrowed under the fourth tranche. In addition, the Company is obligated to pay a final payment fee of 6.25 % of the original principal amount of the term loans at the maturity date. The Company may elect to prepay all, but not less than all, of the term loans prior to the term loan maturity date, subject to a prepayment fee of up to 3.0 % of the then outstanding principal balance. After repayment, no term loans may be borrowed again. Borrowings under the K2HV Facility are secured with a pledge of the borrowers’ equity interests in subsidiaries and collateral over all of the Company’s cash, goods and other personal property, with the exception of (i) under the K2HV Loan Agreement prior to amendment, the Company’s own intellectual property assets, (ii) personal property to the extent that granting of security over any such personal property would constitute a breach of or result in the termination of, or require any consent not obtained under, any license, agreement, instrument or other document evidencing or giving rise to such property, or is otherwise prohibited by any requirement of law, and (iii) the Company’s equity interests in Jaguahr Therapeutics Pte. Ltd. Such pledge and collateral may be enforced only if there has been an event of default as stipulated in the K2HV Loan Agreement. In connection with the closing of the K2HV Facility, the Company issued a warrant to purchase ordinary shares (the K2 Warrant) to K2HV. The number of ordinary shares exercisable under the K2 Warrant equals (i) 2.95 % of the aggregate term loan advances made to the Company from time to time divided by (ii) the warrant price of $ 0.5257 per ordinary share (an equivalent to $ 13.1425 per ADS). The K2 Warrant is exercisable until its expiration on July 12, 2031 . The total proceeds attributed to the K2 Warrant was approximately $ 688,324 based on the relative fair value as of the date of the drawdown. As the number of ADS to be issued under the cashless method will continue to vary dependent on the share price of the Company, the K2 Warrants do not meet the equity classification and are classified as financial liabilities at fair value through profit or loss. In January 2022, the conditions to the second tranche having been satisfied, the Company drew down the second tranche of $ 5 million in full and the funds were received in February 2022. As a result of the drawdown of the second tranche, the number of ordinary shares exercisable under the K2 Warrant increased to 1,402,891 (an equivalent of 56,116 ADS), based on the 2.95 % coverage of the total drawdown facility $ 25 million, being the aggregate term loan advances at that date, divided by the warrant price of $ 0.5257 per ordinary share (an equivalent to $ 13.1425 per ADS). On June 30, 2023, the Company entered into a First Amendment to the K2HV Loan Agreement (Loan Amendment) with K2HV to, among other things, extend the interest-only period under the K2HV Facility to November 1, 2023, February 1, 2024 or August 1, 2024, dependent on the Company’s achievement of certain milestones. On the same day the K2 warrant price was reduced to $ 0.1447 per ordinary shares (an equivalent of $ 3.6175 per ADS). As a result of the warrant price reduction, the number of ADS exercisable under the K2 warrants increased to 203,870 ADS (an equivalent of 5,096,752 ordinary shares). On December 6, 2023, the Company entered into an amendment (Second Amendment) of K2HV Loan Agreement pursuant to which K2HV agreed to extend the period under the K2HV Facility in which the Company is not required to make payments with respect to the outstanding principal amount (during which period interest payments continue to become due and payable in accordance with the terms of the K2HV Loan Agreement).The period for the Company to make monthly principal repayments is from January 1, 2025 until July 1, 2025 , seven months of repayment on the outstanding loan principal of $ 13 million. In addition, pursuant to the Second Amendment, (i) the Company made a payment of $ 12.0 million to K2HV on December 2023 which has been applied to the outstanding principal under the K2HV Loan Agreement (Prepayment), (ii) the lenders and the administrative agent waived a prepayment fee of 2.0 % that otherwise would have been required under the K2HV Loan Agreement with respect to the Prepayment, and (iii) the collateral was amended so that K2HV received a lien on certain of the Company’s intellectual property, subject to customary exceptions. After giving effect to the Prepayment, $ 13.0 million of principal will remain outstanding under the K2HV Loan Agreement. As of December 31, 2023, the Company was in full compliance with the K2HV Loan Agreement and there have been no events of default. As of December 31, 2023, the fair value of the K2 Warrant was valu ed to $ 87,693 with the difference of $ 2,520 (Note 16(b)) being recorded to the profit or loss. See Note 22 for more detail on assumptions used in the valuation of the K2 Warrant. As of December 31, 2023, K2HV had no t exercised any warrants.

Equity

Equity	12 Months Ended
	Dec. 31, 2023
Equity [abstract]
Equity	14. EQUITY a. Ordinary shares December 31, December 31, December 31, 2021 2022 2023 Number of ordinary shares authorized * 500,000,000 500,000,000 1,000,000,000 Authorized par value per share US$ 0.01 US$ 0.01 US$ 0.01 Number of ordinary shares issued and fully paid 348,723,365 348,723,365 439,926,480 Number of equivalent ADSs issued and fully paid 13,948,935 13,948,935 17,597,059 Amount of share capital par value issued and fully paid $ 63,019,962 $ 63,019,962 $ 63,931,993 Amount of share capital surplus issued and fully paid $ 213,098,729 $ 213,098,729 $ 219,774,205 Issuance of new ADS a) Private Placement In February 2021, the Company sold 25,568,180 ordinary shares (an equivalent of 1,022,727 ADSs) in a private placement for net proceeds of approximately $ 18.0 million pursuant to a securities purchase agreement the Company entered into with the purchasers in the private placement (the Securities Purchase Agreement). On February 24, 2023, the Company entered into a Unit Purchase Agreement (the “Purchase Agreement”) with fund entities affiliated with BVF Partners L.P. (collectively, “BVF”) and the other purchasers named therein (the “Purchasers”), pursuant to which the Company agreed to sell to the Purchasers, in a private placement offering, an aggregate of 112,359,550 ordinary shares (an equivalent of 4,494,382 ADSs) , which includes (i) pre-funded warrants (the “Pre-Funded Warrants”) to purchase twenty-five ordinary shares (represented by ADSs) at a purchase price of $ 0.178 per ordinary share (an equivalent of $ 4.45 per ADS) and (ii) $ 4.4475 per Pre-Funded Warrant (or ADS), respectively, which represented a 15 % premium to the ADSs’ ten-day volume-weighted average price (“VWAP”) (the “Private Placement”). The Private Placement closed on February 27, 2023 and the Company received gross proceeds of approximately $ 20.0 million. The Company has issued 59,957,865 ordinary shares (an equivalent of 2,398,315 ADSs) and an additional 52,401,685 ordinary shares (an equivalent of 2,096,067 ADSs) are issuable exercise of the Pre-Funded Warrants. The Pre-Funded Warrants issued have no expiry date. As the Pre-Funded Warrants would be settled by exchange of a fixed number of 52,401,685 ordinary shares (an equivalent of 2,096,068 ADSs) for a fixed consideration of $ 5,240 , the Pre-Funded Warrants were recognized as equity instruments. The value of the Pre-Funded Warrants was approximately $ 8,262,698 based on the relative fair value as of the Initial Exercise Date (February 27, 2023) using the binomial model. As part of the Private Placement, the Purchasers also received two tranches of warrants exercisable in the aggregate for up to 11,061,823 ADSs (or Pre-Funded Warrants). The first tranche of warrants comprised of (i) 50 % of warrants that were exercisable upon issuance and until 60 days after the public announcement of the Company’s topline data from its TREK-AD Phase 2b clinical trial investigating eblasakimab in atopic dermatitis (the “ eblasakimab announcement”) at an exercise price of $ 6.50 per ADS (the “Tranche 1A Warrants”) and (ii) 50 % of warrants that could only be exercised within 60 days after the eblasakimab announcement at an exercise price based on the higher of $ 6.50 and a 50 % discount to the ADS VWAP measured across a specified period after the eblasakimab announcement (the “Tranche 1B Warrants”). The second tranche of warrants similarly comprised (i) 50 % of warrants exercisable upon issuance until 60 days after the public announcement of topline interim data from the Company’s planned Phase 2 proof of concept trial investigating farudodstat (the “ farudodstat announcement”) at an exercise price of $ 8.15 per ADS (the “Tranche 2A Warrants”) and (ii) 50 % of warrants which can only be exercised within 60 days after the farudodstat announcement at an exercise price based on the higher of $ 8.15 and a 50 % discount to the ADS VWAP measured across a specified period after the farudodstat announcement (the “Tranche 2B Warrants,” and together with the Tranche 1A Warrants, Tranche 1B Warrants and Tranche 2A Warrants, the “Tranche Warrants”). The Tranche Warrants have a term of five years and include a mandatory exercise provision, subject to the satisfaction of certain pre-specified conditions. If all Tranche Warrants are fully exercised, the Company will receive an additional $ 80.0 million in gross proceeds. If exercised, the Tranche 1A Warrants and the Tranche 2A Warrants would be settled by issuance of a fixed number of ADSs for a fixed cash consideration upon exercise of the warrants. Hence both Tranche 1A Warrants and Tranche 2A Warrants were recognized as equity instruments and the Tranche 1A Warrants and Tranche 2A Warrants were valued approximately at $ 1,539,117 and $ 2,173,285 , respectively, based on the relative fair values as of the Initial Exercise Date (February 27, 2023) using the binomial model. On September 4, 2023, Tranche 1A Warrants and Tranche 1B Warrants lapsed. As a result Tranche 1A Warrants of $ 1,539,117 has been reclassified from equity instruments to accumulated deficit. The exercise price of the Tranche 1B Warrants and the Tranche 2B warrants is based on the higher of the indicated minimum exercise price and a 50 % discount to the ADS VWAP measured across a specified period after the public disclosure of the Company’s topline data from the relevant clinical trial (the Phase 2B trial for eblasakimab in the case of Tranche 1B; and the Phase 2A trial for farudodstat in the case of Tranche 1B). The variable exercise price does not meet the fixed-for-fixed criteria and hence the Tranche 1B Warrants and Tranche 2B Warrants are recognized as financial liabilities. The Tranche 1B Warrants and Tranche 2B Warrants were valued at approximately $ 1,539,897 and $ 1,925,283 , respectively, based on the relative fair values as of the date of issue (February 27, 2023) using the Monte Carlo model. As of December 31, 2023, Tranche 1B warrants was valued at nil as it has lapsed and the fair value of the Tranche 2B Warrants was revalued to $ 701 . A fair value valuation gain of $ 3,464,479 was recognized in the year ended December 31, 2023, and was recorded under other gains and losses. See Note 22 for more detail on assumptions used in the valuation of the Tranche 1B Warrants and Tranche 2B Warrants. As of December 31, 2023, BVF and the other Purchasers had no t exercised any warrants. * On January 24, 2024, the Company held an Extraordinary General Meeting of shareholders to increase authorized share capital. Please refer to Note 25(a) for subsequent event details. b) Underwritten public offering In March 2021, the Company sold 86,250,000 ordinary shares (an equivalent of 3,450,000 ADSs) in an underwritten public offering for net proceeds of $ 64.9 million after deducting underwriting discounts and commissions and offering expenses. c) At the market ("ATM") sale agreement On October 9, 2020, the Company entered into an Open Market Sale Agreement as amended on September 13, 2022 (the ATM Sale Agreement) with Jefferies LLC, pursuant to which we may issue and sell ADSs from time to time, through at-the-market offerings under which Jefferies LLC will act as sales agent and/or principal. On August 6, 2021, the Company increased the ATM Sale Agreement, with Jefferies LLC whereby in accordance with the revised terms of the ATM Sale Agreement, the Company may offer and sell ADSs having an aggregate offering value of up to $ 85 million from time to time through Jefferies LLC, acting as sales agent. During the year ended December 31, 2021, the Company has raised net proceeds approximately $ 14.1 million under ATM Sale Agreement by offering 24,594,360 ordinary shares (an equivalent of 983,774 ADSs). During the year ended December 31, 2023, the Company had raised net proceeds of approximately $ 3.0 million under the ATM Sale Agreement by offering 31,245,250 ordinary shares (an equivalent of 1,249,810 ADSs). d) Warrants exercised In 2019, the Company entered into a loan facility with certain existing stockholders/directors, affiliates or affiliate of another existing stockholder, for an aggregate amount of $ 2.25 million (collectively, the October/November 2019 Loan Facility). In connection with the October/November 2019 Loan Facility, the Company issued certain warrants (collectively referred to as the “Warrants”). At the same time of the repayment in 2021, holders of Warrants amounting to $ 825,800 of the principal loan amount, exercised and purchased 2,045,355 ordinary shares (representing 81,814 ADSs) at an exercise price of $ 10.10 per ADS. No more warrants are outstanding under October/November 2019 Loan Facility. b. Retained earnings and dividends policy Under ASLAN Cayman’s Articles of Incorporation, ASLAN Cayman may declare dividends by ordinary resolution of ASLAN Cayman’s board of directors, but no dividends shall exceed the amount recommended by the directors of ASLAN Cayman. ASLAN Cayman may set aside out of the funds legally available for distribution, for equalizing dividends or for any other purpose to which those funds may be properly applied, either employed in the business of ASLAN Cayman or invested in such investments as the directors of ASLAN Cayman may from time to time think fit. There were no dividends distributed in years 2021, 2022 and 2023.

Material License Agreements

Material License Agreements	12 Months Ended
	Dec. 31, 2023
Disclosure of transactions between related parties [abstract]
Material License Agreements	15. MATERIAL LICENSE AGREEMENTS Almirall In 2012, the Company originally entered into a global licensing agreement with Almirall to develop DHODH inhibitor, LAS186323, which the Company refers to as farudodstat , for rheumatoid arthritis (excluding any topical formulation), without upfront payments. Under the license agreement, the Company agreed to fund and develop farudodstat to the end of Phase 2 through a development program. The original license agreement was replaced by a new agreement, executed in December 2015 and amended in March 2018 , granting an exclusive, worldwide license to develop, manufacture and commercialize farudodstat products for all human diseases, excluding topically-administered products embodying the compound for keratinocyte and hyperproliferative disorders, and the non-melanoma skin cancers basal cell carcinoma, squamous cell carcinomas and Gorlin Syndrome. Under the license agreement, Almirall is eligible to receive milestone payments and royalties based on the sales generated by the Company and/or sublicensees. As of December 31, 2023, the Company did not accrue for the above contingent payments since the milestones have not yet been achieved. CSL The Company entered into a global license agreement with CSL Limited (“CSL”), in May 2014, to develop the anti-IL13 receptor monoclonal antibody, CSL334 (which the Company refers to as eblasakimab ) and antigen binding fragments thereof, for the treatment, diagnosis or prevention of diseases or conditions in humans, without upfront payments. This license agreement was amended on May 31, 2019, pursuant to which the Company obtained an exclusive, worldwide license to certain intellectual property owned or licensed by CSL, including patents and know-how, to develop, manufacture for clinical trials and commercialize eblasakimab for the treatment, diagnosis or prevention of diseases or conditions in humans. The Company’s development under such agreement is currently focused on the treatment of respiratory and inflammatory conditions, and in particular, atopic dermatitis. Under the amended agreement, the Company is generally obligated to use diligent efforts to develop eblasakimab products in accordance with the development plan, to obtain marketing approvals for eblasakimab products worldwide and to commercialize eblasakimab products, either by itself or through sublicensees. In consideration of the rights granted to the Company under the amended agreement, the Company will make a first payment of $ 30 million to CSL upon commencement of a Phase 3 clinical trial of eblasakimab . The Company will also be required to pay up to an aggregate of $ 95 million to CSL if certain regulatory milestones are achieved, up to an aggregate of $ 655 million if certain sales milestones are achieved and tiered royalties on net sales of eblasakimab products ranging between a mid-single digit percentage and 10 %. The Company is also responsible for all payments to third-party licensors to CSL, to the extent such obligations relate to the exploitation of the rights licensed under CSL’s agreement with those parties and sublicensed to the Company under the amended agreement. As of December 31, 2023, the Phase 2b clinical trial investigating eblasakimab as a therapeutic antibody for moderate-to-severe atopic dermatitis is still ongoing and the aforementioned milestones have not been met and hence no payment is required to be made. For the years ended December 31, 2022 and 2023, the Company made milestone payments of $ 1 million and $ 0 respectively to CSL in fulfilment of our obligation under the CSL agreement to be responsible for payment required to be made by CSL to third party licensors of technology relating to exploitation of the rights subject to the CSL agreement. Zenyaku Kogyo Co., ltd On June 22, 2023 (the “Effective Date”), the Company entered into a development and commercialization agreement (the “Zenyaku Agreement”) with Zenyaku Kogyo Co., Ltd. (“Zenyaku”) under which the Company granted Zenyaku the exclusive rights to develop and commercialize eblasakimab in Japan. In return, the Company has received an unconditional right to consideration of $ 12 million in cash. The Company is eligible to receive future milestone payments of up to $ 123.5 million, triggered upon achievement of certain clinical, regulatory, and commercial milestones as well as tiered royalties on net sales in Japan. As of December 31, 2023, the $ 12 million cash payment had been received. Zenyaku will be solely responsible for all costs related to clinical development and commercialization of eblasakimab in Japan. A joint steering committee has been established between the Company and Zenyaku to oversee and coordinate the overall conduct of such clinical development and commercialization. The Company intend to use the joint steering committee to help assess that the clinical development of eblasakimab in Japan aligns with our overall global development and commercialization strategy and not to direct, nor participate or contribute to such development in Japan. Under the terms of the Zenyaku Agreement, the Company has an option right to buy back the license granted to Zenyaku. The price is agreed to be equal to the aggregate of (i) all prior amounts paid by Zenyaku to the Company in cash under the agreement multiplied by a factor of 3 if the option is exercised before enrollment of first patient in the Phase 3 study of eblasakimab in Japan or multiplied by a factor of 4 if it is after the enrollment of the aforesaid first patient; and (ii) all accumulated development costs incurred and paid by Zenyaku in connection with the development and commercialization of eblasakimab under the Zenyaku Agreement. In addition, the Company undertake to use commercially reasonable efforts to procure for Zenyaku the right to succeed as Japan licensee for another product of ASLAN’s successor which has been granted marketing approval in Japan, or to be granted co-marketing/promotion rights for such product. If this not possible, despite such commercially reasonable efforts, tiered royalties will be payable to Zenyaku. The Zenyaku Agreement will continue until the expiration of the royalty term in Japan unless earlier terminated by the parties. Either party may terminate the Zenyaku Agreement for an uncured material breach or bankruptcy of the other party. Zenyaku may also terminate the Zenyaku Agreement at will upon 90 days’ prior written notice. Under the terms of the Zenyaku Agreement, the Company will have an option right to buy back the license granted to Zenyaku. The Company has reviewed the buy-back option and determined that costs to buy-back the rights is not currently executable as there is insufficient cash and it will require either a third party global partner or an acquisition by a third party, both of which are not within our control. Accordingly, the contract is accounted for under IFRS 15. The transaction price at the Effective Date of the Zenyaku Agreement was $ 12 million in cash upfront which was a non-refundable payment. Developmental and regulatory milestones, and the payment for the manufacture and supply of eblasakimab drug product, were not included in the transaction price or recognized as revenue as the Company determined that such revenue is contingent on future events which it is possible may not occur. Commercial milestones and sales royalties were also excluded and will be recognized when the milestones are achieved or the sales occur in Japan. The performance obligations in the Zenyaku Agreement include the future grant of a license to commercialize eblasakimab until the end of the term, the sharing of certain know how, the sharing of certain clinical and regulatory data, and manufacture and supply of eblasakimab . The Company has determined that the manufacturing and supply was not at a discount and the formulation was also provided to Zenyaku which will allow them to procure it from other sources apart from the Company. The Company has determined that the license and the know how shared with Zenyaku constitutes functional intellectual property and that revenue relating to this should be recognized at a point in time. Consequently, the Company has determined that it has fulfilled its obligations to Zenyaku when it delivered the know how that will allow Zenyaku to file an investigational new drug application in Japan. The Company delivered this know how in the year ended December 31, 2023, and the $ 12 million revenue was therefore recognized as revenue in the year ended. Revenue relating to the manufacture and supply obligations will be recognized when the drug product is delivered.

Loss Before Income Tax

Loss Before Income Tax	12 Months Ended
	Dec. 31, 2023
Profit (loss) [abstract]
Loss Before Income Tax	16. LOSS BEFORE INCOME TAX a. Other income For the year ended December 31 2021 2022 2023 ADS issuance contribution $ 1,076,189 $ — $ 386,908 Government grants for research and development expenditures — 248,613 73,724 Government subsidies 31,112 29,147 — Accretion income — 94,248 — Others 771 14,130 1,689 $ 1,108,072 $ 386,138 $ 462,321 ADS issuance contribution is other income received from J.P. Morgan Chase Bank N.A., the Custodian and the Depositary as part of the conversion of ordinary shares to ADS due to the Taiwan delisting in 2020 and issuance of new ADS. As of December 31, 2021 and 2023, the Company recognized a total of $ 1,076,189 and $ 386,908 respectively as other income. Government grants for research and development expenditures relates to a research and development grant of $ 248,613 and $ 73,724 , approved by the Australian Government during the years of 2022 and 2023 respectively, for research and development activities carried out in Australia. Government subsidies are reliefs from the Singapore government to support and encourage wage increases, raise employability of older Singaporeans and to help employers retain local employees due to economic uncertainty caused by the COVID-19 pandemic. b. Other gains and losses For the year ended December 31 2021 2022 2023 Net foreign exchange (losses) gains $ 512,450 $ ( 85,869 ) $ ( 332,725 ) Gain on disposal of property, plant and equipment — 1,172 148 Net gain on fair value changes of financial assets and 594,046 133,139 3,466,999 Others 14 ( 78,025 ) ( 12,816 ) $ 1,106,510 $ ( 29,583 ) $ 3,121,606 c. Finance costs For the year ended December 31 2021 2022 2023 Interest on government loans $ 443,216 $ 431,052 $ 442,410 Interest on other long-term borrowing 1,191,381 3,224,369 3,871,299 Interest on loans from shareholders 154,773 — — Interest on loans from related parties 50,074 — — Interest on lease liabilities 21,510 12,544 13,074 Others — 7,724 4,878 $ 1,860,954 $ 3,675,689 $ 4,331,661 d. Depreciation and amortization For the year ended December 31 2021 2022 2023 Right-of-use assets $ 264,804 $ 308,682 $ 319,725 Property, plant and equipment 14,856 18,950 24,653 Intangible assets 2,564 4,120 4,120 $ 282,224 $ 331,752 $ 348,498 e. Employee benefits expense For the year ended December 31 2021 2022 2023 Short-term benefits $ 6,940,900 $ 8,423,133 $ 9,622,503 Post-employment benefits 257,128 355,434 415,509 Share-based payments (Note 19) Equity-settled 2,428,128 2,443,894 2,769,279 Cash-settled ( 234,761 ) ( 467,134 ) ( 66,079 ) Total employee benefits expense $ 9,391,395 $ 10,755,327 $ 12,741,212 Employee benefits expense by function General and administrative expenses $ 5,718,646 $ 5,643,217 $ 7,148,068 Research and development expenses 3,672,749 5,112,110 5,593,144 $ 9,391,395 $ 10,755,327 $ 12,741,212

Income Tax Expense

Income Tax Expense	12 Months Ended
	Dec. 31, 2023
Income Tax [Abstract]
Income Taxes Expense	17. INCOME TAX EXPENSE Income Tax recognized in Profit or Loss The tax rate used for the 2023, 2022 and 2021 reconciliations below is the corporate tax rate of 17 % payable by corporate entity in Singapore on taxable loss under tax law in that jurisdiction where the Company’s main operation is at Singapore. For the year ended December 31 2021 2022 2023 Current tax expenses In respect of the current period $ — $ 79,379 $ 113,251 Adjustments for prior periods — 19,842 19,416 $ — $ 99,221 $ 132,667 2021 2022 2023 Loss before income tax $ ( 31,590,582 ) $ ( 51,283,196 ) $ ( 44,086,937 ) Income tax benefits calculated at the statutory rate $ ( 5,370,399 ) $ ( 8,718,143 ) $ ( 7,494,779 ) Tax effect of income not taxable in determining taxable income ( 870,151 ) 19,769 83,729 Non-deductible expenses in determining taxable income 648,651 361,600 549,230 Tax credits for research and development expenditures ( 1,467,816 ) ( 245,802 ) ( 161,510 ) Unrecognized loss carry forwards 6,044,928 7,688,535 6,396,624 Tax effect of share of results of associates and joint venture 405,712 74,125 1,460 Effect of different tax rates of group entities operating in other 609,075 917,106 738,497 Adjustments for prior year' tax — 19,842 19,416 Others — ( 17,811 ) — Income tax expenses recognized in profit or loss $ — $ 99,221 $ 132,667 The accumulated deficits of the Company as of December 31, 2022, and December 31, 2023, were $ 279 million and $ 321 million, respectively, among which the majority of the accumulated deficits arose from its main operating entity, ASLAN Pharmaceuticals Pte. Ltd. ASLAN Pharmaceuticals Pte. Ltd has accumulated unused tax losses of $ 238 million as of December 31, 2022, and $ 275 million as of December 31, 2023 available for offset against future profits. Out of the unused tax losses, $ 77 million and $ 78 million relates to tax credits for research and development expenditure as of December 31, 2022 and December 31, 2023 respectively. No deferred tax asset has been recognized in respect of all the unused tax losses as it is not considered probable that there will be future taxable profits available. Subject to qualifying conditions, the unused tax losses can be carried forward indefinitely. a. Cayman Islands ASLAN Cayman is incorporated in the Cayman Islands. Under the current laws of the Cayman Islands, the Company is not subject to tax on income or capital gains. Additionally, the Cayman Islands does not impose a withholding tax on payments of dividends to shareholders. b. Singapore ASLAN Pharmaceuticals Pte. Ltd. is incorporated in Singapore and subject to the statutory corporate income tax rate of 17 %. ASLAN Pharmaceuticals Pte. Ltd. has no taxable income for the years ended December 31, 2021, 2022 and 2023, no other provision for income tax is required. c. Australia ASLAN Pharmaceuticals Australia Pty Ltd., incorporated in Australia, is subject to the statutory corporate income tax of 30 %. ASLAN Pharmaceuticals Australia Pty Ltd. has no taxable income for the years ended December 31, 2021, 2022 and 2023, and therefore, no provision for income tax is required. d. Hong Kong ASLAN Pharmaceuticals Hong Kong Limited, incorporated in Hong Kong, is subject to the statutory corporate income tax of 16.5 %. Under the Hong Kong tax law, ASLAN Pharmaceuticals Hong Kong Limited is exempted from income tax on its foreign derived income and there are no withholding taxes in Hong Kong on the remittance of dividends. ASLAN Pharmaceuticals Hong Kong Limited has no taxable income for the years ended December 31, 2021, 2022 and 2023, and therefore, no provision for income tax is required. e. China ASLAN Pharmaceuticals (Shanghai) Co. Ltd., incorporated in China, is subject to the statutory corporate income tax rate of 25 %. ASLAN Pharmaceuticals (Shanghai) Co. Ltd. has no taxable income for the years ended December 31, 2021, 2022 and 2023, and therefore, no provision for income tax is required. f. United States of America ASLAN Pharmaceuticals (USA) Inc., incorporated in Delaware, USA in October 2018, is subject to the statutory federal income tax rate of 21 % and state income tax rate of 8.7 %. Due to the Research and Development Service Agreement in place between ASLAN Pharmaceuticals (USA) Inc. and its parent company, it has taxable income of $ 94,487 , $ 377,994 and $ 531,794 for the years ended December 31, 2021, 2022 and 2023 and no provision for income tax is required as fully paid up. g. Taiwan ASLAN Pharmaceuticals Taiwan Limited, incorporated in Taiwan is subject to the statutory corporate income tax of 20 % and the corporate surtax rate of 5 %. The Company disposed of ASLAN Pharmaceuticals Taiwan Limited on December 31, 2022.

Loss Per Ordinary Share

Loss Per Ordinary Share	12 Months Ended
	Dec. 31, 2023
Earnings per share [abstract]
Loss Per Ordinary Share	18. LOSS PER ORDINARY SHARE For the year ended December 31 2021 2022 2023 Basic and diluted loss per ordinary share $ ( 0.10 ) $ ( 0.15 ) $ ( 0.11 ) Basic and diluted loss per equivalent ADS $ ( 2.40 ) $ ( 3.68 ) $ ( 2.69 ) The loss and weighted-average number of ordinary shares outstanding used in the computation of loss per share are as follows: For the year ended December 31 2021 2022 2023 Loss used in the computation of basic and diluted loss per ordinary $ ( 31,321,618 ) $ ( 51,382,417 ) $ ( 44,219,604 ) Weighted-average number of ordinary shares in the computation of 325,684,272 348,723,365 411,242,644 Weighted-average number of equivalent ADS in the computation of 13,027,371 13,948,935 16,449,706

Share-Based Payment Arrangement

Share-Based Payment Arrangements	12 Months Ended
	Dec. 31, 2023
Disclosure of terms and conditions of share-based payment arrangement [abstract]
Share-Based Payment Arrangements	19. SHARE-BASED PAYMENT ARRANGEMENTS Employee Share Option Plan Under the Company’s 2014 employee share option plan (the “2014 Plan”), qualified employees of the Company and its subsidiaries were granted 7,050,211 options (representing 14,100,422 ordinary shares, an equivalent of 564,017 ADSs) from July 2010 to July 2016. The vesting period is four years . If the options remain unexercised after a period of ten years from the date of grant, the options expire. Options are forfeited if the employee leaves the Company before the options vest. Options pursuant to the 2014 plan are also vested in full or forfeited as of December 31, 2022 and 2023. 2014 Plan Information on employee share options granted from the 2014 Plan is as follows. Each option entitles the holder to subscribe for two ordinary shares of the Company: For the Year Ended December 31 2021 2022 2023 Number of Weighted- Number of Weighted- Number of Weighted- Balance at January 1 533,629 $ 17.88 487,829 $ 17.88 371,569 $ 22.00 Options expired — — ( 116,260 ) 8.38 ( 48,800 ) 17.08 Options exercised ( 45,800 ) 5.38 — — — — Balance at December 31 487,829 17.88 371,569 22.00 322,769 22.74 Options exercisable, 487,829 17.88 371,569 22.00 322,769 22.74 2017 Plan Under the Company’s 2017 employee share option plan (the “2017 Plan”), qualified employees of the Company and its subsidiaries were granted 825,833 options (representing 825,833 ordinary shares, an equivalent of 33,033 ADS) in September 2017. The vesting period is two years . If the options remain unexercised after a period of ten years from the date of grant, the options expire. Options are forfeited if the employee leaves the Company before the options vest. Options granted pursuant to the 2017 Plan are all either vested in full or forfeited as of December 31, 2022 and 2023. Information on employee share options granted from the 2017 Plan is as follows. Each option entitles the holder to subscribe for one ordinary share of the Company: For the Year Ended December 31 2021 2022 2023 Number of Weighted- Number of Weighted- Number of Weighted- Balance at January 1 20,048 $ 31.90 20,048 $ 31.90 20,048 $ 31.90 Options forfeited — — — — ( 333 ) 31.90 Balance at December 31 20,048 31.90 20,048 31.90 19,715 31.90 Options exercisable, 20,048 31.90 20,048 31.90 19,715 31.90 2020 Equity Incentive Plan On December 10, 2020, the Board of Directors (the “Board”) of the Company approved the Company’s 2020 Equity Incentive Plan (the “2020 EIP”). The 2020 EIP, among other things, provides for the grant of restricted stock awards, stock options and other equity-based awards to employees, officers, directors and consultants. The vesting period is up to four years or determination that a different vesting schedule shall apply, subject to discretion of Administrator. If the options remain unexercised after a period of ten years from the date of grant, the options expire. Options are forfeited if the employee leaves the Company before the options vest. Each option entitles the holder to subscribe for one ADS of the Company. The options granted are valid for 10 years. No performance conditions were attached to the plan. No more than 62,030,922 ordinary shares (an equivalent of 2,481,237 ADSs) may be issued under the 2020 EIP upon the exercise of options. In addition, the number of ordinary shares reserved for issuance under the 2020 EIP will automatically increase on January 1 of each year, commencing on January 1, 2022, and ending on (and including) January 1, 2030, in an amount equal to 4 % of the total number of ordinary shares outstanding on December 31 of the preceding calendar year. The Board may determine prior to January 1 of a given year that there will be no increase for such year or that the increase for such year will be a lesser number of ordinary shares. In connection with the approval of the 2020 EIP, the maximum number of ordinary shares that may be issued under the 2020 EIP was originally 20,676,974 ordinary shares (an equivalent of 827,079 ADSs). The Board determined that there would be no increase as from January 1, 2021. As from January 1, 2022 and January 1, 2023, there was be an options increase of 13,948,935 ordinary shares (an equivalent of 557,958 ADSs), which represents 4 % of the total outstanding ordinary shares as of December 31, 2021 and December 31, 2022. On December 15, 2020, 764,812 ADSs were granted under the Company’s 2020 EIP. During the year ended December 31, 2021, 56,400 ADSs were granted under the Company’s 2020 EIP, respectively. On January 1, 2022, and on July 1, 2022, 355,030 ADSs and 143,600 ADSs were granted, respectively. On January 1, 2023, on May 1, 2023 and on July 1, 2023, 407,226 ADSs, 370,000 ADSs and 9,600 ADSs were granted, respectively. If an award under the 2020 EIP, expires, lapses or is terminated, exchanged for cash, surrendered, repurchased, cancelled without having been fully exercised, forfeited or is withheld to satisfy a tax withholding obligation in connection with an award or to satisfy a purchase or exercise price of an award, any unused shares subject to the award will, as applicable, become or again be available for new grants under the 2020 EIP. Awards granted under the 2020 EIP in substitution for any options or other equity or equity-based awards granted by an entity before the entity’s merger or consolidation with the Company or the Company’s acquisition of the entity’s property or stock will not reduce the number of ordinary shares available for grant under the 2020 EIP, but will count against the maximum number of ordinary shares that may be issued upon the exercise of incentive stock options. References in this summary to ordinary shares include an equivalent number of the Company’s ADSs. In July 2022, the Remuneration Committee of the Board noted that the exercise price of options previously granted to certain officers and employees of the Company significantly exceeded the current fair market value of the underlying ADS (the “Underwater Options”). In accordance with its powers authorized under the 2020 EIP, the Remuneration Committee therefore resolved to lower the per ADS exercise price of the Underwater Options, believing this to be in the best interests of the Company and its shareholders to motivate and restore incentives for the holders of the Underwater Options. It thus resolved to amend each Underwater Option to reduce the exercise price of each to $ 2.60 per ADS for the 2020 EIP, being the Fair Market Value of the Company’s ADSs effective on the closest trading day to the date of the resolution. The incremental fair value of $ 279,636 has been recognized as an expense over the period from the modification date to the end of vesting period. The expense for the original option grant will be recognized as if the terms had not been modified. The fair value of the modified options was determined using the same models and principles as described below. Information on employee share options granted under the 2020 EIP is as follows. Each option entitles the holder to subscribe for one ADS of the Company: For the Year Ended 2021 2022 2023 Number of Weighted- Number of Weighted- Number of Weighted- Balance at January 1 764,812 $ 10.30 804,312 $ 2.60 1,154,068 $ 2.59 Options granted 56,400 16.20 498,630 2.57 786,827 2.93 Options forfeited ( 16,200 ) 10.30 ( 148,874 ) 2.60 ( 11,375 ) 2.33 Options exercised ( 700 ) 10.30 — — — — Balance at December 31 804,312 $ 10.30 1,154,068 $ 2.59 1,929,520 $ 2.73 Options exercisable, end of period 299,505 $ 10.30 408,964 $ 2.59 803,797 $ 2.59 Weighted-average fair value of each option granted $ 13.15 $ 2.59 $ 2.73 Information on outstanding options as of December 31, 2023 is as follows: Jul Jul Jul Jul Dec Jan - Jul Jan - Jul Jan - Jul Range of $ 6.80 $ 6.80 -$ 9.40 $ 11.30 $ 6.40 $ 2.60 $ 2.60 $ 2.50 -$ 2.60 $ 1.80 -$ 4.15 Weighted- 0.5 1.5 2.5 3.73 6.96 7.21 8.26 9.29 Options granted in the 2014 Plan, the 2017 Plan, and the 2020 EIP were priced using the binomial option pricing model, and the inputs to the model were as follows: Jul Jul Jul Jul Dec Jan- Jan- Jan- Grant- $ 6.80 $ 9.40 $ 11.30 $ 6.40 $ 11.10 $ 11.75 -$ 20.60 $ 2.50 -$ 5.60 $ 1.80 -$ 4.15 Exercise $ 6.80 $ 6.80 -$ 9.40 $ 11.30 $ 6.40 $ 2.60 $ 2.60 $ 2.50 -$ 2.60 $ 1.80 -$ 4.15 Expected volatility 50.86 % 36.37 % 39.34 % 38.33 % 66.25 % 59.99 %- 64.92 % 118.2 %- 122.1 % 118.8 % - 133.5 % Expected 10 10 10 10 5.25 - 7 5.25 - 7 5.25 - 7 5.5 - 7 Risk-free 2.58 % 2.43 % 1.46 % 1.10 % 3.05 %- 3.06 % 3.05 %- 3.06 % 2.90 %- 3.06 % 3.58 %- 3.97 % Expected volatility was based on the average annualized historical share price volatility of comparable companies before the grant date. The expected life used in the model has been adjusted, based on management’s best estimate. Compensation costs recognized for the years ended December 31, 2021, 2022 and 2023, were $ 2,428,128 , $ 2,443,894 and $ 2,769,279 respectively. Long Term Incentive Plan The Company maintains the Senior Management Team (SMT) Long Term Incentive Plans (LTIP), pursuant to which bonus entitlement unit awards were granted in 2017, 2018, and 2019. On August 23, 2017, and February 1, 2018, the Company granted 1,462,000 and 104,000 ordinary shares (an equivalent to 58,480 ADSs and 4,160 ADSs) bonus entitlement units to the Company’s executive officers pursuant to the 2017 LTIP, respectively. On July 30, 2018, the Company granted 48,228 ADSs bonus entitlement units to the executive officers pursuant to the 2018 LTIP, and on July 30, 2019, the Company granted 98,204 ADSs bonus entitlement units to the executive officers pursuant to the 2019 LTIP. Upon vesting and redemption, each unit award is converted into a cash payment equal to the number of units multiplied by the per-share fair market value of the Company’s ordinary shares on the day following the Company’s receipt of a redemption notice. The bonus entitlement unit awards granted pursuant to the 2017 LTIP, the 2018 LTIP and the 2019 LTIP are all either vested in full or forfeited as of December 31, 2023. Up to date, total 56,700 ADSs bonus entitlement units have been forfeited or lapsed and total 62,910 ADSs bonus entitlement units have been redeemed as of December 31, 2023. The quoted fair value on the reporting date is based on the closing price per ADS of $ 1.80 and $ 0.52 as of December 31, 2022, and December 31, 2023, respectively. The LTIPs qualify as cash-settled share-based payment transactions. The Company recognizes the liabilities in respect of its obligations under the LTIPs, which are measured based on the Company’s quoted market price of its ADSs at the reporting date, and takes into account the extent to which the services have been rendered to date. The Company recognized total benefit of $ 66,079 in 2023 and recognized total benefits of $ 234,761, $ 467,134 and $ 66,079 in respect of the LTIPs for the years ended December 31, 2021, 2022 and 2023. As of December 31, 2022, and December 31, 2023, the Company recognized compensation liabilities of $ 234,448 and $ 46,699 as other payables (Note 12). The total intrinsic value at December 31, 2023 and 2022 was $ 234,448 and $ 46,699 , respectively. The Company’s LTIP is described as follows: Number of ADSs units 2021 2022 2023 Balance at January 1 148,906 144,147 144,147 Awards exercised ( 4,759 ) — ( 40,788 ) Awards lapsed — — ( 13,897 ) Balance at December 31 144,147 144,147 89,462 Balance exercisable, end of period 144,147 144,147 89,462

Capital Management

Capital Management	12 Months Ended
	Dec. 31, 2023
Disclosure Of Capital Management [Abstract]
Capital Management	20. CAPITAL MANAGEMENT The Company manages its capital to ensure that entities in the Company will be able to safeguard cash as well as maintain financial liquidity and flexibility to support the development of its product candidates and programs as a going concern through the optimization of the debt and equity balance. The Company’s financial strategy is designed to maintain a flexible capital structure consistent with the objectives stated above and to respond to business growth opportunities and changes in economic conditions. The capital structure of the Company mainly consists of borrowings and equity of the Company. Key management personnel of the Company review the capital structure periodically. To maintain or balance the overall capital structure, the Company may adjust the amounts of long-term borrowings, or the issuance of new shares capital or other equity instruments. As of December 31, 2023, there were no changes in the Company’s capital management policy, and the Company is not subject to any externally imposed capital requirements other than those restrictions disclosed in Note 13 under K2HV Loan Agreement.

Reconciliation of Liabilities A

Reconciliation of Liabilities Arising from Financing Activities	12 Months Ended
	Dec. 31, 2023
Disclosure of reconciliation of liabilities arising from financing activities [abstract]
Reconciliation of Liabilities Arising from Financing Activities	21. RECONCILIATION OF LIABILITIES ARISING FROM FINANCING ACTIVITIES The table below details changes in the Company’s liabilities arising from financing activities, including both cash and non-cash changes. Liabilities arising from financing activities are those for which cash flows were, or future cash flows will be, classified in the Company’s consolidated statements of cash flows as cash flows from financing activities. Non-cash changes January 1, Interest Net Additions/ Others* Interest December 31, Lease Liabilities – current $ 271,624 $ ( 21,510 ) $ ( 353,649 ) $ 281,149 $ — $ 21,510 $ 199,124 Lease Liabilities – non-current 281,149 — — ( 281,149 ) — — — Current borrowings (Note 13) 2,900,971 ( 484,043 ) ( 2,571,701 ) — — 154,773 — Current borrowings from related parties 617,912 ( 117,986 ) ( 550,000 ) — — 50,074 — Long-term borrowings (Note 13) 15,183,421 — 15,939,643 ( 688,324 ) ( 124,827 ) 547,396 30,857,309 Other payable - interest payables (Note 12) 735,510 — ( 1,680,628 ) — — 1,087,201 142,083 Non-cash changes January 1, Interest Net Additions/ Others* Interest December 31, Lease Liabilities – current $ 199,124 $ ( 12,544 ) $ ( 262,798 ) $ 293,460 $ ( 14,115 ) $ 12,544 $ 215,671 Other payable - interest payables (Note 12) 142,083 — — $ ( 142,083 ) — — — Current borrowings (Note 13) — ( 2,338,715 ) — 7,626,678 — 2,460,868 7,748,831 Long-term borrowings (Note 13) 30,857,309 — 5,000,000 ( 7,484,595 ) 88,866 1,194,553 29,656,133 Non-cash changes January 1, Interest Net Additions/ Others* Interest December 31, Lease Liabilities – current $ 215,671 $ ( 10,411 ) $ ( 296,920 ) $ 307,436 $ ( 2,663 ) $ 13,074 $ 226,187 Current borrowings (Note 13) 7,748,831 ( 3,318,576 ) — ( 6,501,167 ) — 3,871,299 1,800,387 Long-term borrowings (Note 13) 29,656,133 — ( 12,000,000 ) 6,501,167 198,842 442,410 24,798,552 Financial liabilities at fair value through profit or loss 90,213 — 3,465,180 **** — ( 3,466,999 ) — 88,394 * Others comprise mainly foreign currency translation differences for long-term borrowings and net gain on fair value changes for financial liabilities measured at fair value through profit or loss. ** The transfer from current to long-term borrowings is due to the amendment (Second Amendment) of K2HV Loan Agreement pursuant to which K2HV agreed to extend the period in which the Company is not required to make payments with respect to the outstanding amount (see Note 14b). *** The Company classified interest paid arising from third party borrowings and leases into operating and financing cash flows activities respectively. **** Net proceeds arising from cash received from Tranche 1B warrants and Tranche 2B warrants as of the date of issue which have been recorded as financial liabilities at fair value through profit or loss (see Note 14a).

Financial Instruments

Financial Instruments	12 Months Ended
	Dec. 31, 2023
Disclosure of detailed information about financial instruments [abstract]
Financial Instruments	22. FINANCIAL INSTRUMENTS a. Fair value of financial instruments not measured at fair value The Company believes that the carrying amounts of financial assets and financial liabilities not measured at fair value approximate to their fair values. b. Fair value of financial instruments measured at fair value on a recurring basis 1) Fair value- hierarchy December 31, 2022 Level 1 Level 2 Level 3 Total Financial assets at fair value through profit or Money Market Fund $ 30,445,339 $ — $ — $ 30,445,339 Financial liabilities at fair value through profit or Derivative financial liabilities – K2 warrants $ — $ — $ 90,213 $ 90,213 December 31, 2023 Level 1 Level 2 Level 3 Total Financial assets at fair value through other comprehensive Foreign unlisted ordinary shares $ — $ — $ 235,567 $ 235,567 Financial liabilities at fair value through profit or Derivative financial liabilities K2 warrants $ — $ — $ 87,693 $ 87,693 Tranche 2B warrants $ — $ — $ 701 $ 701 Derivative financial liabilities $ — $ — $ 88,394 $ 88,394 The following three levels of inputs are used to measure the fair value presented above: Level 1 — Quoted prices in active markets for identical assets and liabilities. Level 2 — Significant other observable inputs. Level 3 — Significant unobservable inputs. There was no transfer between Levels 1, 2 and 3 in the current and prior periods. 2) Reconciliation of Level 3 fair value measurements of financial instruments K2 Warrants Tranche Warrants Unlisted foreign ordinary shares Balance at January 1, 2021 $ — $ — $ — Issues 688,324 — — Subsequent measurement recognized in profit and loss ( 464,972 ) — — Balance at January 1, 2022 $ 223,352 $ — $ — Issues 45,482 — — Subsequent measurement recognized in profit and loss ( 178,621 ) — — Balance at January 1, 2023 $ 90,213 $ — $ — Issues — 3,465,180 — Subsequent measurement recognized in Profit and loss ( 2,520 ) ( 3,464,479 ) — Other comprehensive income — — 235,567 Balance at December 31, 2023 $ 87,693 $ 701 $ 235,567 3) Fair value of the group’s financial assets and financial liabilities that are measured at fair value on a recurring basis The Company’s financial assets and financial liabilities are measured at fair value at the year end. The following table gives information about how the fair values of these financial assets and financial liabilities are determined. Financial assets/ financial liabilities Fair Value Hierarchy Valuation Technique(s) and key input(s) Significant unobservable input(s) Relation and sensitivity of unobservable inputs to fair value 1. Derivative financial liabilities - K2 warrants Level 3 Option Pricing Model (Binomial Tree Model). Volatility The higher the volatility, the higher the fair value. 5 per cent lower while all other variables were held constant, the carrying amount would decrease by US$ 3,631 . If the volatility was 5 per cent higher while all other variables were held constant, the carrying amount would increase by US$ 3,171 . 2. Derivative financial liabilities - 2B warrants Level 3 Option Pricing Model (Monte Carlo Simulation). Volatility The higher the volatility, the higher the fair value. 5 per cent lower while all other variables were held constant, the carrying amount would decrease by US$ 376 . If the volatility was 5 per cent higher while all other variables were held constant, the carrying amount would increase by US$ 552 . 3. Foreign unlisted ordinary shares Level 3 Backsolve Option Pricing Model. Volatility The higher the volatility, the higher the fair value. 5 per cent lower while all other variables were held constant, the carrying amount would decrease by US$ 1,314 . If the volatility was 5 per cent higher while all other variables were held constant, the carrying amount would increase by US$ 1,367 . c. Categories of financial instruments December 31, December 31, December 31, 2021 2022 2023 Financial assets Financial assets at fair value through other comprehensive Foreign unlisted ordinary shares $ — $ — $ 235,567 Financial assets at fair value through profit or loss Money Market Fund $ — $ 30,445,339 $ — Financial assets at amortized cost (1) $ 91,047,060 $ 27,490,152 $ 22,448,527 Financial liabilities Financial liabilities at fair value through profit or Derivative financial liabilities – K2 warrants $ 223,352 $ 90,213 $ 87,693 Derivative financial liabilities – Tranche 2B Warrants $ — $ — $ 701 $ 223,352 $ 90,213 $ 88,394 Financial liabilities at amortized cost (2) $ 36,090,421 $ 41,922,924 $ 36,910,284 Equity instruments Equity instruments Pre-Funded Warrants $ — $ — $ 8,262,698 Tranche 2A Warrants $ — $ — $ 2,173,285 $ — $ — $ 10,435,983 (1) The balances include financial assets at amortized cost, which comprise of cash and cash equivalents (excluding money market funds) and refundable deposits. (2) The balances include financial liabilities at amortized cost, which comprise of trade payables, other payables, current borrowings, lease liabilities and long-term borrowings. d. Financial risk management objectives and policies The Company’s financial risk management objective is to monitor and manage the financial risks relating to the operations of the Company. These risks include market risk (including foreign currency risk and interest rate risk), credit risk and liquidity risk. In order to minimize the effect of financial risks, the Company devoted time and resources to identify and evaluate the uncertainty of the market to mitigate risk exposures. 1) Market risk The Company’s activities exposed it primarily to the financial risks of changes in foreign currency exchange rates (see (a) below) and interest rates (see (b) below). a) Foreign currency risk The Company has foreign currency transactions, which exposed the Company to foreign currency risk. The Company’s significant financial assets and liabilities denominated in foreign currencies were as follows: December 31, 2022 Foreign Exchange Carrying Financial assets Monetary items SGD S $ 2,312,357 0.7461 $ 1,725,279 AUD A $ 2,616,802 0.6820 $ 1,784,606 Financial liabilities Monetary items SGD S $ 16,298,191 0.7461 $ 12,160,288 December 31, 2023 Foreign Exchange Carrying Financial assets Monetary items SGD S $ 2,825,324 0.7577 $ 2,140,748 Financial liabilities Monetary items SGD S $ 18,232,233 0.7577 $ 13,814,563 Sensitivity analysis The Company is mainly exposed to the Singapore Dollar. The following table details the Company’s sensitivity to a 5 % decrease in the U.S. dollar against the relevant foreign currency. The rate of 5 % is the sensitivity rate used when reporting foreign currency risk internally to key management personnel and represents management’s assessment of the reasonably possible change in foreign exchange rates. The sensitivity analysis includes only outstanding foreign currency denominated monetary items. A negative number below indicates an increase in pre-tax loss where the U.S. dollar weakens 5 % against the relevant currency. For a 5 % strengthening of the U.S. dollar against the relevant currency, there would be an equal and opposite impact on pre-tax loss. For the year ended December 31 2021 2022 2023 Profit or loss* SGD $ ( 548,878 ) $ ( 521,750 ) $ ( 583,691 ) AUD $ 87,807 $ 89,230 $ — * This is mainly attributable to the exposure to outstanding deposits in banks and loans in foreign currency at the end of the reporting period. b) Interest rate risk The Company is exposed to interest rate risk because entities in the Company borrowed funds at fixed baseline interest plus floating interest rates. The sensitivity analysis below is determined based on the Company’s exposure to interest rates for investment in money market fund and fixed rate borrowings at the end of the reporting period, and is prepared assuming that the amounts of liabilities outstanding at the end of the reporting period are outstanding for the whole year. A 100-basis point increase or decrease is used when reporting interest rate risk internally to key management personnel and represents management’s assessment of the reasonably possible change in interest rates. If interest rates had been 100 basis points higher and all other variables were held constant, the Company’s pre-tax loss for the years ended December 31, 2021, 2022 and 2023, would have increased by $ 308,573 , $ 69,596 and $ 265,989 , respectively. 2) Credit risk Credit risk refers to the risk that a counterparty will default on its contractual obligations resulting in a financial loss to the Company. The Company adopted a policy of only dealing with creditworthy counterparties and financial institutions, where appropriate, as a means of mitigating the risk of financial loss from defaults. 3) Liquidity risk The Company manages liquidity risk by monitoring and maintaining a level of cash and cash equivalents that are deemed adequate to finance the Company’s operations and mitigate the effects of fluctuations in cash flows. In addition, management monitors the utilization of long-term borrowings and ensures compliance with repayment conditions. As the Company is in the research and development phase, the Company will be seeking future funding based on the requirements of its business operations. The Company is able to exercise discretion and flexibility to deploy its capital resources in the process of the research and development activities according to the amount and timing of the financing activities. The Company intends to explore various means of fundraising to meet its funding requirements to carry out the business operations, such as the issuance of ADS representing its ordinary shares, venture debt and shareholder loasn. The Company may also use other means of financing such as out licensing to generate revenue and cash. The Company’s current cash resources are not sufficient to complete the research and development activities of all of its therapeutic candidates in the absence of any additional funding. Management believes that there is presently insufficient funding available to allow the Company to fund its activities for a period exceeding one year and meet its obligations as they become due within one year, from the date of this filing. However, the future viability of the Company depends on its ability to raise additional capital or partner the drug to finance its operations, in the absence of additional funding there would be substantial doubts about the Company’s ability to continue as a going concern. On February 24, 2023, the Company entered into a Unit Purchase Agreement (the “Purchase Agreement”) with fund entities affiliated with BVF Partners L.P. (collectively, “BVF”) private placement. The Private Placement was on February 27, 2023 (the “Closing”), subject to customary closing conditions. The Private Placement is expected to result in gross proceeds to the Company of approximately $ 20.0 million, and an additional $ 80.0 million in gross proceeds to the Company if all Tranche Warrants are fully-exercised. Please refer to Note 14 for details . On March 12, 2024, the Company entered into a Securities Purchase Agreement with the purchaser’s signatory thereto (the Purchasers), pursuant to which the Company agreed to sell and issue, in a registered direct offering, 125,000,000 ordinary shares in the form of 5,000,000 ADSs, at a gross purchase price of $ 1.00 per ADS (the Registered Offering). The registered offering resulted in net proceeds to the Company of $ 4.5 million, and an additional $ 5.0 million in gross proceeds to the Company if the warrants are full-exercised. Please refer to Note 25(c) for details. The table below break down the Company's financial liabilities into relevant maturity groupings based on their contractual and estimated maturities. The amounts disclosed in the tables are contractual and estimated undiscounted cash flows. Contractual maturities of financial liabilities as of December 31, 2023 On demand or within 1 year Within 2 to 5 years After 5 years Total Non-derivative financial liabilities Trade payable $ 7,918,607 $ — $ — $ 7,918,607 Other payable 3,081,329 — — 3,081,329 Lease liabilities 226,187 — — 226,187 Borrowings - Loan from government (Note 13a) — — 12,496,831 12,496,831 - Other long-term borrowing (Note 13b) 1,818,750 16,723,211 — 18,541,961 Derivative financial liabilities K2HV warrants — — 87,693 87,693 Tranche 2B warrants 701 — — 701 Contractual maturities of financial liabilities as of December 31, 2022 On demand or within 1 year Within 2 to 5 years After 5 years Total Non-derivative financial liabilities Trade payable $ 12,784,485 $ — $ — $ 12,784,485 Other payable 2,325,038 — — 2,325,038 Lease liabilities 215,671 — — 215,671 Borrowings - Loan from government (Note 13a) — — 11,855,579 11,855,579 - Other long-term borrowing (Note 13b) 7,503,091 24,557,362 — 32,060,453 Derivative financial liability K2HV warrants — — 90,213 90,213

Transactions with Related Parti

Transactions with Related Parties	12 Months Ended
	Dec. 31, 2023
Disclosure of transactions between related parties [abstract]
Transactions with Related Parties	23. TRANSACTIONS WITH RELATED PARTIES Balances and transactions between the companies and its subsidiaries which are related parties of the Company, have been eliminated on consolidation and are not disclosed in this note. Besides information disclosed elsewhere in the other notes, details of transactions between the Company and other related parties are disclosed as follows. a. Related party name and category Related Party Name Related Party Category Other Key Management Personnel b. Loans from related parties Interest expense For the year ended December 31 Related Party Category/Name 2021 2022 2023 Related party in substance / JANK Howden Pty Ltd $ 45,522 $ — $ — Key Management Personnel / Others 4,552 — — $ 50,074 $ — $ — The loans from the related parties were repaid on March 22, 2021. c. Compensation of Key Management Personnel For the year ended December 31 Related Party Category/Name 2021 2022 2023 Short-term employee benefits $ 2,881,215 $ 2,783,668 $ 3,115,619 Post-employment benefits 112,095 332,037 140,332 Share-based payments recognized 2,048,669 1,926,199 2,256,528 $ 5,041,979 $ 5,041,904 $ 5,512,479 The remuneration of directors and key executives was determined by the remuneration committee based on the performance of individuals and market trends. In addition, the remuneration of non-executive directors was $ 219,628 , $ 242,782 and $ 280,417 fo r the years ended December 31, 2021, 2022, and 2023, respectively.

Segment Information

Segment Information	12 Months Ended
	Dec. 31, 2023
Disclosure of operating segments [abstract]
Segment Information	24. SEGMENT INFORMATION The Company’s major business is research and development and operates only in one single segment. The Board of directors, which allocates resources and assesses performance of the Company as a whole, has identified that the Company has only one reportable operating segment. The Company has only one reportable operating segment, and therefore, the reportable segment information is the same as the financial statements. The following is an analysis of the Company’s revenue from its major products and services. For the year ended December 31 2021 2022 2023 Out-licensing $ — $ — $ 12,000,000 For the year ended December 31, 2023, there was revenue generated from out-licensing of development and commercialization rights in Japan to Zenyaku Kogyo Co., Ltd. for eblasakimab amounting to $ 12 million. Please refer to Note 15 for details

Other Items_Subsequent Events

Other Items/Subsequent Events	12 Months Ended
	Dec. 31, 2023
Disclosure of non-adjusting events after reporting period [abstract]
Other Items/Subsequent Events	25. OTHER ITEMS/SUBSEQUENT EVENTS a) On January 5, 2024, the Company received a notice (the “Notice”) from the Nasdaq Stock Market LLC (“Nasdaq”) that the Company is not currently in compliance with the $ 1.00 minimum bid price requirement for continued listing on the Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”). The Notice indicated that, consistent with Nasdaq Listing Rule 5810(c)(3)(A), the Company has 180 days, or until July 3, 2024 (the “Compliance Deadline”), to regain compliance with the Minimum Bid Price Requirement by having the closing bid price of the Company’s ADSs meet or exceed $ 1.00 per ADS for at least ten consecutive business days. The Notice is only a notification of deficiency and has no immediate effect on the listing of the Company’s ADSs. The Company’s ADSs will continue to trade on the Nasdaq Capital Market at this time. The Company’s receipt of the Notice does not impact the Company’s business, operations or reporting requirements with the Securities and Exchange Commission. The Company announced the receipt of the Notice through a press release on January 8, 2024. If the Company does not regain compliance by the Compliance Deadline, the Company may be afforded an additional 180 calendar day period to regain compliance. To qualify, the Company would be required to meet the continued listing requirement for market value of publicly held securities and all other initial listing standards for the Nasdaq Capital Market, except for the Minimum Bid Price Requirement. In addition, the Company would be required to notify Nasdaq of its intent to cure the deficiency during the second compliance period. If the Company does not regain compliance with the Minimum Bid Price Requirement by the end of the compliance period (or the second compliance period, if applicable), the Company’s ADSs will become subject to delisting. In the event that the Company receives notice that its ADSs are being delisted, the Nasdaq listing rules permit the Company to appeal a delisting determination to a Nasdaq hearings panel. b) On January 24, 2024, the Company held an Extraordinary General Meeting of shareholders. At the Extraordinary General Meeting, the Company’s requisite shareholders approved (i) an ordinary resolution to increase the Company’s authorized share capital from US$ 10,000,000 divided into 1,000,000,000 ordinary shares of a nominal or par value of US$ 0.01 each to US$ 50,000,000 divided into 5,000,000,000 ordinary shares of a nominal or par value of US$ 0.01 each, and (ii) a special resolution to replace existing Memorandum and Articles of Association of the Company (being the Tenth Amended and Restated Memorandum and Articles of Association of the Company) with a new Memorandum and Articles of Association (being the Eleventh Amended and Restated Memorandum and Articles of Association of the Company) under the Companies Act (as amended) of the Cayman Islands. c) On March 12, 2024, the Company entered into a securities purchase agreement (the Purchase Agreement), with the purchasers signatory thereto (the Purchasers), pursuant to which the Company agreed to sell and issue, in a registered direct offering, 125,000,000 ordinary shares in the form of 5,000,000 ADSs, at a gross purchase price of $ 1.00 per ADS (the Registered Offering). The ADSs were offered by the Company pursuant to an effective shelf registration statement on Form F-3, which was originally filed with the Securities and Exchange Commission on March 24, 2023 and was declared effective on April 6, 2023 and a prospectus supplement thereunder. Pursuant to the Purchase Agreement, in a concurrent private placement, the Company also agreed to sell and issue to the Purchasers unregistered warrants (the Warrants) to purchase up to 125,000,000 ordinary shares in the form of 5,000,000 ADSs (the Private Placement and together with the Registered Offering, the Offering). The Warrants are exercisable upon issuance (the Initial Exercise Date) at an exercise price of $ 1.00 per ADS and will expire on the five-year anniversary of the Initial Exercise Date. Pursuant to the terms of Purchase Agreement, on March 26, 2024, the Company filed a registration statement on Form F-3 covering the sale of the ADS underlying the Warrants (the Resale Registration Statement). Upon effectiveness of the Resale Registration Statement, the shares underlying the Warrants will be freely tradeable in the United States. The Registered Offering closed on March 14, 2024. The aggregate gross proceeds to the Company from the Registered Offering were $ 5 million, before deducting offering expenses payable by the Company. Pursuant to the terms of the Purchase Agreement, the Company agreed (i) not to issue, enter into an agreement to issue or announce the issuance or proposed issuance of any of its ADSs, ordinary shares or ordinary share equivalents, or (ii) file any registration statement or any amendment or supplement thereto, subject to certain exceptions, until 30 days following the closing of this offering. In addition, pursuant to the terms of the Warrant, the Company also agreed that at any time on or after the Initial Exercise Date but on or prior to the Termination Date, if the Company grants, issues or sells any ordinary share equivalents or rights to purchase shares, warrants, securities or other property pro rata to the record holders of any class of ordinary shares or ADSs (the “Purchase Rights”), the Purchaser in this Offering shall, in the aggregate, have the right to participate in such financing the aggregate Purchase Rights which the Purchaser could have acquired if the Purchaser had held the number of ordinary shares or ADSs acquirable upon complete exercise of the Warrant.

Summary of Material Accountin_2

Summary of Material Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2023
Disclosure Of Significant Accounting Policies [Abstract]
Statement of compliance	a. Statement of compliance The material accounting policies applied in the preparation of these consolidated financial statements are set out below. These policies have been consistently applied to all the periods presented, unless otherwise stated. The accompanying consolidated financial statements have been prepared in conformity with IFRS Accounting Standards issued by the IASB.
Basis of preparation	b. Basis of preparation The consolidated financial statements have been prepared on the historical cost basis except for financial instruments and long-term incentive plan payable arising from cash-settled share-based payment arrangements which are measured at fair value.
Going concern	c. Going concern Through December 31, 2023, the Company has an accumulated deficit of $ 321 million arising from recurring losses from operations and negative cash flows from operating activities. The Company’s activities have been funded primarily through public and private offerings. As the Company is in the clinical research and development phase, it will be seeking future funding based on the requirements of our business operations. The Company intends to continue to explore various means of fundraising to meet our funding requirements to carry out our business operations, such as offerings of ADSs via its at the market offering sales agreement, follow-on offerings of ADSs, venture debt and shareholder loans. It may also use other means of financing such as out-licensing, which is subject to negotiation, to generate revenue and cash. The Company has the ability to exercise discretion and flexibility to deploy our capital resources used in research and development activities according to the amount and timing of the financing activities. In March 2024, the Company raised additional funds of $ 5.0 million in gross proceeds pursuant to the Securities Purchase Agreement. See Note 25 c) for details. The Company will incur additional losses as it continues to focus its resources on advancing the development of its therapeutic candidates that will result in negative cash flows from operating activities. The Company’s current cash resources are not sufficient to complete the research and development activities of all of its therapeutic candidates in the absence of any additional funding. Management believes that there is presently insufficient funding available to allow the Company to fund its activities for a period exceeding one year and meet its obligations as they become due within one year from the date of this filing. In the absence of additional funding, these conditions and events indicate that there is substantial doubt about the Company’s ability to continue as a going concern. The accompanying financial statements have been prepared assuming that the Company will continue as a going concern.
Basis of consolidation	d. Basis of consolidation The consolidated financial statements include the financial statements of ASLAN Cayman and entities controlled by ASLAN Cayman (its subsidiaries). The consolidated financial statements incorporate the financial statements of ASLAN Cayman and entities controlled by ASLAN Cayman (its subsidiaries) made up to December 31 each year. Control is achieved when the Company: • Has the power over the investee; • Is exposed, or has rights, to variable returns from its involvement with the investee; and • Has the ability to use its power to affects its returns. The Company reassesses whether or not it controls an investee if facts and circumstances indicate that there are changes to one or more of the three elements of control listed above. When the Company has less than a majority of the voting rights of an investee, it considers that it has power over the investee when the voting rights are sufficient to give it the practical ability to direct the relevant activities of the investee unilaterally. The Company considers all relevant facts and circumstances in assessing whether or not the Company’s voting rights in an investee are sufficient to give it power, including: • The size of the Company’s holding of voting rights relative to the size and dispersion of holdings of the other vote holders; • Potential voting rights held by the Company, other vote holders or other parties; • Rights arising from other contractual arrangements; and • Any additional facts and circumstances that indicate that the Company has, or does not have, the current ability to direct the relevant activities at the time that decisions need to be made, including voting patterns at previous shareholders’ meetings. Consolidation of a subsidiary begins when the Company obtains control over the subsidiary and ceases when the Company loses control of the subsidiary. Specifically, the results of subsidiaries acquired or disposed of during the year are included in profit or loss from the date the Company gains control until the date when the Company ceases to control the subsidiary. When necessary, adjustments are made to the financial statements of subsidiaries to bring their accounting policies into line with those used by the Company. All intragroup assets and liabilities, equity, income, expenses and cash flows relating to transactions between the members of the Company are eliminated on consolidation. Non-controlling interests in subsidiaries are identified separately from the Company’s equity therein. Those interests of non-controlling shareholders that are present ownership interests entitling their holders to a proportionate share of net assets upon liquidation may initially be measured at fair value or at the non-controlling interests’ proportionate share of the fair value of the acquiree’s identifiable net assets. The choice of measurement is made on an acquisition-by-acquisition basis. Other non-controlling interests are initially measured at fair value. Subsequent to acquisition, the carrying amount of non-controlling interests is the amount of those interests at initial recognition plus the non-controlling interests’ share of subsequent changes in equity. Profit or loss and each component of other comprehensive income are attributed to the stockholders of the Company and to the non-controlling interests. Total comprehensive income of the subsidiaries is attributed to the stockholders of the Company and to the non-controlling interests even if this results in the non-controlling interests having a deficit balance. Changes in the Company’s ownership interests in subsidiaries that do not result in the Company losing control over the subsidiaries are accounted for as equity transactions. The carrying amounts of the interests of the Company and the non-controlling interests are adjusted to reflect the changes in their relative interests in the subsidiaries. Any difference between the amount by which the non-controlling interests are adjusted and the fair value of the consideration paid or received is recognized directly in equity and attributed to stockholders of the Company. When the Company loses control of a subsidiary, the gain or loss on disposal recognized in profit or loss is calculated as the difference between (i) the aggregate of the fair value of the consideration received and the fair value of any retained interest and (ii) the previous carrying amount of the assets (including goodwill), less liabilities of the subsidiary and any non-controlling interests. All amounts previously recognized in other comprehensive income in relation to that subsidiary are accounted for as if the Company had directly disposed of the related assets or liabilities of the subsidiary (i.e. reclassified to profit or loss or transferred to another category of equity as required/permitted by applicable IFRS Accounting Standards). The fair value of any investment retained in the former subsidiary at the date when control is lost is regarded as the fair value on initial recognition for subsequent accounting under IFRS 9 when applicable, or the cost on initial recognition of an investment in an associate or a joint venture. Associates An associate is an entity over which the Company has significant influence and that is neither a subsidiary nor an interest in a joint venture. Significant influence is the power to participate in the financial and operating policy decisions of the investee but is not control or joint control over those policies. The results and assets and liabilities of associates are incorporated in these financial statements using the equity method of accounting, except when the investment is classified as held for sale, in which case it is accounted for in accordance with IFRS 5 “Non-current Assets Held for Sale and Discontinued Operations”. Under the equity method, an investment in an associate is initially recognized in the consolidated balance sheet at cost and adjusted thereafter to recognize the Company’s share of the profit or loss and other comprehensive income of the associate. When the Company’s share of losses of an associate exceeds the Company’s interest in that associate (which includes any long-term interests that, in substance, form part of the Company’s net investment in the associate), the Company discontinues recognizing its share of further losses. Additional losses are recognized only to the extent that the Company has incurred legal or constructive obligations or made payments on behalf of the associate. An investment in an associate is accounted for using the equity method from the date on which the investee becomes an associate. On acquisition of the investment in an associate, any excess of the cost of the investment over the Company’s share of the net fair value of the identifiable assets and liabilities of the investee is recognized as goodwill, which is included within the carrying amount of the investment. Any excess of the Company’s share of the net fair value of the identifiable assets and liabilities over the cost of the investment, after reassessment, is recognized immediately in profit or loss in the period in which the investment is acquired. The requirements of IAS 36 Impairment of Assets are applied to determine whether it is necessary to recognize any impairment loss with respect to the Company’s investment in an associate. When necessary, the entire carrying amount of the investment (including goodwill) is tested for impairment in accordance with IAS 36 as a single asset by comparing its recoverable amount (higher of value in use and fair value less costs of disposal) with its carrying amount, any impairment loss recognized forms part of the carrying amount of the investment. Any reversal of that impairment loss is recognized in accordance with IAS 36 to the extent that the recoverable amount of the investment subsequently increases.
Foreign currencies	e. Foreign currencies Both the functional currency and presentation currency of the Company is the U.S. dollar. Monetary assets and liabilities denominated in currencies other than the applicable functional currencies are translated into the functional currencies at the prevailing rates of exchange at the end of the reporting period. Nonmonetary assets and liabilities are remeasured into the applicable functional currencies at historical exchange rates. Transactions in currencies other than the applicable functional currencies during the year are converted into the functional currencies at the applicable rates of exchange prevailing at the dates of the transactions. Exchange differences are recognized in “other gains and losses, net” in the consolidated statement of comprehensive loss.
Impairment of tangible and intangible assets	f. Impairment of tangible and intangible assets At the end of each reporting period, the Company reviews the carrying amounts of its tangible and intangible assets in order to determine whether there is any indication that those assets have suffered any impairment loss. If any such indication exists, the recoverable amount of an asset is estimated in order to determine the extent of the impairment loss. When it is not possible to estimate the recoverable amount of an individual asset, the Company estimates the recoverable amount of the cash-generating unit to which the asset belongs. Intangible assets with indefinite useful lives and intangible assets not yet available are not subject to amortization but are tested annually for impairment or more frequently if there are indicators of impairment. In respect of the impairment indicators, the Company considers both internal and external sources of information to determine whether an asset may be impaired, which may include the significant underperformance of the business in relation to expectations, significant negative industry or economic trends, and significant changes or planned changes with adverse effects in the use of the assets, as well as the internal reporting which indicates the economic performance of an asset is worse than expected. If any such indicators exist, the Company will estimate the recoverable amount of such indefinite-lived intangible asset and compare it with its carrying amount. The recoverable amount is the higher of fair value less costs of disposal and value in use. If the recoverable amount of an asset or cash-generating unit is estimated to be less than its carrying amount, the carrying amount of the asset or cash-generating unit is reduced to its recoverable amount, with the resulting impairment loss recognized in profit or loss. When an impairment loss is subsequently reversed, the carrying amount of the corresponding asset or cash-generating unit is increased to the revised estimate of its recoverable amount, but only to the extent of the carrying amount that would have been determined had no impairment loss been recognized on the asset or cash-generating unit in prior years. A reversal of an impairment loss is recognized in profit or loss.
Financial instruments	h. Financial instruments Financial assets and financial liabilities are recognized when a Company becomes a party to the contractual provisions of the instruments. Financial assets and financial liabilities are initially measured at fair value. Transaction costs that are directly attributable to the acquisition or issuance of financial assets and financial liabilities (other than financial assets and financial liabilities at fair value through profit or loss (i.e., FVTPL)) are added to or deducted from the fair value of the financial assets or financial liabilities, as appropriate, on initial recognition. Transaction costs directly attributable to the acquisition of financial assets or financial liabilities at FVTPL are recognized immediately in profit or loss. 1) Financial asset All regular way purchases or sales of financial assets are recognized and derecognized on a trade date basis. a) Measurement categories Financial assets are classified into the following categories: Financial assets at FVTPL, financial assets at amortized cost and equity instruments at fair value through other comprehensive income (i.e., FVOCI). i. Financial assets at FVTPL Money market funds are classified as FVTPL as they do not meet the conditions to be classified as amortized cost or FVOCI. Financial assets at FVTPL are subsequently measured at fair value, with any gains or losses arising on remeasurement recognized in other gains or losses. ii. Financial assets at amortized cost A financial asset shall be measured at amortized cost if both of the following conditions are met: i) The financial asset is held within a business model whose objective is to hold financial assets in order to collect contractual cash flows; and ii) The contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding. For the financial assets measured at amortized cost (including cash and cash equivalents and refundable deposits), the Company applies the effective interest method to the gross carrying amount at amortized cost less any impairment from initial recognition. Any foreign exchange gains and losses are recognized in profit or loss. Interest income is calculated by applying the effective interest rate to the gross carrying amount of such a financial asset. Short-term investments have been purchased during the year and have matured before the end of the year. These have been assessed to be financial assets held at amortized cost. Interest accretion income on short-term investment is recognized in profit or loss and as part of "Other Income" line item. Cash equivalents include time deposits and money markets funds, which are highly liquid, readily convertible to a known amount of cash and are subject to an insignificant risk of changes in value. These cash equivalents are held for the purpose of meeting short-term cash commitments. iii. Investments in equity instruments at FVOCI On initial recognition, the Company may make an irrevocable election to designate investments in equity instruments as at FVOCI. Designation as at FVOCI is not permitted if the equity investment is held for trading or if it is contingent consideration recognized by an acquirer in a business combination. Investments in equity instruments at FVOCI are subsequently measured at fair value with gains and losses arising from changes in fair value recognized in other comprehensive income and accumulated in other equity. The cumulative gain or loss will not be reclassified to profit or loss on disposal of the equity investments; instead, it will be transferred to retained earnings. Dividends on these investments in equity instruments are recognized in profit or loss when the Company’s right to receive the dividends is established, unless the dividends clearly represent a recovery of part of the cost of the investment. Fair value hierarchy levels 1 to 3 are based on the degree to which the fair value is observable: • Level 1 fair value measurements are those derived from quoted prices (unadjusted) in active markets for identical assets or liabilities; • Level 2 fair value measurements are those derived from inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly (i.e. as prices) or indirectly (i.e. derived from prices); and • Level 3 fair value measurements are those derived from valuation techniques that include inputs for the asset or liability that are not based on observable market data (unobservable inputs). b) Impairment of financial assets The Company recognizes a loss allowance for expected credit losses on financial assets at amortized cost. For financial instruments, the Company recognizes lifetime expected credit losses (i.e., ECLs) when there has been a significant increase in credit risk since initial recognition. If, on the other hand, the credit risk on a financial instrument has not increased significantly since initial recognition, the Company measures the loss allowance for that financial instrument at an amount equal to 12-month ECLs. Expected credit losses reflect the weighted average of credit losses with the respective risks of default occurring as the weights. Lifetime ECLs represent the expected credit losses that will result from all possible default events over the expected life of a financial instrument. In contrast, 12-month ECLs represent the portion of lifetime ECLs that is expected to result from default events on a financial instrument that are possible within 12 months after the reporting date. The Company recognizes an impairment gain or loss in profit or loss for all financial instruments with a corresponding adjustment to their carrying amount through a loss allowance account. c) Derecognition of financial assets The Company derecognizes a financial asset only when the contractual rights to the cash flows from the asset expire or when it transfers the financial asset and substantially all the risks and rewards of ownership of the asset to another party. On derecognition of a financial asset at amortized cost in its entirety, the difference between the asset’s carrying amount and the sum of the consideration received and receivable is recognized in profit or loss. On derecognition of an investment in an equity instrument at FVOCI, the cumulative gain or loss previously accumulated in the investments revaluation reserve is reclassified to profit or loss. In contrast, on derecognition of an investment in an equity instrument which the group has elected on initial recognition to measure at FVOCI, the cumulative gain or loss previously accumulated in the investments revaluation reserve is not reclassified to profit or loss, but is transferred to retained earnings. 2) Equity instruments Debt and equity instruments issued by the Company entity are classified as either financial liabilities or as equity in accordance with the substance of the contractual arrangements and the definitions of a financial liability and an equity instrument. Equity instruments issued by the Company entity are recognized at the proceeds received, net of direct issue costs. Expired equity instruments will be reclassified to accumulated deficit. No gain or loss is recognized in profit or loss on the issuance of the Company’s own equity instruments. 3) Financial liabilities a) Subsequent measurement Except the following situations, all financial liabilities are measured at amortized cost using the effective interest method: 1) Financial liabilities at FVTPL Financial liabilities are classified as at FVTPL when such financial liabilities are either held for trading or are designated as at FVTPL. Financial liabilities held for trading are stated at fair value, and any gains or losses on such financial liabilities are recognized in other gains or losses. Fair value is determined in the manner described in Note 22. b) Derecognition of financial liabilities The difference between the carrying amount of a financial liability derecognized and the consideration paid and payable, including any non-cash assets transferred or liabilities assumed, is recognized in profit or loss. When the Company exchanges with the existing lender one debt instrument into another one with substantially different terms, such exchange is accounted for as an extinguishment of the original financial liability and the recognition of a new financial liability. Similarly, the Company accounts for substantial modification of terms of an existing liability or part of it as an extinguishment of the original financial liability and the recognition of a new liability. It is assumed that the terms are substantially different if the discounted present value of the cash flows under the new terms, including any fees paid net of any fees received and discounted using the original effective rate is at least 10 per cent different from the discounted present value of the remaining cash flows of the original financial liability. If the modification is not substantial, the difference between: (1) the carrying amount of the liability before the modification; and (2) the present value of the cash flows after modification is recognized in profit or loss as the modification gain or loss within other gains and losses. 4) Compound instruments The component parts of compound instruments issued by the Company are classified separately as financial liabilities and equity in accordance with the substance of the contractual arrangements and the definitions of a financial liability and an equity instrument. A component part that will be settled by the exchange of a fixed amount of cash or another financial asset for a fixed number of the Company’s own equity instruments is an equity instrument. At the date of issue, the fair value of the liability component is estimated using the prevailing market interest rate for similar non-convertible instruments. This amount is recorded as a liability on an amortized cost basis using the effective interest method until extinguished upon conversion or upon the instrument’s maturity date. 5) Derivative financial instruments Derivatives embedded in non-derivative host contracts that are not financial assets that is within the scope of IFRS 9 (e.g. financial liabilities) are treated as separate derivatives when they meet the definition of a derivative; their risks and characteristics are not closely related to those of the host contracts; and the host contracts are not measured at FVTPL. The derivatives are measured at FVTPL (Notes 13(b) and 14(a)).
Research and development expenses	g. Research and development expenses Elements of research and development expenses primarily include: 1) Payroll and other related costs of personnel engaged in research and development activities; 2) Costs related to preclinical testing of the Company’s technologies under development and clinical trials, such as payments to contract research organizations (“CROs”), investigators and clinical trial sites that conduct the Company’s clinical studies; 3) Costs to develop the product candidates, including raw materials, supplies and product testing related expenses; and 4) Other research and development expenses. Research and development expenses are expensed as incurred when these expenditures relate to the Company’s research and development services and have no alternative future uses. The conditions enabling the capitalization of development costs as an asset have not yet been met and, therefore, all development expenditures are recognized in profit or loss when incurred.
Share-based payment arrangements	i. Share-based payment arrangements Equity-settled share-based payments to employees are measured at the fair value of the equity instruments at the grant date. The fair value determined at the grant date of the employee share options is expensed on a straight-line basis over the vesting period, based on the Company’s estimate of the number of employee share options that will eventually vest, with a corresponding increase in “capital surplus - share options reserve”. The fair value determined at the grant date of the employee share options is recognized as an expense in full at the grant date when the share options granted vest immediately. At the end of each reporting period, the Company revises its estimate of the number of employee share options expected to vest. The impact of the revision of the original estimates is recognized in profit or loss such that the cumulative expense reflects the revised estimate, with a corresponding adjustment to the capital surplus. The LTIPs qualify as cash-settled share-based payment transactions. For cash-settled share-based payments, the fair value of the amount payable to beneficiaries in respect of bonus entitlement unit grants, which are settled in cash, is recognized as an expense with a corresponding increase in liabilities, over the period during which the beneficiaries become unconditionally entitled to payment. The amount is remeasured at each reporting date and at settlement based on the fair value of the bonus entitlement units. Any changes in the liability are recognized in profit or loss. Modification of the terms on which equity instruments were granted may have an effect on the expense that will be recorded. In accordance with IFRS 2, modifications also apply to instruments modified after their vesting date. If the fair value of the new instruments is more than the fair value of the old instruments (e.g., by reduction of the exercise price or issuance of additional instruments), the incremental amount is recognized over the remaining vesting period in a manner similar to the original amount. If the modification occurs after the vesting period, the incremental amount is recognized immediately. If the fair value of the new instruments is less than the fair value of the old instruments, the original fair value of the equity instruments granted is expensed as if the modification never occurred.
Taxation	j. Taxation The provision for income tax recognized in profit or loss comprises current and deferred tax. Current tax is income tax paid and payable for the current year based on the taxable profit of the year and any adjustments to tax payable (or receivable) in respect of prior years. Deferred tax is accounted for using the balance sheet liability method in respect of temporary differences arising from differences between the carrying amount of assets and liabilities in the financial statements and the corresponding tax basis used in the computation of taxable profit or loss. Deferred tax assets are recognized to the extent that it is probable that future taxable profits will be available against which the temporary differences can be utilized. The carrying amount is reviewed at the end of each reporting period on the same basis. Deferred tax is measured at the tax rates that are expected to apply in the period in which the asset or liability is settled, based on tax rates that have been enacted or substantively enacted by the end of the reporting period.
Revenue recognition	k. Revenue recognition Revenue comprises the fair value of the consideration received or receivable for the out-licensing of experimental drugs that have reached ‘proof of concept’ to business partners for ongoing global development and launch, in the ordinary course of the Company’s activities. Revenue is presented, net of goods and services tax, rebates and discounts. See Note 15 for details of the Company’s licensing agreements. The Company recognizes revenue when it has completed the out-licensing of the experimental drug to business partners, and such partners have accepted the products. Thus, the collectability of the related receivables is reasonably assured. Typically the consideration received from out-licensing may take the form of upfront payments, option payments, milestone payments, and royalty payments on licensed products. To determine revenue recognition for contracts with customers, the Company performs the following five steps: 1) Identify the contract with a customer; 2) Identify the performance obligations in the contract; 3) Determine the transaction price; 4) Allocate the transaction price to the performance obligations in the contract; and 5) Recognize revenue when (or as) the Company satisfies the performance obligations. At the inception of a contract, the Company assesses the goods or services promised within each contract to determine whether each promised good or service is distinct and identify those that are performance obligations. The Company recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. Upfront License Fees If a license to the Company’s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company will recognize revenues from non-refundable, upfront fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other distinct performance obligations, the Company uses judgment to assess the nature of the combined performance obligation to determine whether it is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress at the end of each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. Milestone Payments At the inception of each contract with customers that includes development or regulatory milestone payments (i.e., the variable consideration), the Company includes some or all amount of variable consideration in the transaction price estimated only to the extent that it is highly probable that a significant reversal in the amount of cumulative revenue recognized would not occur when the uncertainty related to the variable consideration is subsequently resolved. Milestone payments that are contingent upon the achievement of events that are uncertain or not controllable, such as regulatory approvals, are generally not considered highly probable of being achieved until those approvals are received. Therefore, they are not included in the transaction price. At the end of each reporting period, the Company evaluates the probability of achievement of such milestone payments and any related constraints and, if necessary, adjusts the Company’s estimate of the overall transaction price. Royalties For arrangements that include sales-based royalties, including commercial milestone payments based on the level of sales, and for which the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of the following: 1) When the subsequent sales occur, or 2) When the performance obligation, to which some or all of the royalty has been allocated, has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue resulting from any of out-licensing arrangements.

Application of New Amended an_2

Application of New Amended and Revised Standards and Interpretations (Tables)	12 Months Ended
	Dec. 31, 2023
Disclosure of initial application of standards or interpretations [abstract]
Schedule of New Amended or Revised Accounting Standards and Interpretations	At the date of authorization of these financial statements, the Company has not applied the following new and revised IFRS Accounting Standards that have been issued but are not yet effective: New IFRS Accounting Standards Description IFRS 10 and IAS 28 (amendments) Sale or Contribution of Assets between an Investor and its Associate or Joint Venture Amendments to IAS 1 Classification of Liabilities as Current or Non-current Amendments to IAS 1 Non-current Liabilities with Covenants Amendments to IAS 7 and IFRS 7 Supplier Finance Agreement Amendments to IAS 21 Lack of Exchangeability Amendments to IFRS 16 Lease Liability in a Sale and Leaseback The Company anticipates that the application of these amendments may have an impact on the consolidated financial statements in future periods and is in the process of assessing the potential impact of these amendments.

Cash and Cash Equivalents (Tabl

Cash and Cash Equivalents (Tables)	12 Months Ended
	Dec. 31, 2023
Cash and cash equivalents [abstract]
Summary of Cash and Cash Equivalents	December 31, December 31, 2022 2023 Cash in hand $ 256 $ 648 Cash in banks 26,456,482 21,251,410 Money market fund 30,445,339 — $ 56,902,077 $ 21,252,058

Other Assets (Tables)

Other Assets (Tables)	12 Months Ended
	Dec. 31, 2023
Other Assets Current And Non Current [Abstract]
Summary of Other Assets	December 31, December 31, 2022 2023 Other receivable $ — $ 171,441 Prepayments $ 2,942,936 $ 1,681,465 Refundable deposits 1,033,414 1,025,028 $ 3,976,350 $ 2,877,934

Financial Instruments at Fair_3

Financial Instruments at Fair Value Through Profit or Loss (Tables)	12 Months Ended
	Dec. 31, 2023
Financial assets at fair value through profit or loss [abstract]
Summary of Financial Instruments at Fair Value Through Profit or Loss	December 31, December 31, 2022 2023 Financial liabilities at fair value through profit or loss (FVTPL) Derivative financial liabilities – K2HV warrants $ 90,213 $ 87,693 Derivative financial liabilities – Tranche 2B warrants — 701 $ 90,213 $ 88,394

Financial Instruments at Fair_4

Financial Instruments at Fair Value Through Other Comprehensive Income (Tables)	12 Months Ended
	Dec. 31, 2023
Disclosure of fair value of investments in equity instruments designated at fair value through other comprehensive income [abstract]
Summary of Financial Instruments at Fair Value Through Other Comprehensive Income	December 31, December 31, 2022 2023 Financial asset at fair value through other comprehensive income (FVOCI) Investment in equity instruments at FVOCI - Foreign unlisted ordinary shares $ — $ 235,567

Subsidiaries (Tables)

Subsidiaries (Tables)	12 Months Ended
	Dec. 31, 2023
Disclosure of subsidiaries [abstract]
Summary of Subsidiaries Included in Consolidated Financial Statements	Proportion of December 31 Investor Investee Nature of Activities 2022 2023 Subsidiaries ASLAN ASLAN New drug research 100 % 100 % ASLAN ASLAN New drug research 100 % 100 % ASLAN ASLAN New drug research 100 % 100 % ASLAN ASLAN New drug research 100 % 100 % ASLAN ASLAN New drug research 100 % 100 %

Investment in Associate Compa_2

Investment in Associate Company (Tables)	12 Months Ended
	Dec. 31, 2023
Disclosure of associates [abstract]
Summary of Financial Information Before Intragroup Eliminations	Summarized financial information of Jaguahr Therapeutics Pte. Ltd. is set out below. The summarized financial information below represents amounts in associate company financial statements prepared in accordance with IFRS Accounting Standards. December 31 December 31 2022 2023 Current asset $ 54,906 $ 192,641 Current liabilities ( 30,371 ) ( 543,278 ) Equity/(Capital deficiency) $ 24,535 $ ( 350,637 )

Trade And Other Payables (Table

Trade And Other Payables (Tables)	12 Months Ended
	Dec. 31, 2023
Trade and other payables [abstract]
Schedule of Other Payables	Other payables December 31, December 31, 2022 2023 Payables for cash-settled long-term incentive plan (Note 19) $ 234,448 $ 46,699 Payables for salaries and bonuses 1,375,627 1,748,901 Payables for professional fees 560,578 1,098,536 Others 154,385 187,193 Total other payables $ 2,325,038 $ 3,081,329 Maturity analysis: On demand or within 1 year $ 2,325,038 $ 3,081,329

Borrowings (Tables)

Borrowings (Tables)	12 Months Ended
	Dec. 31, 2023
Borrowings [abstract]
Summary of Loans	December 31, December 31, 2022 2023 Unsecured borrowings at amortized cost Loans from government (a) $ 11,855,579 $ 12,496,831 Secured borrowings at amortized cost Other long-term borrowings (b) $ 25,549,385 $ 14,102,108 Total borrowings $ 37,404,964 $ 26,598,939 Analyzed as: Current and repayable on demand or within 1 year $ 7,748,831 $ 1,800,387 Non-current and repayable more than 1 year $ 29,656,133 $ 24,798,552 Total borrowings $ 37,404,964 $ 26,598,939

Equity (Tables)

Equity (Tables)	12 Months Ended
	Dec. 31, 2023
Equity [abstract]
Schedule of Ordinary Shares	a. Ordinary shares December 31, December 31, December 31, 2021 2022 2023 Number of ordinary shares authorized * 500,000,000 500,000,000 1,000,000,000 Authorized par value per share US$ 0.01 US$ 0.01 US$ 0.01 Number of ordinary shares issued and fully paid 348,723,365 348,723,365 439,926,480 Number of equivalent ADSs issued and fully paid 13,948,935 13,948,935 17,597,059 Amount of share capital par value issued and fully paid $ 63,019,962 $ 63,019,962 $ 63,931,993 Amount of share capital surplus issued and fully paid $ 213,098,729 $ 213,098,729 $ 219,774,205

Loss Before Income Tax (Tables)

Loss Before Income Tax (Tables)	12 Months Ended
	Dec. 31, 2023
Profit (loss) [abstract]
Summary of Other Income	a. Other income For the year ended December 31 2021 2022 2023 ADS issuance contribution $ 1,076,189 $ — $ 386,908 Government grants for research and development expenditures — 248,613 73,724 Government subsidies 31,112 29,147 — Accretion income — 94,248 — Others 771 14,130 1,689 $ 1,108,072 $ 386,138 $ 462,321
Schedule of Other Gains and Losses	b. Other gains and losses For the year ended December 31 2021 2022 2023 Net foreign exchange (losses) gains $ 512,450 $ ( 85,869 ) $ ( 332,725 ) Gain on disposal of property, plant and equipment — 1,172 148 Net gain on fair value changes of financial assets and 594,046 133,139 3,466,999 Others 14 ( 78,025 ) ( 12,816 ) $ 1,106,510 $ ( 29,583 ) $ 3,121,606
Summary of Finance costs	c. Finance costs For the year ended December 31 2021 2022 2023 Interest on government loans $ 443,216 $ 431,052 $ 442,410 Interest on other long-term borrowing 1,191,381 3,224,369 3,871,299 Interest on loans from shareholders 154,773 — — Interest on loans from related parties 50,074 — — Interest on lease liabilities 21,510 12,544 13,074 Others — 7,724 4,878 $ 1,860,954 $ 3,675,689 $ 4,331,661
Schedule of Depreciation and Amortization	d. Depreciation and amortization For the year ended December 31 2021 2022 2023 Right-of-use assets $ 264,804 $ 308,682 $ 319,725 Property, plant and equipment 14,856 18,950 24,653 Intangible assets 2,564 4,120 4,120 $ 282,224 $ 331,752 $ 348,498
Schedule of Employee Benefits Expense	e. Employee benefits expense For the year ended December 31 2021 2022 2023 Short-term benefits $ 6,940,900 $ 8,423,133 $ 9,622,503 Post-employment benefits 257,128 355,434 415,509 Share-based payments (Note 19) Equity-settled 2,428,128 2,443,894 2,769,279 Cash-settled ( 234,761 ) ( 467,134 ) ( 66,079 ) Total employee benefits expense $ 9,391,395 $ 10,755,327 $ 12,741,212 Employee benefits expense by function General and administrative expenses $ 5,718,646 $ 5,643,217 $ 7,148,068 Research and development expenses 3,672,749 5,112,110 5,593,144 $ 9,391,395 $ 10,755,327 $ 12,741,212

Income Tax Expense (Tables)

Income Tax Expense (Tables)	12 Months Ended
	Dec. 31, 2023
Income Tax [Abstract]
Summary of Income Tax Recognised in Profit or Loss	Income Tax recognized in Profit or Loss The tax rate used for the 2023, 2022 and 2021 reconciliations below is the corporate tax rate of 17 % payable by corporate entity in Singapore on taxable loss under tax law in that jurisdiction where the Company’s main operation is at Singapore. For the year ended December 31 2021 2022 2023 Current tax expenses In respect of the current period $ — $ 79,379 $ 113,251 Adjustments for prior periods — 19,842 19,416 $ — $ 99,221 $ 132,667 2021 2022 2023 Loss before income tax $ ( 31,590,582 ) $ ( 51,283,196 ) $ ( 44,086,937 ) Income tax benefits calculated at the statutory rate $ ( 5,370,399 ) $ ( 8,718,143 ) $ ( 7,494,779 ) Tax effect of income not taxable in determining taxable income ( 870,151 ) 19,769 83,729 Non-deductible expenses in determining taxable income 648,651 361,600 549,230 Tax credits for research and development expenditures ( 1,467,816 ) ( 245,802 ) ( 161,510 ) Unrecognized loss carry forwards 6,044,928 7,688,535 6,396,624 Tax effect of share of results of associates and joint venture 405,712 74,125 1,460 Effect of different tax rates of group entities operating in other 609,075 917,106 738,497 Adjustments for prior year' tax — 19,842 19,416 Others — ( 17,811 ) — Income tax expenses recognized in profit or loss $ — $ 99,221 $ 132,667

Loss Per Ordinary Share (Tables

Loss Per Ordinary Share (Tables)	12 Months Ended
	Dec. 31, 2023
Earnings per share [abstract]
Summary of Earnings Per Share	For the year ended December 31 2021 2022 2023 Basic and diluted loss per ordinary share $ ( 0.10 ) $ ( 0.15 ) $ ( 0.11 ) Basic and diluted loss per equivalent ADS $ ( 2.40 ) $ ( 3.68 ) $ ( 2.69 )
Summary of Loss and Weighted-Average Number of Ordinary Shares Outstanding	The loss and weighted-average number of ordinary shares outstanding used in the computation of loss per share are as follows: For the year ended December 31 2021 2022 2023 Loss used in the computation of basic and diluted loss per ordinary $ ( 31,321,618 ) $ ( 51,382,417 ) $ ( 44,219,604 ) Weighted-average number of ordinary shares in the computation of 325,684,272 348,723,365 411,242,644 Weighted-average number of equivalent ADS in the computation of 13,027,371 13,948,935 16,449,706

Share-Based Payment Arrangeme_2

Share-Based Payment Arrangements (Tables)	12 Months Ended
	Dec. 31, 2023
Disclosure of terms and conditions of share-based payment arrangement [abstract]
Summary of Employee Share Options	Information on employee share options granted from the 2014 Plan is as follows. Each option entitles the holder to subscribe for two ordinary shares of the Company: For the Year Ended December 31 2021 2022 2023 Number of Weighted- Number of Weighted- Number of Weighted- Balance at January 1 533,629 $ 17.88 487,829 $ 17.88 371,569 $ 22.00 Options expired — — ( 116,260 ) 8.38 ( 48,800 ) 17.08 Options exercised ( 45,800 ) 5.38 — — — — Balance at December 31 487,829 17.88 371,569 22.00 322,769 22.74 Options exercisable, 487,829 17.88 371,569 22.00 322,769 22.74 Information on employee share options granted from the 2017 Plan is as follows. Each option entitles the holder to subscribe for one ordinary share of the Company: For the Year Ended December 31 2021 2022 2023 Number of Weighted- Number of Weighted- Number of Weighted- Balance at January 1 20,048 $ 31.90 20,048 $ 31.90 20,048 $ 31.90 Options forfeited — — — — ( 333 ) 31.90 Balance at December 31 20,048 31.90 20,048 31.90 19,715 31.90 Options exercisable, 20,048 31.90 20,048 31.90 19,715 31.90 Information on employee share options granted under the 2020 EIP is as follows. Each option entitles the holder to subscribe for one ADS of the Company: For the Year Ended 2021 2022 2023 Number of Weighted- Number of Weighted- Number of Weighted- Balance at January 1 764,812 $ 10.30 804,312 $ 2.60 1,154,068 $ 2.59 Options granted 56,400 16.20 498,630 2.57 786,827 2.93 Options forfeited ( 16,200 ) 10.30 ( 148,874 ) 2.60 ( 11,375 ) 2.33 Options exercised ( 700 ) 10.30 — — — — Balance at December 31 804,312 $ 10.30 1,154,068 $ 2.59 1,929,520 $ 2.73 Options exercisable, end of period 299,505 $ 10.30 408,964 $ 2.59 803,797 $ 2.59 Weighted-average fair value of each option granted $ 13.15 $ 2.59 $ 2.73
Summary of Outstanding Options	Information on outstanding options as of December 31, 2023 is as follows: Jul Jul Jul Jul Dec Jan - Jul Jan - Jul Jan - Jul Range of $ 6.80 $ 6.80 -$ 9.40 $ 11.30 $ 6.40 $ 2.60 $ 2.60 $ 2.50 -$ 2.60 $ 1.80 -$ 4.15 Weighted- 0.5 1.5 2.5 3.73 6.96 7.21 8.26 9.29
Summary of Options Granted Priced Using Binomial Option Pricing Model	Options granted in the 2014 Plan, the 2017 Plan, and the 2020 EIP were priced using the binomial option pricing model, and the inputs to the model were as follows: Jul Jul Jul Jul Dec Jan- Jan- Jan- Grant- $ 6.80 $ 9.40 $ 11.30 $ 6.40 $ 11.10 $ 11.75 -$ 20.60 $ 2.50 -$ 5.60 $ 1.80 -$ 4.15 Exercise $ 6.80 $ 6.80 -$ 9.40 $ 11.30 $ 6.40 $ 2.60 $ 2.60 $ 2.50 -$ 2.60 $ 1.80 -$ 4.15 Expected volatility 50.86 % 36.37 % 39.34 % 38.33 % 66.25 % 59.99 %- 64.92 % 118.2 %- 122.1 % 118.8 % - 133.5 % Expected 10 10 10 10 5.25 - 7 5.25 - 7 5.25 - 7 5.5 - 7 Risk-free 2.58 % 2.43 % 1.46 % 1.10 % 3.05 %- 3.06 % 3.05 %- 3.06 % 2.90 %- 3.06 % 3.58 %- 3.97 %
Summary of Long Term Incentive Plan	The Company’s LTIP is described as follows: Number of ADSs units 2021 2022 2023 Balance at January 1 148,906 144,147 144,147 Awards exercised ( 4,759 ) — ( 40,788 ) Awards lapsed — — ( 13,897 ) Balance at December 31 144,147 144,147 89,462 Balance exercisable, end of period 144,147 144,147 89,462

Reconciliation of Liabilities_2

Reconciliation of Liabilities Arising from Financing Activities (Tables)	12 Months Ended
	Dec. 31, 2023
Disclosure of reconciliation of liabilities arising from financing activities [abstract]
Summary of Changes in Liabilities Arising from Financing Activities, Including Both Cash and Non-cash Changes	The table below details changes in the Company’s liabilities arising from financing activities, including both cash and non-cash changes. Liabilities arising from financing activities are those for which cash flows were, or future cash flows will be, classified in the Company’s consolidated statements of cash flows as cash flows from financing activities. Non-cash changes January 1, Interest Net Additions/ Others* Interest December 31, Lease Liabilities – current $ 271,624 $ ( 21,510 ) $ ( 353,649 ) $ 281,149 $ — $ 21,510 $ 199,124 Lease Liabilities – non-current 281,149 — — ( 281,149 ) — — — Current borrowings (Note 13) 2,900,971 ( 484,043 ) ( 2,571,701 ) — — 154,773 — Current borrowings from related parties 617,912 ( 117,986 ) ( 550,000 ) — — 50,074 — Long-term borrowings (Note 13) 15,183,421 — 15,939,643 ( 688,324 ) ( 124,827 ) 547,396 30,857,309 Other payable - interest payables (Note 12) 735,510 — ( 1,680,628 ) — — 1,087,201 142,083 Non-cash changes January 1, Interest Net Additions/ Others* Interest December 31, Lease Liabilities – current $ 199,124 $ ( 12,544 ) $ ( 262,798 ) $ 293,460 $ ( 14,115 ) $ 12,544 $ 215,671 Other payable - interest payables (Note 12) 142,083 — — $ ( 142,083 ) — — — Current borrowings (Note 13) — ( 2,338,715 ) — 7,626,678 — 2,460,868 7,748,831 Long-term borrowings (Note 13) 30,857,309 — 5,000,000 ( 7,484,595 ) 88,866 1,194,553 29,656,133 Non-cash changes January 1, Interest Net Additions/ Others* Interest December 31, Lease Liabilities – current $ 215,671 $ ( 10,411 ) $ ( 296,920 ) $ 307,436 $ ( 2,663 ) $ 13,074 $ 226,187 Current borrowings (Note 13) 7,748,831 ( 3,318,576 ) — ( 6,501,167 ) — 3,871,299 1,800,387 Long-term borrowings (Note 13) 29,656,133 — ( 12,000,000 ) 6,501,167 198,842 442,410 24,798,552 Financial liabilities at fair value through profit or loss 90,213 — 3,465,180 **** — ( 3,466,999 ) — 88,394 * Others comprise mainly foreign currency translation differences for long-term borrowings and net gain on fair value changes for financial liabilities measured at fair value through profit or loss. ** The transfer from current to long-term borrowings is due to the amendment (Second Amendment) of K2HV Loan Agreement pursuant to which K2HV agreed to extend the period in which the Company is not required to make payments with respect to the outstanding amount (see Note 14b). *** The Company classified interest paid arising from third party borrowings and leases into operating and financing cash flows activities respectively. **** Net proceeds arising from cash received from Tranche 1B warrants and Tranche 2B warrants as of the date of issue which have been recorded as financial liabilities at fair value through profit or loss (see Note 14a).

Financial Instruments (Tables)

Financial Instruments (Tables)	12 Months Ended
	Dec. 31, 2023
Disclosure of detailed information about financial instruments [abstract]
Fair Value of Financial Instruments Measured at Fair Value on Recurring Basis	December 31, 2022 Level 1 Level 2 Level 3 Total Financial assets at fair value through profit or Money Market Fund $ 30,445,339 $ — $ — $ 30,445,339 Financial liabilities at fair value through profit or Derivative financial liabilities – K2 warrants $ — $ — $ 90,213 $ 90,213 December 31, 2023 Level 1 Level 2 Level 3 Total Financial assets at fair value through other comprehensive Foreign unlisted ordinary shares $ — $ — $ 235,567 $ 235,567 Financial liabilities at fair value through profit or Derivative financial liabilities K2 warrants $ — $ — $ 87,693 $ 87,693 Tranche 2B warrants $ — $ — $ 701 $ 701 Derivative financial liabilities $ — $ — $ 88,394 $ 88,394
Summary of Reconciliation of Level 3 Fair Value Measurements of Financial Instruments	2) Reconciliation of Level 3 fair value measurements of financial instruments K2 Warrants Tranche Warrants Unlisted foreign ordinary shares Balance at January 1, 2021 $ — $ — $ — Issues 688,324 — — Subsequent measurement recognized in profit and loss ( 464,972 ) — — Balance at January 1, 2022 $ 223,352 $ — $ — Issues 45,482 — — Subsequent measurement recognized in profit and loss ( 178,621 ) — — Balance at January 1, 2023 $ 90,213 $ — $ — Issues — 3,465,180 — Subsequent measurement recognized in Profit and loss ( 2,520 ) ( 3,464,479 ) — Other comprehensive income — — 235,567 Balance at December 31, 2023 $ 87,693 $ 701 $ 235,567 3) Fair value of the group’s financial assets and financial liabilities that are measured at fair value on a recurring basis
Summary of Fair Value of Financial Assets and Financial Liabilities Measured at Fair Value on Recurring Basis	The following table gives information about how the fair values of these financial assets and financial liabilities are determined. Financial assets/ financial liabilities Fair Value Hierarchy Valuation Technique(s) and key input(s) Significant unobservable input(s) Relation and sensitivity of unobservable inputs to fair value 1. Derivative financial liabilities - K2 warrants Level 3 Option Pricing Model (Binomial Tree Model). Volatility The higher the volatility, the higher the fair value. 5 per cent lower while all other variables were held constant, the carrying amount would decrease by US$ 3,631 . If the volatility was 5 per cent higher while all other variables were held constant, the carrying amount would increase by US$ 3,171 . 2. Derivative financial liabilities - 2B warrants Level 3 Option Pricing Model (Monte Carlo Simulation). Volatility The higher the volatility, the higher the fair value. 5 per cent lower while all other variables were held constant, the carrying amount would decrease by US$ 376 . If the volatility was 5 per cent higher while all other variables were held constant, the carrying amount would increase by US$ 552 . 3. Foreign unlisted ordinary shares Level 3 Backsolve Option Pricing Model. Volatility The higher the volatility, the higher the fair value. 5 per cent lower while all other variables were held constant, the carrying amount would decrease by US$ 1,314 . If the volatility was 5 per cent higher while all other variables were held constant, the carrying amount would increase by US$ 1,367 .
Summary of Categories of Financial Instruments	December 31, December 31, December 31, 2021 2022 2023 Financial assets Financial assets at fair value through other comprehensive Foreign unlisted ordinary shares $ — $ — $ 235,567 Financial assets at fair value through profit or loss Money Market Fund $ — $ 30,445,339 $ — Financial assets at amortized cost (1) $ 91,047,060 $ 27,490,152 $ 22,448,527 Financial liabilities Financial liabilities at fair value through profit or Derivative financial liabilities – K2 warrants $ 223,352 $ 90,213 $ 87,693 Derivative financial liabilities – Tranche 2B Warrants $ — $ — $ 701 $ 223,352 $ 90,213 $ 88,394 Financial liabilities at amortized cost (2) $ 36,090,421 $ 41,922,924 $ 36,910,284 Equity instruments Equity instruments Pre-Funded Warrants $ — $ — $ 8,262,698 Tranche 2A Warrants $ — $ — $ 2,173,285 $ — $ — $ 10,435,983 (1) The balances include financial assets at amortized cost, which comprise of cash and cash equivalents (excluding money market funds) and refundable deposits. (2) The balances include financial liabilities at amortized cost, which comprise of trade payables, other payables, current borrowings, lease liabilities and long-term borrowings.
Summary of Significant Financial Assets and Liabilities Denominated in Foreign Currencies	The Company’s significant financial assets and liabilities denominated in foreign currencies were as follows: December 31, 2022 Foreign Exchange Carrying Financial assets Monetary items SGD S $ 2,312,357 0.7461 $ 1,725,279 AUD A $ 2,616,802 0.6820 $ 1,784,606 Financial liabilities Monetary items SGD S $ 16,298,191 0.7461 $ 12,160,288 December 31, 2023 Foreign Exchange Carrying Financial assets Monetary items SGD S $ 2,825,324 0.7577 $ 2,140,748 Financial liabilities Monetary items SGD S $ 18,232,233 0.7577 $ 13,814,563
Sensitivity Analysis of Foreign Currency Risk	For the year ended December 31 2021 2022 2023 Profit or loss* SGD $ ( 548,878 ) $ ( 521,750 ) $ ( 583,691 ) AUD $ 87,807 $ 89,230 $ — * This is mainly attributable to the exposure to outstanding deposits in banks and loans in foreign currency at the end of the reporting period.
Summary of Contractual Maturities of Financial Liabilities	The table below break down the Company's financial liabilities into relevant maturity groupings based on their contractual and estimated maturities. The amounts disclosed in the tables are contractual and estimated undiscounted cash flows. Contractual maturities of financial liabilities as of December 31, 2023 On demand or within 1 year Within 2 to 5 years After 5 years Total Non-derivative financial liabilities Trade payable $ 7,918,607 $ — $ — $ 7,918,607 Other payable 3,081,329 — — 3,081,329 Lease liabilities 226,187 — — 226,187 Borrowings - Loan from government (Note 13a) — — 12,496,831 12,496,831 - Other long-term borrowing (Note 13b) 1,818,750 16,723,211 — 18,541,961 Derivative financial liabilities K2HV warrants — — 87,693 87,693 Tranche 2B warrants 701 — — 701 Contractual maturities of financial liabilities as of December 31, 2022 On demand or within 1 year Within 2 to 5 years After 5 years Total Non-derivative financial liabilities Trade payable $ 12,784,485 $ — $ — $ 12,784,485 Other payable 2,325,038 — — 2,325,038 Lease liabilities 215,671 — — 215,671 Borrowings - Loan from government (Note 13a) — — 11,855,579 11,855,579 - Other long-term borrowing (Note 13b) 7,503,091 24,557,362 — 32,060,453 Derivative financial liability K2HV warrants — — 90,213 90,213

Transactions with Related Par_2

Transactions with Related Parties (Tables)	12 Months Ended
	Dec. 31, 2023
Disclosure of transactions between related parties [abstract]
Disclosure of Transactions Between Group and Other Related Parties	a. Related party name and category Related Party Name Related Party Category Other Key Management Personnel b. Loans from related parties Interest expense For the year ended December 31 Related Party Category/Name 2021 2022 2023 Related party in substance / JANK Howden Pty Ltd $ 45,522 $ — $ — Key Management Personnel / Others 4,552 — — $ 50,074 $ — $ —
Schedule of Key Management Personnel Compensation	c. Compensation of Key Management Personnel For the year ended December 31 Related Party Category/Name 2021 2022 2023 Short-term employee benefits $ 2,881,215 $ 2,783,668 $ 3,115,619 Post-employment benefits 112,095 332,037 140,332 Share-based payments recognized 2,048,669 1,926,199 2,256,528 $ 5,041,979 $ 5,041,904 $ 5,512,479

Segment Information (Tables)

Segment Information (Tables)	12 Months Ended
	Dec. 31, 2023
Disclosure of operating segments [abstract]
Analysis of the Company Revenue from Major Products and Services	The Company has only one reportable operating segment, and therefore, the reportable segment information is the same as the financial statements. The following is an analysis of the Company’s revenue from its major products and services. For the year ended December 31 2021 2022 2023 Out-licensing $ — $ — $ 12,000,000

Application of New Amended an_3

Application of New Amended and Revised Standards and Interpretations - Schedule of New Amended or Revised Accounting Standards and Interpretations (Detail)	12 Months Ended
	Dec. 31, 2023
IFRS 10 and IAS 28 (amendments)
Description Of Expected Impact Of Initial Application Of New Standards Or Interpretations [Line Items]
New, Amended or Revised Standards and Interpretations	IFRS 10 and IAS 28 (amendments)
Description of nature of impending change in accounting policy	Sale or Contribution of Assets between an Investor and its Associate or Joint Venture
Amendments to IAS 1
Description Of Expected Impact Of Initial Application Of New Standards Or Interpretations [Line Items]
New, Amended or Revised Standards and Interpretations	Amendments to IAS 1
Description of nature of impending change in accounting policy	Classification of Liabilities as Current or Non-current
Amendments to IAS 1
Description Of Expected Impact Of Initial Application Of New Standards Or Interpretations [Line Items]
New, Amended or Revised Standards and Interpretations	Amendments to IAS 1
Description of nature of impending change in accounting policy	Non-current Liabilities with Covenants
Amendments to IAS 7 and IFRS 7
Description Of Expected Impact Of Initial Application Of New Standards Or Interpretations [Line Items]
New, Amended or Revised Standards and Interpretations	Amendments to IAS 7 and IFRS 7
Description of nature of impending change in accounting policy	Supplier Finance Agreement
Amendments to IAS 21
Description Of Expected Impact Of Initial Application Of New Standards Or Interpretations [Line Items]
New, Amended or Revised Standards and Interpretations	Amendments to IAS 21
Description of nature of impending change in accounting policy	Lack of Exchangeability
Amendments to IFRS 16
Description Of Expected Impact Of Initial Application Of New Standards Or Interpretations [Line Items]
New, Amended or Revised Standards and Interpretations	Amendments to IFRS 16
Description of nature of impending change in accounting policy	Lease Liability in a Sale and Leaseback

Summary of Material Accountin_3

Summary of Material Accounting Policies - Additional Information (Detail) - USD ($)		1 Months Ended	12 Months Ended
	Feb. 24, 2023	Mar. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Disclosure Of Significant Accounting Policies [Line Items]
Impairment loss recognised for the asset or cash-generating unit			$ 0
Accumulated deficit			321,067,236	$ 278,386,749
Proceeds from issue of ordinary shares	$ 20,000,000		$ 23,027,787
Major ordinary share transactions [member]
Disclosure Of Significant Accounting Policies [Line Items]
Proceeds from issue of ordinary shares		$ 5,000,000

Critical Accounting Judgments_2

Critical Accounting Judgments and Key Sources of Estimation Uncertainty - Additional Information (Detail) $ in Millions	Jun. 22, 2023 USD ($)
Zenyaku Kogyo Co., Ltd
Disclosure of transactions between related parties [line items]
Consideration received	$ 12

Cash and Cash Equivalents - Sum

Cash and Cash Equivalents - Summary of Cash and Cash Equivalents (Detail) - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Cash and cash equivalents [abstract]
Cash in hand	$ 648	$ 256
Cash in banks	21,251,410	26,456,482
Money market fund		30,445,339
Cash	$ 21,252,058	$ 56,902,077

Other Assets - Summary of Other

Other Assets - Summary of Other Assets (Detail) - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Other Assets Current And Non Current [Abstract]
Other receivable	$ 171,441
Prepayments	1,681,465	$ 2,942,936
Refundable deposits	1,025,028	1,033,414
Other current assets	$ 2,877,934	$ 3,976,350

Financial Instruments at Fair_5

Financial Instruments at Fair Value Through Profit or Loss - Summary of Financial Instruments at Fair Value Through Profit or Loss (Detail) - USD ($)	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Financial liabilities at fair value through profit or loss (FVTPL)
Financial liabilities designated as at FVTPL	$ 88,394	$ 90,213	$ 223,352
K2HV Warrants
Financial liabilities at fair value through profit or loss (FVTPL)
Financial liabilities designated as at FVTPL	87,693	$ 90,213
Tranche 2B Warrants
Financial liabilities at fair value through profit or loss (FVTPL)
Financial liabilities designated as at FVTPL	$ 701

Financial Instruments at Fair_6

Financial Instruments at Fair Value Through Other Comprehensive Income - Summary of Financial Instruments at Fair Value Through Other Comprehensive Income (Details)	Dec. 31, 2023 USD ($)
Financeial asset at fair value through other comprehensive income (FVOCI)
Investment in equity instruments at FVOCI - Foreign unlisted ordinary shares	$ 235,567

Subsidiaries - Summary of Subsi

Subsidiaries - Summary of Subsidiaries Included in Consolidated Financial Statements (Detail)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
ASLAN Pharmaceuticals Pte. Ltd.
Disclosure Of Significant Investments In Subsidiaries [Line Items]
Name of Investor	ASLAN Pharmaceuticals Limited ("ASLAN Cayman")
Name of Investee	ASLAN Pharmaceuticals Pte. Ltd.
Nature of Activities	New drug researchand development
Proportion of Ownership (%)	100%	100%
ASLAN Pharmaceuticals (USA) Inc.
Disclosure Of Significant Investments In Subsidiaries [Line Items]
Name of Investor	ASLAN Pharmaceuticals Pte. Ltd.
Name of Investee	ASLAN Pharmaceuticals (USA) Inc.
Nature of Activities	New drug researchand development
Proportion of Ownership (%)	100%	100%
ASLAN Pharmaceuticals Australia Pty Ltd
Disclosure Of Significant Investments In Subsidiaries [Line Items]
Name of Investor	ASLAN Pharmaceuticals Pte. Ltd.
Name of Investee	ASLAN Pharmaceuticals Australia Pty Ltd
Nature of Activities	New drug researchand development
Proportion of Ownership (%)	100%	100%
ASLAN Pharmaceuticals Hong Kong Limited
Disclosure Of Significant Investments In Subsidiaries [Line Items]
Name of Investor	ASLAN Pharmaceuticals Pte. Ltd.
Name of Investee	ASLAN Pharmaceuticals Hong Kong Limited
Nature of Activities	New drug researchand development
Proportion of Ownership (%)	100%	100%
ASLAN Pharmaceuticals (Shanghai) Co. Ltd.
Disclosure Of Significant Investments In Subsidiaries [Line Items]
Name of Investor	ASLAN Pharmaceuticals Hong Kong Limited
Name of Investee	ASLAN Pharmaceuticals (Shanghai) Co. Ltd.
Nature of Activities	New drug researchand development
Proportion of Ownership (%)	100%	100%

Investment in Associate Compa_3

Investment in Associate Company - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Disclosure Of Significant Investments In Associates [Line Items]
Loss for the year	$ (43,735,597)	$ (47,882,487)	$ (33,846,452)
Net cash (outflow)/inflow from operating activities	$ (46,638,998)	(38,405,247)	$ (33,995,550)
Investments in associates		$ 8,587
Jaguahr Therapeutics Pte.Ltd
Disclosure Of Significant Investments In Associates [Line Items]
Proportion of ownership interest in associate	35%	35%
Loss for the year	$ 375,171	$ 1,245,805
Net cash (outflow)/inflow from operating activities	137,735	(1,329,339)
Losses of associate amount	8,587	486,141
Investments in associates	$ 0	$ 8,587

Investment in Associate Compa_4

Investment in Associate Company - Summary of Financial Information Before Intragroup Eliminations (Detail) - USD ($)	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Disclosure of subsidiaries [line items]
Current asset	$ 24,129,992	$ 60,878,427
Current liabilities	(13,114,904)	(23,164,238)
Equity/(Capital deficiency)	(13,286,931)	8,365,220	$ 57,303,743	$ (10,152,284)
Jaguahr Therapeutics Pte.Ltd
Disclosure of subsidiaries [line items]
Current asset	192,641	54,906
Current liabilities	(543,278)	(30,371)
Equity/(Capital deficiency)	$ (350,637)	$ 24,535

Trade And Other Payables - Addi

Trade And Other Payables - Additional Information (Details) - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Trade and other payables [abstract]
Trade payables	$ 7,918,607	$ 12,784,485

Trade And Other Payables - Sche

Trade And Other Payables - Schedule of Other Payables (Detail) - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Trade and other payables [abstract]
Payables for cash-settled long-term incentive plan	$ 46,699	$ 234,448
Payables for salaries and bonuses	1,748,901	1,375,627
Payables for professional fees	1,098,536	560,578
Others	187,193	154,385
Total other payables	3,081,329	2,325,038
Maturity analysis:
On demand or within 1 year	$ 3,081,329	$ 2,325,038

Borrowings - Summary of Loans (

Borrowings - Summary of Loans (Detail) $ in Millions	Dec. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)	Apr. 27, 2011 SGD ($)
Disclosure Of Detailed Information About Borrowings [Line Items]
Long-term borrowings - unsecured	$ 24,798,552	$ 29,656,133
Total borrowings	26,598,939	37,404,964
Current borrowings - unsecured	1,800,387	7,748,831
Not Later Than One Year
Disclosure Of Detailed Information About Borrowings [Line Items]
Long-term borrowings - unsecured	1,800,387	7,748,831
Later Than One Year
Disclosure Of Detailed Information About Borrowings [Line Items]
Long-term borrowings - unsecured	24,798,552	29,656,133
Loans from Government
Disclosure Of Detailed Information About Borrowings [Line Items]
Long-term borrowings - unsecured	12,496,831	11,855,579	$ 10
Other Long-term Borrowings
Disclosure Of Detailed Information About Borrowings [Line Items]
Long-term borrowings - unsecured	$ 14,102,108	$ 25,549,385

Borrowings - Additional Informa

Borrowings - Additional Information (Detail) $ / shares in Units, $ in Millions					1 Months Ended	12 Months Ended
	Dec. 06, 2023 USD ($)	Jun. 30, 2023 $ / shares shares	Jul. 12, 2021 USD ($) $ / shares	Apr. 27, 2011 SGD ($)	Jan. 31, 2022 USD ($) $ / shares shares	Dec. 31, 2023 USD ($) d $ / shares	Dec. 31, 2021 USD ($) $ / shares	Dec. 31, 2022 USD ($) $ / shares
Disclosure Of Detailed Information About Borrowings [Line Items]
Long-term borrowings - unsecured						$ 24,798,552		$ 29,656,133
Repayment loan amount owed						12,000,000	$ 7,784,087
Long term borrowings						26,598,939		37,404,964
Principal outstanding amount						$ 26,598,939		$ 37,404,964
Warrant price per share | $ / shares						$ 0.01	$ 0.01	$ 0.01
Loans from Government
Disclosure Of Detailed Information About Borrowings [Line Items]
Long-term borrowings - unsecured				$ 10		$ 12,496,831		$ 11,855,579
Principal loan amount						7,509,524		7,390,655
Loan repayable period				five-year
Borrowings, interest rate				6%
Loans from Government
Disclosure Of Detailed Information About Borrowings [Line Items]
Long-term borrowings - unsecured						$ 12,496,831		$ 11,855,579
Two H V Loan Agreement [Member]
Disclosure Of Detailed Information About Borrowings [Line Items]
Borrowings, interest rate					2.95%
Number of other equity instruments exercised or vested in share-based payment arrangement | d						0
Two H V Loan Agreement [Member] | Second Tranche [Member]
Disclosure Of Detailed Information About Borrowings [Line Items]
Proceeds from non-current borrowings					$ 5,000,000
Two H V Loan Agreement [Member] | Ordinary Shares
Disclosure Of Detailed Information About Borrowings [Line Items]
Warrant price per share | $ / shares					$ 0.5257
Two H V Loan Agreement [Member] | Ordinary Shares | Second Tranche [Member]
Disclosure Of Detailed Information About Borrowings [Line Items]
Number Of Shares Exercisable Under The Warrants | shares					1,402,891
Two H V Loan Agreement [Member] | American Depositary Share
Disclosure Of Detailed Information About Borrowings [Line Items]
Warrant price per share | $ / shares					$ 13.1425
Two H V Loan Agreement [Member] | American Depositary Share | Second Tranche [Member]
Disclosure Of Detailed Information About Borrowings [Line Items]
Number Of Shares Exercisable Under The Warrants | shares					56,116
Two H V Loan Agreement [Member] | Top of Range [Member] | Second Tranche [Member]
Disclosure Of Detailed Information About Borrowings [Line Items]
Proceeds from non-current borrowings					$ 25,000,000
K2HV Loan Agreement
Disclosure Of Detailed Information About Borrowings [Line Items]
Warrant expiration date			July 12, 2031
Borrowings, interest rate			2.95%
Loan Facility Term			4 years
Term loans bear prime interest rate			plus 5.00%
Term loans annual interest rate			8.25%
Facility fee			$ 255,000
Percentage of additional facility fee			0.85%
Percentage of final payment fee			6.25%
Percentage of prepayment fee			3%
Fair value of first tranche loan			$ 19,311,676
Fair value of warrants			688,324			$ 87,693
Difference of fair value of warrants						$ 2,520
K2HV Loan Agreement | First Tranche [Member]
Disclosure Of Detailed Information About Borrowings [Line Items]
Current borrowings			20,000,000
K2HV Loan Agreement | Second Tranche [Member]
Disclosure Of Detailed Information About Borrowings [Line Items]
Current borrowings			$ 25,000,000
K2HV Loan Agreement | Ordinary Shares
Disclosure Of Detailed Information About Borrowings [Line Items]
Number Of Shares Exercisable Under The Warrants | shares		5,096,752
Warrant price per share | $ / shares		$ 0.1447	$ 0.5257
K2HV Loan Agreement | American Depositary Share
Disclosure Of Detailed Information About Borrowings [Line Items]
Number Of Shares Exercisable Under The Warrants | shares		203,870
Warrant price per share | $ / shares		$ 3.6175	$ 13.1425
K2HV Loan Agreement | Top of Range [Member]
Disclosure Of Detailed Information About Borrowings [Line Items]
Long term borrowings			$ 45,000,000
Principal outstanding amount			$ 45,000,000
Second Amendment Agreement
Disclosure Of Detailed Information About Borrowings [Line Items]
Repayments of borrowings	$ 12,000,000
Long term borrowings	$ 13,000,000
Term loan maturity date	Jul. 01, 2025
Percentage of prepayment fee	2%
Principal outstanding amount	$ 13,000,000

Equity - Schedule of Ordinary S

Equity - Schedule of Ordinary Shares (Detail) - USD ($)	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Disclosure Of Classes Of Share Capital [Line Items]
Number of ordinary shares authorised	1,000,000,000	500,000,000	500,000,000
Authorized par value per share	$ 0.01	$ 0.01	$ 0.01
Amount of share capital par value issued and fully paid	$ 63,931,993	$ 63,019,962	$ 63,019,962
Ordinary Shares
Disclosure Of Classes Of Share Capital [Line Items]
Number of ordinary shares issued and fully paid	439,926,480	348,723,365	348,723,365
American Depositary Share
Disclosure Of Classes Of Share Capital [Line Items]
Number of ordinary shares issued and fully paid	17,597,059	13,948,935	13,948,935
Ordinary Surplus [Member]
Disclosure Of Classes Of Share Capital [Line Items]
Amount of share capital surplus issued and fully paid	$ 219,774,205	$ 213,098,729	$ 213,098,729

Equity - Additional Information

Equity - Additional Information (Detail) - USD ($)					1 Months Ended		12 Months Ended
	Sep. 04, 2023	Feb. 27, 2023	Feb. 24, 2023	Aug. 06, 2021	Mar. 31, 2021	Feb. 28, 2021	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2019
Net Proceeds from offering of shares			$ 20,000,000				$ 23,027,787
Proceeds from issuance initial public offering					$ 64,900,000
Number of ordinary shares authorised							1,000,000,000	500,000,000	500,000,000
Warrant price per share							$ 0.01	$ 0.01	$ 0.01
Dividends distribution							$ 0	$ 0	$ 0
Convertible Loan Facility and October / November 2019 Loan Facility | Warrants
Warrants amounting to principal loan amount									$ 825,800
Warrants issued to Purchase ordinary shares.									2,045,355
Warrants to purchase American Depository Shares									81,814
Exercise price									$ 10.1
October / November 2019 Loan Facility | Warrants
Loan facility										$ 2,250,000
Warrants outstanding									0
ATM Sales Agreement [Member] | Jefferies LLC
Net Proceeds from offering of shares							$ 3,000,000
ATM Sales Agreement [Member] | Jefferies LLC | Top of Range [Member]
Aggregate offering value				$ 85,000,000
Purchase Agreement
Warrant price per share			$ 4.4475
Private Placement
Proceeds from issuance of private placement						$ 18,000,000
Proceeds from exercise of warrants		$ 20,000,000
Number of warrants exercisable							0
Pre-funded warrants value		$ 8,262,698
Gain (loss) fair value valuation of warrants							$ 3,464,479
Ordinary Shares
Number of shares issued					86,250,000
Ordinary Shares | ATM Sales Agreement [Member] | Jefferies LLC
Number of shares issued				24,594,360			31,245,250
Ordinary Shares | Purchase Agreement
Number of shares issued		59,957,865	112,359,550
Offering price per share			$ 0.178
Number of additional shares issued		52,401,685
Ordinary Shares | Private Placement
Number of shares issued						25,568,180
Number of shares issued in settlement of pre funded warrants			52,401,685
Fixed consideration of pre-funded warrants			$ 5,240
American Depositary Share
Number of shares issued					3,450,000
American Depositary Share | ATM Sales Agreement [Member] | Jefferies LLC
Number of shares issued				983,774			1,249,810
Net Proceeds from offering of shares				$ 14,100,000
American Depositary Share | Purchase Agreement
Number of shares issued		2,398,315	4,494,382
Offering price per share			$ 4.45
Percentage of share premium			15%
Number of additional shares issued		2,096,067
Warrant price per share			$ 4.4475
American Depositary Share | Private Placement
Number of shares issued						1,022,727
Number of warrants exercisable			11,061,823
Additional amount from exercise of warrants			$ 80,000,000
Number of shares issued in settlement of pre funded warrants			2,096,068
Tranche 1A Warrants
Reclassification adjustments from equity instruments to accumulated deficit							$ 1,539,897
Tranche 1A Warrants | Private Placement
Percentage of warrants exercisable until 60 days			50%
Pre-funded warrants value		$ 1,539,117
Reclassification adjustments from equity instruments to accumulated deficit	$ 1,539,117
Tranche 1A Warrants | American Depositary Share
Percentage of warrants exercisable until 60 days			50%
Warrant exercise price			$ 6.5
Tranche 1B Warrants
Warrant exercise price			$ 6.5
Tranche 1B Warrants | Private Placement
Pre-funded warrants value		$ 1,539,897
Pre funded warrants fair value valued amount							0
Tranche 1B Warrants | American Depositary Share
Discount rate on warrant exercise price			50%
Tranche 1B Warrants | American Depositary Share | Private Placement
Discount rate on warrant exercise price		50%
Tranche 2A Warrants | Private Placement
Pre-funded warrants value		$ 2,173,285
Tranche 2A Warrants | American Depositary Share | Private Placement
Percentage of warrants exercisable until 60 days			50%
Warrant exercise price			$ 8.15
Tranche 2B Warrants
Percentage of warrants exercisable until 60 days			50%
Tranche 2B Warrants | Private Placement
Pre-funded warrants value		$ 1,925,283
Pre funded warrants fair value revalued amount							$ 701
Tranche 2B Warrants | American Depositary Share | Private Placement
Discount rate on warrant exercise price		50%	50%
Tranche 2B Warrants | American Depositary Share | Private Placement | Bottom of Range [Member]
Warrant exercise price			$ 8.15
Pre-funded Warrants | American Depositary Share | Purchase Agreement
Number of shares issued			25

Material License Agreements - A

Material License Agreements - Additional Information (Detail) - License Agreements - USD ($)			12 Months Ended
	Dec. 31, 2023	Jun. 22, 2023	Dec. 31, 2023	Dec. 31, 2022
Almirall
Disclosure Of Transactions Between Related Parties [Line Items]
Agreement date			Dec. 31, 2015
Agreement amended date			Mar. 31, 2018
CSL Limited
Disclosure Of Transactions Between Related Parties [Line Items]
First Payment			$ 30,000,000
Regulatory milestones linked payments estimated			95,000,000
Sales mile stones linked payments estimated			655,000,000
Milestone payments			0	$ 1,000,000
Zenyaku Kogyo Co., ltd
Disclosure Of Transactions Between Related Parties [Line Items]
Non refundable upfront payment		$ 12,000,000
Upfront payment			$ 12,000,000
Cash consideration for development and commercialization agreement		12,000,000
Cash payment received for development and commercialization project	$ 12,000,000
Top of Range [Member] | CSL Limited
Disclosure Of Transactions Between Related Parties [Line Items]
Percentage of entity's revenue			10%
Top of Range [Member] | Zenyaku Kogyo Co., ltd
Disclosure Of Transactions Between Related Parties [Line Items]
Milestone payments		$ 123,500,000

Loss Before Income Tax - Summar

Loss Before Income Tax - Summary of Other Income (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Profit (loss) [abstract]
ADS issuance contribution	$ 386,908		$ 1,076,189
Government grants for research and development expenditures	73,724	$ 248,613
Government subsidies		29,147	31,112
Accretion income		94,248
Others	1,689	14,130	771
Other income	$ 462,321	$ 386,138	$ 1,108,072

Loss Before Income Tax - Additi

Loss Before Income Tax - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Loss Before Income Tax [Line Items]
Other non-operating income	$ 386,908		$ 1,076,189
Government grants for research and development expenditures	73,724	$ 248,613
Australia
Loss Before Income Tax [Line Items]
Government grants for research and development expenditures	$ 73,724	$ 248,613

Loss Before Income Tax - Schedu

Loss Before Income Tax - Schedule of Other Gains and Losses (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Profit (loss) [abstract]
Net foreign exchange (losses) gains	$ (332,725)	$ (85,869)	$ 512,450
Gain on disposal of property, plant and equipment	148	1,172
Net gain on fair value changes of financial assets and liabilities at fair value through profit or loss (Notes 13(b) and 14(a))	3,466,999	133,139	594,046
Others	(12,816)	(78,025)	14
Other gains and losses	$ 3,121,606	$ (29,583)	$ 1,106,510

Loss Before Income Tax - Summ_2

Loss Before Income Tax - Summary of Finance costs (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Profit (loss) [abstract]
Interest on government loans	$ 442,410	$ 431,052	$ 443,216
Interest on other long term borrowing	3,871,299	3,224,369	1,191,381
Interest on loans from shareholders			154,773
Interest on loans from related parties			50,074
Interest on lease liabilities	13,074	12,544	21,510
Others	4,878	7,724
Finance costs	$ 4,331,661	$ 3,675,689	$ 1,860,954

Loss Before Income Tax - Sche_2

Loss Before Income Tax - Schedule of Depreciation and Amortization (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Disclosure Of Property Plant And Equipment [Line Items]
Depreciation and amortization	$ 348,498	$ 331,752	$ 282,224
Right-of-Use Assets
Disclosure Of Property Plant And Equipment [Line Items]
Depreciation and amortization	319,725	308,682	264,804
Property, Plant and Equipment
Disclosure Of Property Plant And Equipment [Line Items]
Depreciation and amortization	24,653	18,950	14,856
Intangible Assets
Disclosure Of Property Plant And Equipment [Line Items]
Depreciation and amortization	$ 4,120	$ 4,120	$ 2,564

Loss Before Income Tax - Sche_3

Loss Before Income Tax - Schedule of Employee Benefits Expense (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Profit (loss) [abstract]
Short-term benefits	$ 9,622,503	$ 8,423,133	$ 6,940,900
Post-employment benefits	415,509	355,434	257,128
Share-based payments
Equity-settled	2,769,279	2,443,894	2,428,128
Cash-settled	(66,079)	(467,134)	(234,761)
Total employee benefits expense	12,741,212	10,755,327	9,391,395
Employee benefits expense by function
General and administrative expenses	7,148,068	5,643,217	5,718,646
Research and development expenses	5,593,144	5,112,110	3,672,749
Total employee benefits expense	$ 12,741,212	$ 10,755,327	$ 9,391,395

Income Taxe Expense - Summary o

Income Taxe Expense - Summary of Income Tax Recognised in Profit or Loss (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Current tax expenses
In respect of the current period	$ 113,251	$ 79,379
Adjustments for prior periods	19,416	19,842
Income tax expenses recognized in profit or loss	132,667	99,221
Loss before income tax	(44,086,937)	(51,283,196)	$ (31,590,582)
Income tax benefits calculated at the statutory rate	(7,494,779)	(8,718,143)	(5,370,399)
Tax effect of expense revenue exempt from taxation	83,729	19,769	(870,151)
Non-deductible expenses in determining taxable income	549,230	361,600	648,651
Tax credits for research and development expenditures	(161,510)	(245,802)	(1,467,816)
Unrecognized loss carry forwards	6,396,624	7,688,535	6,044,928
Tax effect of share of results of associates and joint venture	1,460	74,125	405,712
Effect of different tax rates of group entities operating in other jurisdictions	$ 738,497	917,106	$ 609,075
Others		$ (17,811)

Income Tax Expense - Additional

Income Tax Expense - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Major Components Of Tax Expense Income [Line Items]
Taxable income	$ (44,086,937)	$ (51,283,196)	$ (31,590,582)
Accumulated deficit	(321,067,236)	(278,386,749)
Tax credits for research and development expenditures	161,510	245,802	1,467,816
Research and development expense	42,495,379	38,000,494	$ 22,021,321
Provision for income tax	132,667	99,221
ASLAN Pharmaceuticals Pte. Ltd.
Major Components Of Tax Expense Income [Line Items]
Accumulated unused tax losses	275,000,000	238,000,000
Accumulated deficit	321,000,000	279,000,000
Tax credits for research and development expenditures	$ 78,000,000	$ 77,000,000
Taiwan
Major Components Of Tax Expense Income [Line Items]
Statutory corporate income tax rate	20%
Corporate surtax rate	5%
Singapore
Major Components Of Tax Expense Income [Line Items]
Statutory corporate income tax rate	17%	17%	17%
Provision for income tax	$ 0	$ 0	$ 0
Singapore | ASLAN Pharmaceuticals Pte. Ltd.
Major Components Of Tax Expense Income [Line Items]
Taxable income	0	0	0
Australia
Major Components Of Tax Expense Income [Line Items]
Taxable income	$ 0	0	0
Statutory corporate income tax rate	30%
Provision for income tax	$ 0	0	0
Hong Kong
Major Components Of Tax Expense Income [Line Items]
Taxable income	$ 0	0	0
Statutory corporate income tax rate	16.50%
Provision for income tax	$ 0	0	0
China
Major Components Of Tax Expense Income [Line Items]
Taxable income	$ 0	0	0
Statutory corporate income tax rate	25%
Provision for income tax	$ 0	0	0
UNITED STATES
Major Components Of Tax Expense Income [Line Items]
Taxable income	531,794	377,994	94,487
Provision for income tax	$ 0	$ 0	$ 0
Federal income tax rate	21%
State income tax rate	8.70%

Loss Per Ordinary Share - Summa

Loss Per Ordinary Share - Summary of Earnings Per Share (Detail) - $ / shares	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Earnings Per Share [Line Items]
Basic loss per ordinary share	$ (0.11)	$ (0.15)	$ (0.1)
Diluted loss per ordinary share	(0.11)	(0.15)	(0.1)
Ordinary Share
Earnings Per Share [Line Items]
Basic loss per ordinary share	(0.11)	(0.15)	(0.1)
Diluted loss per ordinary share	(0.11)	(0.15)	(0.1)
American Depositary Share
Earnings Per Share [Line Items]
Basic loss per ordinary share	(2.69)	(3.68)	(2.4)
Diluted loss per ordinary share	$ (2.69)	$ (3.68)	$ (2.4)

Loss Per Ordinary Share - Sum_2

Loss Per Ordinary Share - Summary of Loss and Weighted Average Number of Ordinary Shares Outstanding (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Earnings Per Share [Line Items]
Loss used in the computation of basic and diluted loss per ordinary share	$ (44,219,604)	$ (51,382,417)	$ (31,321,618)
Ordinary Shares
Earnings Per Share [Line Items]
Weighted-average number of ordinary shares in the computation of basic loss per ordinary share	411,242,644	348,723,365	325,684,272
American Depositary Share
Earnings Per Share [Line Items]
Weighted-average number of ordinary shares in the computation of basic loss per ordinary share	16,449,706	13,948,935	13,027,371

Share-based Payment Arrangeme_3

Share-based Payment Arrangements - Additional Information (Detail)

1 Months Ended

7 Months Ended

12 Months Ended

Jul. 01, 2023 shares

May 01, 2023 shares

Jan. 01, 2023 shares

Jul. 01, 2022 shares

Jan. 01, 2022 shares

Dec. 15, 2020 shares

Dec. 10, 2020 shares

Jul. 30, 2019 shares

Jul. 30, 2018 shares

Feb. 01, 2018 shares

Aug. 23, 2017 shares

Jul. 31, 2022 USD ($) $ / shares

Dec. 31, 2020 $ / shares

Sep. 30, 2017 shares

Jul. 31, 2017 $ / shares

Jul. 31, 2016 $ / shares

Jul. 31, 2014 $ / shares

Jul. 31, 2010 shares

Jul. 31, 2021 $ / shares

Dec. 31, 2023 USD ($) shares

Dec. 31, 2022 USD ($) shares

Dec. 31, 2021 USD ($) shares

Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]

Exercise price | $ / shares

$ 2.6

$ 2.6

$ 6.4

$ 11.3

$ 6.8

$ 2.6

Incremental fair value recognised | $

$ 279,636

Compensation costs recognised | $

$ 2,769,279

$ 2,443,894

$ 2,428,128

Other Payable

Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]

Recognized compensation liabilities, Current | $

$ 46,699

$ 234,448

2014 Plan

Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]

Option granted

7,050,211

Share option granted expiration period

10 years

Share based payment, vesting period

4 years

Vesting description

If the options remain unexercised after a period of ten years from the date of grant, the options expire. Options are forfeited if the employee leaves the Company before the options vest.

2014 Plan | Ordinary Shares

Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]

Option granted

14,100,422

2014 Plan | American Depositary Share

Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]

Option granted

564,017

2020 Equity Incentive Plan

Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]

Share option granted expiration period

10 years

10 years

Maximum number of ordinary shares issued

20,676,974

62,030,922

Share based payment, vesting period

4 years

Issuance of new share capital, shares

13,948,935

13,948,935

Percentage of increase in outstanding shares

4%

4%

4%

Vesting description

If the options remain unexercised after a period of ten years from the date of grant, the options expire. Options are forfeited if the employee leaves the Company before the options vest.

2020 Equity Incentive Plan | American Depositary Share

Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]

Option granted

9,600

370,000

407,226

143,600

355,030

764,812

786,827

498,630

56,400

Maximum number of ordinary shares issued

827,079

2,481,237

Issuance of new share capital, shares

557,958

557,958

2017 Plan

Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]

Option granted

825,833

Share option granted expiration period

10 years

Share based payment, vesting period

2 years

Vesting description

If the options remain unexercised after a period of ten years from the date of grant, the options expire.

2017 Plan | Ordinary Shares

Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]

Option granted

825,833

2017 Plan | American Depositary Share

Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]

Option granted

33,033

Long Term Incentive Plan Granted in 2017

Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]

Long term incentive plan bonus entitlement units granted

104,000

1,462,000

Long Term Incentive Plan Granted in 2017 | American Depositary Share

Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]

Long term incentive plan bonus entitlement units granted

4,160

58,480

Long Term Incentive Plan Granted in 2018

Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]

Long term incentive plan bonus entitlement units granted

48,228

Long Term Incentive Plan Granted in 2019

Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]

Long term incentive plan bonus entitlement units granted

98,204

Long Term Incentive Plans

Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]

Number of units forfeited

13,897

0

0

Reporting date fair value of award | $

$ 0.52

$ 1.8

Recognised total (expense) benefit | $

66,079

467,134

$ 234,761

Total intrinsic value | $

$ 234,448

$ 46,699

Long Term Incentive Plans | American Depositary Share

Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]

Number of units forfeited

56,700

Number of units redeemed

62,910

Share-based Payment Arrangeme_4

Share-based Payment Arrangements - Summary of Employee Share Options (Detail)							1 Months Ended		12 Months Ended
	Jul. 01, 2023 shares	May 01, 2023 shares	Jan. 01, 2023 shares $ / shares	Jul. 01, 2022 shares	Jan. 01, 2022 shares $ / shares	Dec. 15, 2020 shares	Sep. 30, 2017 shares	Jul. 31, 2010 shares	Dec. 31, 2023 shares $ / shares	Dec. 31, 2022 shares $ / shares	Dec. 31, 2021 shares $ / shares
2014 Plan
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Number of Equivalent ADSs, Options granted								7,050,211
2017 Plan
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Number of Equivalent ADSs, Options granted							825,833
American Depositary Share | 2014 Plan
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Number of Equivalent ADSs, Beginning of Period			371,569		487,829				371,569	487,829	533,629
Number of Equivalent ADSs, Options granted								564,017
Number of Equivalent ADSs, Options expired									(48,800)	(116,260)	0
Number of Equivalent ADSs, Options exercised									0	0	(45,800)
Number of Equivalent ADSs, Ending of Period									322,769	371,569	487,829
Number of Equivalent ADSs, Options exercisable, end of period									322,769	371,569	487,829
Weighted- average Exercise Price, Beginning of Period | $ / shares			$ 22		$ 17.88				$ 22	$ 17.88	$ 17.88
Weighted- average Exercise Price, Options expired | $ / shares									17.08	8.38	0
Weighted-average Exercise Price, Options exercised | $ / shares									0	0	5.38
Weighted- average Exercise Price, End of Period | $ / shares									22.74	22	17.88
Weighted- average Exercise Price, Options exercisable end of period | $ / shares									$ 22.74	$ 22	$ 17.88
American Depositary Share | 2017 Plan
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Number of Equivalent ADSs, Beginning of Period			20,048		20,048				20,048	20,048	20,048
Number of Equivalent ADSs, Options granted							33,033
Number of Equivalent ADSs, Options forfeited									(333)	0	0
Number of Equivalent ADSs, Ending of Period									19,715	20,048	20,048
Number of Equivalent ADSs, Options exercisable, end of period									19,715	20,048	20,048
Weighted- average Exercise Price, Beginning of Period | $ / shares			$ 31.9		$ 31.9				$ 31.9	$ 31.9	$ 31.9
Weighted- average Exercise Price, Options forfeited | $ / shares									31.9	0	0
Weighted- average Exercise Price, End of Period | $ / shares									31.9	31.9	31.9
Weighted- average Exercise Price, Options exercisable end of period | $ / shares									$ 31.9	$ 31.9	$ 31.9
American Depositary Share | 2020 Equity Incentive Plan
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Number of Equivalent ADSs, Beginning of Period			1,154,068		804,312				1,154,068	804,312	764,812
Number of Equivalent ADSs, Options granted	9,600	370,000	407,226	143,600	355,030	764,812			786,827	498,630	56,400
Number of Equivalent ADSs, Options forfeited									(11,375)	(148,874)	(16,200)
Number of Equivalent ADSs, Options exercised											(700)
Number of Equivalent ADSs, Ending of Period									1,929,520	1,154,068	804,312
Number of Equivalent ADSs, Options exercisable, end of period									803,797	408,964	299,505
Weighted- average Exercise Price, Beginning of Period | $ / shares			$ 2.59		$ 10.3				$ 2.59	$ 10.3	$ 10.3
Weighted- average Exercise Price, Options granted | $ / shares									2.93	2.57	16.2
Weighted- average Exercise Price, Options forfeited | $ / shares									2.33	2.6	10.3
Weighted-average Exercise Price, Options exercised | $ / shares											10.3
Weighted- average Exercise Price, End of Period | $ / shares									2.73	2.59	10.3
Weighted- average Exercise Price, Options exercisable end of period | $ / shares									2.59	2.59	10.3
Weighted-average fair value of each option granted | $ / shares									$ 2.73	2.59	13.15
American Depositary Share | 2020 Equity Incentive Plan | Amended ADS Exercise Price
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Weighted- average Exercise Price, Beginning of Period | $ / shares					$ 2.6					$ 2.6
Weighted- average Exercise Price, End of Period | $ / shares											$ 2.6

Share-based Payment Arrangeme_5

Share-based Payment Arrangements - Summary of Outstanding Options (Detail)	12 Months Ended
	Dec. 31, 2023 $ / shares
July 2014
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Range of Exercise Price	$ 6.8
Weighted-average Remaining Contractual Life (Years)	6 months
July 2015
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Weighted-average Remaining Contractual Life (Years)	1 year 6 months
July 2015 | Top of Range [Member]
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Range of Exercise Price	$ 9.4
July 2015 | Bottom of Range [Member]
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Range of Exercise Price	6.8
July 2016
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Range of Exercise Price	$ 11.3
Weighted-average Remaining Contractual Life (Years)	2 years 6 months
July 2017
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Range of Exercise Price	$ 6.4
Weighted-average Remaining Contractual Life (Years)	3 years 8 months 23 days
December 2020
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Range of Exercise Price	$ 2.6
Weighted-average Remaining Contractual Life (Years)	6 years 11 months 15 days
January-July 2021
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Range of Exercise Price	$ 2.6
Weighted-average Remaining Contractual Life (Years)	7 years 2 months 15 days
January-July 2022
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Weighted-average Remaining Contractual Life (Years)	8 years 3 months 3 days
January-July 2022 | Top of Range [Member]
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Range of Exercise Price	$ 2.6
January-July 2022 | Bottom of Range [Member]
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Range of Exercise Price	$ 2.5
January-July 2023
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Weighted-average Remaining Contractual Life (Years)	9 years 3 months 14 days
January-July 2023 | Top of Range [Member]
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Range of Exercise Price	$ 4.15
January-July 2023 | Bottom of Range [Member]
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Range of Exercise Price	$ 1.8

Share-based Payment Arrangeme_6

Share-based Payment Arrangements - Summary of Options Granted Priced Using Binomial Option Pricing Model (Detail)	1 Months Ended						7 Months Ended
	Jul. 31, 2022 $ / shares	Dec. 31, 2020 yr $ / shares	Jul. 31, 2017 yr $ / shares	Jul. 31, 2016 yr $ / shares	Jul. 31, 2015 yr $ / shares	Jul. 31, 2014 yr $ / shares	Jul. 31, 2023 yr $ / shares	Jul. 31, 2022 yr $ / shares	Jul. 31, 2021 yr $ / shares
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Grant-date share price		$ 11.1	$ 6.4	$ 11.3	$ 9.4	$ 6.8
Exercise price	$ 2.6	$ 2.6	$ 6.4	$ 11.3		$ 6.8			$ 2.6
Expected volatility		66.25%	38.33%	39.34%	36.37%	50.86%
Expected life | yr			10	10	10	10
Risk-free interest rate			1.10%	1.46%	2.43%	2.58%
Bottom of Range
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Grant-date share price							$ 1.8	$ 2.5	$ 11.75
Exercise price					$ 6.8		$ 1.8	$ 2.5
Expected volatility							118.80%	118.20%	59.99%
Expected life | yr		5.25					5.5	5.25	5.25
Risk-free interest rate		3.05%					3.58%	2.90%	3.05%
Top of Range
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Grant-date share price							$ 4.15	$ 5.6	$ 20.6
Exercise price					$ 9.4		$ 4.15	$ 2.6
Expected volatility							133.50%	122.10%	64.92%
Expected life | yr		7					7	7	7
Risk-free interest rate		3.06%					3.97%	3.06%	3.06%

Share-based Payment Arrangeme_7

Share-based Payment Arrangements - Summary of Long Term Incentive Plan (Detail) - Long Term Incentive Plans - shares	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Beginning balance	144,147	144,147	148,906
Awards exercised	(40,788)	0	(4,759)
Awards lapsed	(13,897)	0	0
Ending balance	89,462	144,147	144,147
Balance exercisable, end of period	89,462	144,147	144,147

Reconciliation of Liabilities_3

Reconciliation of Liabilities Arising from Financing Activities - Summary of Changes in Liabilities Arising from Financing Activities, Including Both Cash and Non-cash Changes (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Disclosure Of Reconciliation Of Liabilities Arising From Financing Activities [Line Items]
Liabilities arising from financing activities		$ 142,083
Net proceeds / (repayment)	$ 10,720,456	4,724,658	$ 109,867,301
Liabilities arising from financing activities			142,083
Lease Liabilities Current
Disclosure Of Reconciliation Of Liabilities Arising From Financing Activities [Line Items]
Liabilities arising from financing activities	215,671	199,124	271,624
Interest paid	(10,411)	(12,544)	(21,510)
Net proceeds / (repayment)	(296,920)	(262,798)	(353,649)
Additions / (Transfer)	307,436	293,460	281,149
Others	(2,663)	(14,115)
Interest expense	13,074	12,544	21,510
Liabilities arising from financing activities	226,187	215,671	199,124
Lease Liabilities Non-Current
Disclosure Of Reconciliation Of Liabilities Arising From Financing Activities [Line Items]
Liabilities arising from financing activities			281,149
Additions / (Transfer)			(281,149)
Current Borrowings
Disclosure Of Reconciliation Of Liabilities Arising From Financing Activities [Line Items]
Liabilities arising from financing activities	7,748,831		2,900,971
Interest paid	(3,318,576)	(2,338,715)	(484,043)
Net proceeds / (repayment)			(2,571,701)
Additions / (Transfer)	(6,501,167)	7,626,678
Interest expense	3,871,299	2,460,868	154,773
Liabilities arising from financing activities	1,800,387	7,748,831
Current Borrowings From Related Parties
Disclosure Of Reconciliation Of Liabilities Arising From Financing Activities [Line Items]
Liabilities arising from financing activities			617,912
Interest paid			(117,986)
Net proceeds / (repayment)			(550,000)
Interest expense			50,074
Long-Term Borrowings
Disclosure Of Reconciliation Of Liabilities Arising From Financing Activities [Line Items]
Liabilities arising from financing activities	29,656,133	30,857,309	15,183,421
Net proceeds / (repayment)	(12,000,000)	5,000,000	15,939,643
Additions / (Transfer)	6,501,167	(7,484,595)	(688,324)
Others	198,842	88,866	(124,827)
Interest expense	442,410	1,194,553	547,396
Liabilities arising from financing activities	24,798,552	29,656,133	30,857,309
Interest Payables
Disclosure Of Reconciliation Of Liabilities Arising From Financing Activities [Line Items]
Liabilities arising from financing activities		142,083	735,510
Net proceeds / (repayment)			(1,680,628)
Additions / (Transfer)		(142,083)
Interest expense			1,087,201
Liabilities arising from financing activities			$ 142,083
Financial Liabilities at Fair Value Through Profit or Loss
Disclosure Of Reconciliation Of Liabilities Arising From Financing Activities [Line Items]
Liabilities arising from financing activities	90,213
Net proceeds / (repayment)	3,465,180
Others	(3,466,999)
Liabilities arising from financing activities	$ 88,394	$ 90,213

Financial Instruments - Fair Va

Financial Instruments - Fair Value of Financial Instruments Measured at Fair Value on Recurring Basis (Detail) - USD ($)	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Financial liabilities at fair value through profit or loss
Derivative financial liabilities	$ 88,394	$ 90,213	$ 223,352
K2 Warrants
Financial liabilities at fair value through profit or loss
Derivative financial liabilities	87,693	90,213	$ 223,352
Tranche 2B Warrants
Financial liabilities at fair value through profit or loss
Derivative financial liabilities	701
Money Market Fund [Member]
Financial assets at fair value through profit or loss
Financial assets at fair value through profit or loss		30,445,339
Financial liabilities at fair value through profit or loss
Financial assets at fair value through profit or loss		30,445,339
Foreign Unlisted Ordinary Shares
Financial liabilities at fair value through profit or loss
Financial assets at fair value through other comprehensive income	235,567
Fair Value Measured on Recurring Basis
Financial liabilities at fair value through profit or loss
Derivative financial liabilities	88,394
Fair Value Measured on Recurring Basis | K2 Warrants
Financial liabilities at fair value through profit or loss
Derivative financial liabilities	87,693	90,213
Fair Value Measured on Recurring Basis | Tranche 2B Warrants
Financial liabilities at fair value through profit or loss
Derivative financial liabilities	701
Fair Value Measured on Recurring Basis | Money Market Fund [Member]
Financial assets at fair value through profit or loss
Financial assets at fair value through profit or loss		30,445,339
Financial liabilities at fair value through profit or loss
Financial assets at fair value through profit or loss		30,445,339
Fair Value Measured on Recurring Basis | Foreign Unlisted Ordinary Shares
Financial liabilities at fair value through profit or loss
Financial assets at fair value through other comprehensive income	235,567
Fair Value Measured on Recurring Basis | Level 1 | Money Market Fund [Member]
Financial assets at fair value through profit or loss
Financial assets at fair value through profit or loss		30,445,339
Financial liabilities at fair value through profit or loss
Financial assets at fair value through profit or loss		30,445,339
Fair Value Measured on Recurring Basis | Level 3
Financial liabilities at fair value through profit or loss
Derivative financial liabilities	88,394
Fair Value Measured on Recurring Basis | Level 3 | K2 Warrants
Financial liabilities at fair value through profit or loss
Derivative financial liabilities	87,693	$ 90,213
Fair Value Measured on Recurring Basis | Level 3 | Tranche 2B Warrants
Financial liabilities at fair value through profit or loss
Derivative financial liabilities	701
Fair Value Measured on Recurring Basis | Level 3 | Foreign Unlisted Ordinary Shares
Financial liabilities at fair value through profit or loss
Financial assets at fair value through other comprehensive income	$ 235,567

Financial Instruments - Additio

Financial Instruments - Additional Information (Detail) - USD ($)			1 Months Ended	12 Months Ended
	Mar. 12, 2024	Feb. 24, 2023	Mar. 31, 2024	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Disclosure Of Financial Instruments [Line Items]
Transfer between Level 1 and 2, assets				$ 0	$ 0	$ 0
Transfer between Level 1 and 2, liabilities				0	0	0
Transfer between Level 2 and 1, Assets				0	0	0
Transfer between Level 2 and 1, liabilities				0	0	0
Transfers into Level 3 of fair value hierarchy, assets				0	0	0
Transfers out of Level 3 of fair value hierarchy, assets				0	0	0
Transfers into Level 3 of fair value hierarchy, liabilities				0	0	0
Transfers out of Level 3 of fair value hierarchy, liabilities				0	0	$ 0
Money market fund					$ 30,445,339
Net Proceeds from offering of shares		$ 20,000,000		$ 23,027,787
Addition To gross proceeds related to tranche warrants exercised		80,000,000
Par value per share				$ 0.01	$ 0.01	$ 0.01
Net proceeds from registered offering		$ 20,000,000		$ 23,027,787
Securities Purchase Agreement
Disclosure Of Financial Instruments [Line Items]
Net Proceeds from offering of shares			$ 5,000,000
Net proceeds from registered offering			$ 5,000,000
Securities Purchase Agreement - Registered Direct Offering | Securities Purchase Agreement
Disclosure Of Financial Instruments [Line Items]
Gross proceeds from warrants exercised	$ 5,000,000
Ordinary Shares | Securities Purchase Agreement - Registered Direct Offering | Securities Purchase Agreement
Disclosure Of Financial Instruments [Line Items]
Net Proceeds from offering of shares	$ 4,500,000
Number of shares agreed to sell and issue	125,000,000
Par value per share	$ 1
Net proceeds from registered offering	$ 4,500,000
Ordinary Shares | Securities Purchase Agreement - Registered Direct Offering | American Depositary Shares | Securities Purchase Agreement
Disclosure Of Financial Instruments [Line Items]
Number of shares agreed to sell and issue	5,000,000
Foreign Currency Risk
Disclosure Of Financial Instruments [Line Items]
Sensitivity rate used in reporting foreign currency risk					5%
Percentage of increase on exchange rate of foreign currency					5%
Percentage of decrease on exchange rate of foreign currency					5%
Interest Rate Risk
Disclosure Of Financial Instruments [Line Items]
Borrowings, interest rate basis				1%	1%
Increase in pre-tax loss				$ 265,989	$ 69,596	$ 308,573

Financial Instruments - Summary

Financial Instruments - Summary of Reconciliation of Level 3 Fair Value Measurements of Financial Instruments (Details) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Disclosure of fair value measurement of equity [line items]
Beginning balance	$ 52,820,371
Ending balance	37,913,456	$ 52,820,371
Beginning balance	8,365,220	57,303,743	$ (10,152,284)
Ending balance	(13,286,931)	8,365,220	57,303,743
Level 3 | Unlisted Foreign Ordinary Shares
Disclosure of fair value measurement of equity [line items]
Subsequent measurement recognized in Other comprehensive income	235,567
Ending balance	235,567
Level 3 | K2 Warrants
Disclosure of fair value measurement of equity [line items]
Beginning balance	90,213	223,352
Issues		45,482	688,324
Subsequent measurement recognized in profit and loss	(2,520)	(178,621)	(464,972)
Ending balance	87,693	$ 90,213	$ 223,352
Level 3 | Tranche Warrants
Disclosure of fair value measurement of equity [line items]
Issues	3,465,180
Subsequent measurement recognized in profit and loss	(3,464,479)
Ending balance	$ 701

Financial Instruments - Summa_2

Financial Instruments - Summary of Fair Value of Financial Assets and Financial Liabilities Measured at Fair Value on Recurring Basis (Detail) - Level 3 - Historical volatility for shares, measurement input [member]	12 Months Ended
	Dec. 31, 2023 USD ($)
K2 Warrants | Binomial Tree
Disclosure of detailed information about financial instruments [line items]
Valuation Technique(s) and key input(s)	Option Pricing Model (Binomial Tree Model).The following variable were taken into consideration: Time to maturity, current share price, strike price, risk free rate, dividend yield and volatility
Significant unobservable input(s)	Volatility
Relation and sensitivity of unobservable inputs to fair value	The higher the volatility, the higher the fair value. If the volatility was 5 per cent lower while all other variables were held constant, the carrying amount would decrease by US$3,631. If the volatility was 5 per cent higher while all other variables were held constant, the carrying amount would increase by US$3,171.
Percentage of higher volatility	5%
Percentage of lower volatility	5%
Increase in carrying amount due to 5% higher volatility	$ 3,171
Decrease in carrying amount due to 5% lower volatility	$ 3,631
Tranche 2B Warrants | Monte Carlo
Disclosure of detailed information about financial instruments [line items]
Valuation Technique(s) and key input(s)	Option Pricing Model (Monte Carlo Simulation).The following variable were taken into consideration: Time to maturity, current share price, strike price, risk free rate, dividend yield and volatility
Significant unobservable input(s)	Volatility
Relation and sensitivity of unobservable inputs to fair value	The higher the volatility, the higher the fair value. If the volatility was 5 per cent lower while all other variables were held constant, the carrying amount would decrease by US$376. If the volatility was 5 per cent higher while all other variables were held constant, the carrying amount would increase by US$552.
Percentage of higher volatility	5%
Percentage of lower volatility	5%
Increase in carrying amount due to 5% higher volatility	$ 552
Decrease in carrying amount due to 5% lower volatility	$ 376
Unlisted Foreign Ordinary Shares | Back Solve Option Pricing Model
Disclosure of detailed information about financial instruments [line items]
Valuation Technique(s) and key input(s)	Backsolve Option Pricing Model.The following variable were taken into consideration: Expected holding period, risk free rate, dividend yield and volatility
Significant unobservable input(s)	Volatility
Relation and sensitivity of unobservable inputs to fair value	The higher the volatility, the higher the fair value. If the volatility was 5 per cent lower while all other variables were held constant, the carrying amount would decrease by US$1,314. If the volatility was 5 per cent higher while all other variables were held constant, the carrying amount would increase by US$1,367.
Percentage of higher volatility	5%
Percentage of lower volatility	5%
Decrease in carrying amount due to 5% lower volatility	$ 1,314
Increase in carrying amount due to 5% higher volatility	$ 1,367

Financial Instruments - Summa_3

Financial Instruments - Summary of Categories of Financial Instruments (Detail) - USD ($)		Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Financial assets at fair value through profit or loss
Financial assets at amortized cost	[1]	$ 22,448,527	$ 27,490,152	$ 91,047,060
Financial assets at fair value through other comprehensive income
Equity instruments		235,567
Financial liabilities at fair value through profit or loss
Derivative financial liabilities		88,394	90,213	223,352
Financial liabilities at amortized cost	[2]	36,910,284	41,922,924	36,090,421
Equity Instruments
Financial assets at fair value through other comprehensive income
Equity instruments		10,435,983
Pre-funded Warrants | Equity Instruments
Financial assets at fair value through other comprehensive income
Equity instruments		8,262,698
Tranche 2A Warrants | Equity Instruments
Financial assets at fair value through other comprehensive income
Equity instruments		2,173,285
K2 Warrants
Financial liabilities at fair value through profit or loss
Derivative financial liabilities		87,693	90,213	$ 223,352
Tranche 2B Warrants
Financial liabilities at fair value through profit or loss
Derivative financial liabilities		701
Money Market Fund [Member]
Financial assets at fair value through profit or loss
Financial assets at fair value through profit or loss			$ 30,445,339
Foreign Unlisted Ordinary Shares
Financial assets at fair value through profit or loss
Financial assets at fair value through other comprehensive income		$ 235,567
[1] The balances include financial assets at amortized cost, which comprise of cash and cash equivalents (excluding money market funds) and refundable deposits. The balances include financial liabilities at amortized cost, which comprise of trade payables, other payables, current borrowings, lease liabilities and long-term borrowings.

Financial Instruments - Summa_4

Financial Instruments - Summary of Significant Financial Assets and Liabilities Denominated in Foreign Currencies (Detail)	12 Months Ended
	Dec. 31, 2023 SGD ($)	Dec. 31, 2022 SGD ($)	Dec. 31, 2022 SGD ($) AUD ($)	Dec. 31, 2022 AUD ($)
Disclosure of detailed information about financial instruments [abstract]
Financial assets, Foreign Currencies	$ 2,825,324	$ 2,312,357	$ 2,312,357	$ 2,616,802
Financial assets, Exchange Rate	0.7577	0.7461	0.682
Financial assets, Carrying Amount	$ 2,140,748	$ 1,725,279	$ 1,725,279	$ 1,784,606
Financial liabilities, Foreign Currencies	$ 18,232,233	$ 16,298,191	16,298,191
Financial liabilities, Exchange Rate	0.7577	0.7461
Financial Liabilities, Carrying Amount	$ 13,814,563	$ 12,160,288	$ 12,160,288

Financial Instruments - Sensiti

Financial Instruments - Sensitivity Analysis of Foreign Currency Risk (Detail)	12 Months Ended
	Dec. 31, 2023 SGD ($)	Dec. 31, 2022 SGD ($)	Dec. 31, 2022 AUD ($)	Dec. 31, 2021 SGD ($)	Dec. 31, 2021 AUD ($)
Foreign Currency Risk
Disclosure Of Nature And Extent Of Risks Arising From Financial Instruments [Line Items]
Impact of a 5% change in foreign exchange rates on profit or loss	$ (583,691)	$ (521,750)	$ 89,230	$ (548,878)	$ 87,807

Financial Instruments - Summa_5

Financial Instruments - Summary of Contractual Maturities of Financial Liabilities (Detail) - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Disclosure of detailed information about financial instruments [line items]
Trade payable	$ 7,918,607	$ 12,784,485
Other payable	3,081,329	2,325,038
Lease liabilities	226,187	215,671
Borrowings	26,598,939	37,404,964
Loan From Government
Disclosure of detailed information about financial instruments [line items]
Borrowings	12,496,831	11,855,579
Other Long Term Borrowing
Disclosure of detailed information about financial instruments [line items]
Borrowings	18,541,961	32,060,453
K2HV Warrants
Disclosure of detailed information about financial instruments [line items]
Derivative financial liabilities	87,693	90,213
Tranche 2B Warrants
Disclosure of detailed information about financial instruments [line items]
Derivative financial liabilities	701
On Demand or Within 1 year
Disclosure of detailed information about financial instruments [line items]
Trade payable	7,918,607	12,784,485
Other payable	3,081,329	2,325,038
Lease liabilities	226,187	215,671
On Demand or Within 1 year | Other Long Term Borrowing
Disclosure of detailed information about financial instruments [line items]
Borrowings	1,818,750	7,503,091
On Demand or Within 1 year | Tranche 2B Warrants
Disclosure of detailed information about financial instruments [line items]
Derivative financial liabilities	701
Within 2 to 5 years | Other Long Term Borrowing
Disclosure of detailed information about financial instruments [line items]
Borrowings	16,723,211	24,557,362
After 5 years | Loan From Government
Disclosure of detailed information about financial instruments [line items]
Borrowings	12,496,831	11,855,579
After 5 years | K2HV Warrants
Disclosure of detailed information about financial instruments [line items]
Derivative financial liabilities	$ 87,693	$ 90,213

Transactions with Related Par_3

Transactions with Related Parties - Schedule of a Related Party Name and Category (Detail) - Key Management Personnel	12 Months Ended
	Dec. 31, 2023
Disclosure Of Transactions Between Related Parties [Line Items]
Related party name	Other
Related party category	Key Management Personnel

Transactions with Related Par_4

Transactions with Related Parties - Schedule of Interest Expense from Related Parties (Detail)	12 Months Ended
	Dec. 31, 2021 USD ($)
Disclosure Of Transactions Between Related Parties [Line Items]
Interest on loans from related parties	$ 50,074
Related Party in Substance / JANK Howden Pty Ltd
Disclosure Of Transactions Between Related Parties [Line Items]
Interest on loans from related parties	45,522
Key Management Personnel / Others
Disclosure Of Transactions Between Related Parties [Line Items]
Interest on loans from related parties	$ 4,552

Transactions with Related Par_5

Transactions with Related Parties - Schedule of Key Management Personnel Compensation (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Disclosure of transactions between related parties [abstract]
Short-term employee benefits	$ 3,115,619	$ 2,783,668	$ 2,881,215
Post-employment benefits	140,332	332,037	112,095
Share-based payments recognized	2,256,528	1,926,199	2,048,669
Key management personnel compensation	$ 5,512,479	$ 5,041,904	$ 5,041,979

Transactions with Related Par_6

Transactions with Related Parties - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Disclosure of transactions between related parties [abstract]
Remuneration of non-executive directors	$ 280,417	$ 242,782	$ 219,628

Segment Information - Additiona

Segment Information - Additional Information (Detail)	12 Months Ended
	Dec. 31, 2023 USD ($) Segment
Disclosure Of Operating Segments [Line Items]
Number of reportable segment | Segment	1
Revenue	$ 12,000,000
Zenyaku Kogyo Co., ltd
Disclosure Of Operating Segments [Line Items]
Revenue	12,000,000
Out-licensing
Disclosure Of Operating Segments [Line Items]
Revenue	$ 12,000,000

Segment Information - Summary o

Segment Information - Summary of Analysis of Company's Revenue from Products and Services (Detail)	12 Months Ended
	Dec. 31, 2023 USD ($)
Disclosure of operating segments [line items]
Revenue	$ 12,000,000
Out-licensing
Disclosure of operating segments [line items]
Revenue	$ 12,000,000

Other Items_Subsequent Events -

Other Items/Subsequent Events - Additional Information (Detail) - USD ($)	Mar. 14, 2024	Mar. 13, 2024	Mar. 12, 2024	Jan. 05, 2024	Feb. 24, 2023	Jan. 24, 2024	Dec. 31, 2023	Jun. 30, 2023	Dec. 31, 2022	Dec. 31, 2021	Jul. 12, 2021
Disclosure Of Nonadjusting Events After Reporting Period [Line Items]
Number of ordinary shares authorised							1,000,000,000		500,000,000	500,000,000
Warrant price per share							$ 0.01		$ 0.01	$ 0.01
Securities Purchase Agreement - Registered Direct Offering
Disclosure Of Nonadjusting Events After Reporting Period [Line Items]
Aggregate gross proceeds from registered offering	$ 5,000,000
Nasdaq Capital Market
Disclosure Of Nonadjusting Events After Reporting Period [Line Items]
Minimum bid price requirement				$ 1
Securities Purchase Agreement | Securities Purchase Agreement - Registered Direct Offering
Disclosure Of Nonadjusting Events After Reporting Period [Line Items]
Expiration term			5 years
Securities Purchase Agreement | Top of Range | Securities Purchase Agreement - Registered Direct Offering
Disclosure Of Nonadjusting Events After Reporting Period [Line Items]
Number of shares that can be purchased with warrants		125,000,000
Purchase Agreement
Disclosure Of Nonadjusting Events After Reporting Period [Line Items]
Warrant price per share					$ 4.4475
ADS Ratio Change | Bottom of Range
Disclosure Of Nonadjusting Events After Reporting Period [Line Items]
Bid price				$ 1
Ordinary Shares | Securities Purchase Agreement | Securities Purchase Agreement - Registered Direct Offering
Disclosure Of Nonadjusting Events After Reporting Period [Line Items]
Warrant price per share			$ 1
Exercise price		$ 1
Number of shares agreed to sell and issue			125,000,000
Ordinary Shares | Securities Purchase Agreement | Securities Purchase Agreement - Registered Direct Offering | American Depositary Shares
Disclosure Of Nonadjusting Events After Reporting Period [Line Items]
Gross purchase price of share			$ 1
Number of shares agreed to sell and issue			5,000,000
Number of shares that can be purchased with warrants		5,000,000
Ordinary Shares | Extraordinary General Meeting of Shareholders
Disclosure Of Nonadjusting Events After Reporting Period [Line Items]
Amount of ordinary shares authorised						$ 10,000,000
Number of ordinary shares authorised						1,000,000,000
Warrant price per share						$ 0.01
Ordinary Shares | Purchase Agreement
Disclosure Of Nonadjusting Events After Reporting Period [Line Items]
Gross purchase price of share					0.178
Ordinary Shares | Increase in Authorised Share Capital | Extraordinary General Meeting of Shareholders
Disclosure Of Nonadjusting Events After Reporting Period [Line Items]
Amount of ordinary shares authorised						$ 50,000,000
Number of ordinary shares authorised						5,000,000,000
Warrant price per share						$ 0.01
American Depositary Share | Purchase Agreement
Disclosure Of Nonadjusting Events After Reporting Period [Line Items]
Warrant price per share					4.4475
Gross purchase price of share					$ 4.45
K2HV Loan Agreement | Ordinary Shares
Disclosure Of Nonadjusting Events After Reporting Period [Line Items]
Warrant price per share								$ 0.1447			$ 0.5257
K2HV Loan Agreement | American Depositary Share
Disclosure Of Nonadjusting Events After Reporting Period [Line Items]
Warrant price per share								$ 3.6175			$ 13.1425